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General introduction
Over the past decades, the ageing of the population with a changed demand for 
healthcare and advanced medical technology has increasingly pressured the sustainability 
of healthcare systems in Western countries. The demand has changed from patients 
with acute diseases requiring timely care from a single provider to persons with chronic 
diseases requiring highly coordinated care from providers over the entire continuum of 
care, cure and prevention. Yet, current health systems are fragmented and inefficient to 
meet the demand and are increasingly challenged to improve value.
Value is defined as the ratio between outputs (such as health outcomes) and inputs (such 
as spending) of health services. That implies that value can be increased by improving 
health outcomes while maintaining (or increasing) spending levels, for example by 
stimulating high-value services utilization such as care coordination pathways. Value 
can also be improved by maintaining (or improving) health outcomes while lowering 
spending levels, for example by reducing low-value service utilization such as the use of 
antibiotics in non-bacterial infections.
In an attempt to meet the changed demand, population health management (PHM) 
initiatives have emerged in a number of countries which aim to enhance value from a 
network perspective, for example in Germany (Gesundes Kinzigtal) and in the United 
States of America (Accountable Health Communities). Commonly, PHM initiatives 
aim to improve value by integration of services across care, cure and prevention within 
regional networks of providers, municipalities and insurers.
This thesis aims to contribute to the existing literature on PHM in two ways. First, in 
Part A, we explore how to measure value in a PHM context in order to make informed 
budget allocation decisions and monitor interventions across and within PHM regions. 
Second, in Part B, we gain insight into the different types of alternative payment models 
(APMs) and their effects on value and what experiences are with the implementation of 
APMs, in order to assess their role in PHM. This is important as many PHM initiatives 
are experimenting with payment reforms, but research on the effects of APMs on value 
and empirical research on the implementation of APMs is still lacking.
This thesis uses the context of PHM initiatives within the Dutch health care system. 
PHM initiatives emerged as a increased decentralization led to a larger role for regions 
and municipalities. Along with the developments that led to Dutch PHM initiatives, 
the Dutch government stimulated the integration of care for subpopulations including 
chronic diseases and episodes of care among which diabetes mellitus type 2 and 
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maternity care. Since Januari 2017 it is possible for maternity care providers organized in 
regional Maternity Care Networks (MCNs) to adopt bundled payment contracts. These 
bundled payment contracts are interventions that may be adopted in a PHM setting.
Part A: Measuring value in a population health management context
Part A explored how to measure the concept of value by reviewing the current state of 
low-value service indicators (chapter 2) and how to operationalize the concept of value 
within observational datasets (chapter 3 and chapter 4).
Low-value services are defined as services that provide no benefit to patients or can 
even cause harm. Chapter 2 showed that the majority of low-value care indicators 
are in medical (primary or secondary) care (87 out of the 115 listed low-value care 
indicators). The remaining indicators were found in prevention (n=25) and in long-term 
care (n=3). No indicators were found in social care. Three indicators were assigned the 
highest level of evidence as they were underpinned by both guidelines and evidence from 
the literature. Other indicators were underpinned by clinical guidelines or Choosing 
Wisely recommendations. Despite the fact that several indicators are used in APMs, no 
information on the validity of the indicators was found in the literature.
Chapter 3 analyzed the drivers of regional variation in medical spending by looking 
at subgroups (i.e. individuals with diabetes and depression) in addition to the total 
population. Heterogeneity issues with regard to case-mix were aimed to overcome 
by using an extensive dataset (secondary health survey data linked with claims data, 
healthcare supply data and municipality registration data), in addition to the selection 
of subgroups. The results showed that PHM regions with above (or below) average 
spending for the general population mostly showed above (or below) average spending 
for diabetes and depression as well. Individual demand variables explained around 62% 
of the total variance. Less than 1% of the total variance was attributed to the regional 
level. Yet, the drivers of the variation at the regional level varied between subgroups. 
Demand factors explained nearly all variation across regions for depression but explained 
88% of the variation for diabetes. The variation left unexplained (12% for diabetes) 
indicates differences across regions due to inefficiencies. This suggests that the extent 
to which regional variation in medical spending can be considered as inefficiency may 
differ between regions and subgroups.
In a first attempt to measure the value of maternity care, chapter 4 described the 
variation of six proposed value-indicators for maternity care across Dutch MCNs. 
Specifically, we used the association between low-value services utilization (inputs) and 
541371-L-bw-deVries
Processed on: 24-2-2020 PDF page: 16
16
maternal and neonatal health outcomes (outputs) as measures of value across the MCNs. 
For example, the association of the rate of caesarean sections in low-risk pregnancies 
and the rate of Apgar score lower than 7 after 5 minutes at the regional (MCN) level. 
We found substantial variation across MCNs for the six value-indicators. The additional 
analyses showed that the inputs, i.e. the low-value care indicators, may have captured a 
part of the concept of value. However, despite the use of many case-mix variables, we 
could not rule out that these findings were due to population heterogeneity.
Part B: Alternative payment models in population health management
Part B gained insight into the current state of APMs using international literature 
(chapter 5) and experiences of PHM stakeholders in the Netherlands (chapter 6).
Chapter 5 reviewed what types of APMs have been implemented in maternity care in 
Western countries. Seventeen initiatives employed APMs in the United States (n=13), the 
United Kingdom (n=2), New Zealand (n=1) and in the Netherlands (n=1). Within these 
initiatives, pay-for-performance models (n=2), shared savings models (n=7) and bundled 
payment models (n=8) were found. Key design elements (such as eligible population, 
episode time span, care providers that participated in the model, care activities covered 
by the model, risk mitigation strategies) varied highly. Key terms describing the type of 
payment model (e.g. shared savings and bundled payments) were used interchangeably. 
APMs that shifted more financial accountability toward providers tended to include 
more strategies that mitigated financial risks. The first evaluations (n=4) on the effects 
of APMs are tentatively positive on different indicators of health and spending. Two 
studies found a positive association between the APM and health outcomes and two 
studies found a reduction in medical spending.
Chapter 6 investigated what types of payment models were implemented in the Dutch 
PHM regions and what barriers were experienced towards payment reform. After three 
years of PHM, shared savings models for pharmaceutical care (n=4) and extensions 
of the included services existing (bundled) payment models adding providers into the 
model (n=5) were adopted. The experienced barriers included information asymmetry 
between providers and insurers, worsening reputation of insurers, lack of trust as a result 
of failed reform attempts, misaligned incentives in the hospital settings, hesitation to 
accept financial accountability and lack of start-up funding, leadership and intrinsic 
motivation to reform. According to the interviewees, these experienced barriers were 
partly due to a lack of a sense of urgency.
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Finally, chapter 7 discussed several issues that were encountered in the exploration to 
measure value and the effort to gain insight in the use and effects of APMs in a PHM 
context. One of the issues that were addressed was the need to develop comprehensive 
sets of value-indicators which capture the full continuum of cure, care and prevention. 
Currently, there are gaps in the availability of indicators of value. For example, low-value 
care indicators were mainly found in cure, while research has shown that low-value care 
is also present outside of cure and PHM initiatives increasingly develop interventions 
outside the cure sector. Another gap is the lack of indicators that reflect experiences that 
are reported by the population.
Another methodological issue is that operationalizing the spending part of the value-
equation is problematic due to endogeneity. The problem is that spending encompasses 
(among others) the treatment and the complications that may be caused by the treatment 
itself. Moreover, we found that despite access to many case-mix variables, health 
spending may reflect the health status of the population rather than the quality of care 
at the regional level. We aimed to bypass this problem by using low-value care indicators 
as inputs instead of spending. This approach seemed to be able to capture a part of the 
value concept, but also raised new questions regarding the optimal amount of low-
value care indicators to include, and other dimensions of value that are important (for 
instance high-value care). Therefore, in the future efforts to design a comprehensive set 
of value indicators, there also should also be attention for the development of high-value 
indicators and the development of guidance for deciding which and how many indicators 
should be included in which situation. Depending on the (level of the) question at hand 
the set of indicators may vary in number and contents.
Furthermore, progress to validly measure value is essential for the design and adoption 
of APMs. Only if value is measured validly, we are able to identify which key elements 
of APMs are essential in the progression towards value. We also discussed that adoption 
of APM is complicated by the lack of a common language for the APM typology. It is 
important to establish a common language, because APMs are complex and they operate 
in complex care settings; key elements vary highly among models and initiatives. In the 
meantime, APMs should be carefully designed to context at hand, while acknowledging 
the level of risk providers are able and willing to bear. In addition, it is important to be 
transparent about the stage of development of the APM, available evidence and have 
realistic expectations. Still many steps have to be taken to fully grasp the concept of 
value in a PHM context. This thesis hopes to have contributed to that goal.
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Algemene introductie
In de afgelopen decennia is de houdbaarheid van zorgstelsels in Westerse landen onder 
druk komen te staan. Als verklaring hiervoor worden doorgaans drie aspecten genoemd: 
de vergrijzing, een veranderde zorgvraag en de steeds grotere beschikbaarheid van 
geavanceerde medische technologie. De zorgvraag is verschoven van patiënten met een 
acute zorgvraag naar chronisch zieken met een vraag naar (complexe) geïntegreerde zorg. 
Bij geïntegreerde zorg staat de patiënt centraal en wordt samengewerkt tussen aanbieders 
over het gehele continuüm van zorg, welzijn en preventie. De huidige zorgstelsels in 
Westerse landen zijn echter gefragmenteerd en kunnen niet op een efficiënte manier 
tegemoetkomen aan de veranderingen in de zorgvraag. Daarnaast wordt een steeds 
groter deel van het Bruto Nationaal Product uitgegeven aan de zorg en verwacht men 
een verdere stijging van de zorgkosten in de toekomst. Westerse landen zijn daarom 
steeds meer op zoek naar manieren om de waarde (value) van zorgstelsels te verhogen. 
Waarde is gedefinieerd als de ratio tussen wat we uitgeven aan de zorg (bijvoorbeeld 
in euro’s) en wat de uitkomsten zijn van zorg (bijvoorbeeld gezondheid). De waarde 
kan verhoogd worden door uitkomsten te verbeteren en de uitgaven aan zorg gelijk te 
houden (of iets te verhogen). Dit kan bijvoorbeeld door het stimuleren van het gebruik 
van zorg die bijdraagt aan de gezondheid van de populatie (hoog-waarde zorg of 
high-value care), zoals de hielprikscreening bij pasgeboren baby’s. De waarde kan ook 
verhoogd worden door de uitkomsten gelijk te houden en de zorguitgaven te verlagen. 
Dit kan bijvoorbeeld door het reduceren van het gebruik van zorg die niet bijdraagt aan 
gezondheid (laag-waarde zorg of low-value care), zoals het gebruik van antibiotica bij 
niet-bacteriële infecties. 
Eén van de ontwikkelingen, om de veranderende zorgvraag en de houdbaarheid van 
het systeem het hoofd te bieden, is het initiëren van populatiemanagement (PM). PM-
initiatieven streven naar het verhogen van waarde door, afgestemd op de behoefte van 
de populatie, zorg over de domeinen van zorg, welzijn en preventie te integreren. PM-
initiatieven zijn regionale netwerken van aanbieders, gemeenten en zorgverzekeraars. 
Bekende voorbeelden zijn Gesundes Kinzigtal in Duitsland en de Accountable Health 
Communities in de Verenigde Staten. 
Dit proefschrift draagt op twee manieren bij aan de huidige literatuur over PM. In 
Deel A is verkend hoe waarde gemeten kan worden in een PM-context. Het doel was 
om goed geïnformeerde beslissingen te kunnen nemen over nieuwe interventies voor 
specifieke subpopulaties en om de voortgang van de PM-initiatieven te kunnen meten. 
In Deel B is onderzocht wat de mogelijke rol van alternatieve bekostigingsmodellen 
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in PM kan zijn. Dat is belangrijk, omdat veel PM-initiatieven experimenteren met 
alternatieve bekostigingsmodellen, terwijl onderzoek naar de effecten van alternatieve 
bekostigingsmodellen op waarde nog ontbreekt. Daarnaast is er nog weinig bekend over 
de ervaringen met het implementeren van alternatieve bekostigingsmodellen.
Dit proefschrift is geschreven met behulp van data uit de literatuur (review) en twee 
landelijke studies: de landelijke monitor proeftuinen (2013-2018), waarin negen 
regio’s zijn gevolgd in hun ontwikkeling naar PM en de monitor integrale bekostiging 
geboortezorg (2015-2020), waarin de ontwikkeling van integrale bekostigingscontracten 
wordt gevolgd en wat de effecten zijn van integrale bekostiging op kwaliteit, 
toegankelijkheid en betaalbaarheid van de geboortezorg.
Deel A: Het meten van waarde in populatiemanagement
In Deel A is gekeken naar de wijze waarop waarde gemeten kan worden. 
Allereerst is in de literatuur (hoofdstuk 2) gekeken naar indicatoren voor laag-waarde 
zorg. Dat wil zeggen, welke indicatoren worden gebruikt voor het meten van het gebruik 
van zorg (of welzijn of preventie) die niet bijdraagt aan de gezondheid van de patiënt, en 
deze zelfs schade kan toebrengen. De systematische review laat zien dat het merendeel 
van de indicatoren voor laag-waarde zorg in het domein van zorg (eerste lijn of tweede 
lijn) vallen (87 van de 115 gevonden indicatoren). De overige indicatoren gaan over 
preventie (n=25) of langdurige zorg (n=3). Er zijn geen indicatoren voor laag-waarde 
zorg in het domein van welzijn gevonden. Daarnaast bleek dat slechts drie van de 115 
indicatoren zijn ontwikkeld op basis van bewijs in de literatuur en in richtlijnen, en zijn 
daarom aangemerkt als ‘goed ondersteund door bewijslast’. Andere indicatoren zijn 
ontwikkeld op basis van informatie uit richtlijnen en Choosing Wisely-aanbevelingen. 
Ondanks het feit dat meerdere indicatoren worden gebruikt in de zorgcontractering door 
zorgverzekeraars, vonden wij geen informatie over de validiteit van deze indicatoren in 
de wetenschappelijke literatuur.
In hoofdstuk 3 is onderzocht welke factoren een rol spelen bij regionale variatie 
in zorguitgaven door niet alleen de totale populatie te analyseren, maar ook twee 
subpopulaties (diabetes en depressie). Er is hierbij onderscheid gemaakt tussen variatie 
op individueel niveau en variatie op regionaal niveau. Voor populatieheterogeniteit 
is rekening gehouden door te controleren voor een uitgebreide set aan variabelen 
waaronder leeftijd, geslacht, sociaal economische status, diagnose-kosten groepen, 
zelfgerapporteerde gezondheidsstatus en afstand tot verschillende zorgaanbieders. 
Hiertoe is een dataset gecreëerd waarbij bestaande registraties en monitors werden 
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gekoppeld (een vragenlijst over gezondheid (de Gezondheidsmonitor), declaratiegegevens 
van zorgverzekeraars (Vektis) en data over locaties van zorginstellingen en de 
Gemeentelijke Basisadministratie). De resultaten laten zien dat PM-regio’s die voor 
de totale populatie meer (of minder) zorguitgaven hebben dan gemiddeld, ook voor de 
subgroepen (diabetes en depressie) meer (of minder) zorguitgaven hebben. Ongeveer 62% 
van de variatie op individueel niveau kon worden toegeschreven aan de zorgbehoefte, 
waarbij zelfgerapporteerde gezondheidsstatus de belangrijkste was (28%). Minder dan 
1% van de totale variatie kon worden toegeschreven aan het regionale niveau. Echter, 
factoren die een rol spelen bij het verklaren van de variatie op het regionale niveau bleken 
te variëren tussen de subgroepen. Bij depressie konden factoren die te maken hebben 
met de zorgbehoefte nagenoeg alle variatie op regionaal niveau verklaren; bij diabetes 
is dat 88%. Dat betekent dat bij diabetes 12% van de variatie op regionaal niveau niet 
verklaard kon worden. Dit wijst op mogelijke verschillen in efficiency, zowel tussen 
regio’s als tussen subgroepen.
Vervolgens is in hoofdstuk 4 de waarde van geboortezorg onderzocht op basis van 
gegevens over de variatie tussen verloskundige samenwerkingsverbanden (VSV’s) 
(uitgedrukt in zes indicatoren voor waarde). Er werd gekeken naar associaties tussen 
het gebruik van laag-waarde zorg en maternale en neonatale gezondheidsuitkomsten als 
mogelijke operationalisatie van waarde. Er is, onder andere, gekeken naar de associatie 
tussen de proportie keizersneden in laag-risico zwangerschappen en de proportie 
Apgar score lager dan zeven na vijf minuten op regionaal niveau (VSV). Voor alle 
zes de voorgestelde indicatoren voor waarde is substantiële variatie gevonden tussen 
VSV’s. Additionele analyses wijzen erop dat de indicatoren die gebruikt werden om 
het gebruik van laag-waarde zorg te meten, daadwerkelijk (een deel van) het concept 
van waarde meten. Ondanks het gebruik van een veelheid aan variabelen om voor 
populatieverschillen te controleren, is het mogelijk dat onze resultaten beïnvloed zijn 
door verschillen die in werkelijkheid toe te schrijven zijn aan de populatie (in plaats van 
aan de VSV’s).
Deel B: Alternatieve bekostigingsmodellen in populatiemanagement
In Deel B van dit proefschrift is een overzicht gegeven van typen en effecten van 
alternatieve bekostigingsmodellen en ervaringen met het implementeren van dergelijke 
modellen.
Eerst is in hoofdstuk 5 geanalyseerd welke typen alternatieve bekostigingsmodellen 
in de geboortezorg tot op heden werden geïmplementeerd in Westerse landen. Er zijn 
zeventien initiatieven gevonden waarbij alternatieve bekostigingsmodellen werden 
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geïmplementeerd. Dertien van deze initiatieven zijn gevonden in de Verenigde Staten, 
twee in Engeland, één in Nieuw Zeeland en één in Nederland. Er zijn pay-for-performance 
modellen (n=2), shared savings modellen (n=7) en integrale bekostigingsmodellen (n=8) 
geïmplementeerd. Het ontwerp van belangrijke elementen in de modellen (zoals de in 
aanmerking komende populatie, tijdspanne, (type) aanbieders die deelnemen aan het 
model, zorgactiviteiten die binnen het model vallen, risicoverzachtende strategieën) 
varieerde tussen de initiatieven. Daarnaast is gevonden dat belangrijke termen 
die gebruikt werden om het type model te beschrijven, door elkaar zijn gebruikt 
(bijvoorbeeld shared savings en integrale bekostiging). Alternatieve bekostigingsmodellen 
met (intrinsiek) meer financieel risico voor aanbieders hadden ook meer strategieën 
om dit risico te verminderen. De eerste empirische evaluaties (n=4) over de effecten 
van alternatieve bekostigingsmodellen waren voorzichtig positief op verschillende 
indicatoren van gezondheid en zorguitgaven. Twee studies vonden een positief verband 
met gezondheidsuitkomsten en twee studies vonden een reductie van zorguitgaven.
In hoofdstuk 6 is onderzocht welke typen alternatieve bekostigingsmodellen in de 
Nederlandse PM-regio’s zijn geïmplementeerd en wat ervaren barrières waren om te 
komen tot bekostigingshervorming. Na drie jaar PM in Nederland zijn er shared savings 
modellen geïmplementeerd in de farmaceutische zorg (n=4) en zijn bestaande alternatieve 
bekostigingsmodellen uitgebreid met nieuwe (typen) zorg en aanbieders in het model 
(n=5). Er werden meerdere barrières om te komen tot bekostigingshervorming genoemd 
door de geïnterviewden. De meest relevante waren een informatieasymmetrie tussen 
aanbieders en zorgverzekeraars, verslechtering van de reputatie van zorgverzekeraars, 
gebrek aan vertrouwen door mislukte pogingen tot bekostigingshervorming, 
tegengestelde prikkels in de ziekenhuissetting, terughoudendheid met het accepteren 
van financieel risico en een gebrek aan de initiële investeringen tijdens de opstartfase, 
leiderschap en intrinsieke motivatie. Volgens de geïnterviewden zijn deze ervaren 
barrières deels het gevolg van een gebrek aan gevoel van urgentie.
Algemene discussie
Tot slot zijn in hoofdstuk 7 een aantal aspecten besproken die aan het licht zijn gekomen 
bij de verkenning naar manieren om waarde te meten en in het verkrijgen van inzicht in 
alternatieve bekostigingsmodellen, beide in een PM-context. 
Eén van die aspecten is dat het van belang is om een set van indicatoren voor waarde te 
ontwikkelen die het volledige continuüm van zorg, welzijn en preventie beslaat. Op dit 
moment zijn er namelijk hiaten in de beschikbaarheid van indicatoren die waarde kunnen 
meten. Zo werden indicatoren voor laag-waarde zorg voornamelijk gevonden in het 
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zorgdomein, terwijl er ook bewijs is dat laag-waarde zorg bestaat buiten het zorgdomein. 
Een ander voorbeeld is dat landelijke registratiedata alleen routinematig verzamelde 
gegevens van het primaire zorgproces bevatten en bijvoorbeeld geen patiëntervaringen.
Een tweede belangrijk aspect is dat het gebruik van zorguitgaven bij het meten van 
waarde kan leiden tot bias. Deze bias ontstaat doordat zorguitgaven een optelsom 
is van (onder andere) de behandelingen, maar ook van de complicaties van die 
behandelingen. Daarbij is (onder andere) in dit proefschrift gevonden dat, zelfs als we 
uitgebreid corrigeren voor populatieverschillen, de zorguitgaven op regionaal niveau 
de gezondheidstoestand van de populatie weergeeft, in plaats van kwaliteitsverschillen 
op regionaal niveau. Om dit probleem te omzeilen hebben we waarde geprobeerd te 
meten door indicatoren voor laag-waarde zorg te gebruiken in plaats van zorguitgaven. 
Ondanks dat met deze aanpak een deel van het concept van waarde gemeten kan worden, 
roept het ook nieuwe vragen op. Daarom is geadviseerd om bij de ontwikkeling van 
een set van indicatoren om waarde te kunnen meten ook te kijken naar de mogelijke 
bijdrage van indicatoren die hoog-waarde zorg meten. Daarnaast is het van belang om 
goed te bekijken welke indicatoren gebruikt kunnen worden om antwoord te geven op 
de voorliggende vraag. Afhankelijk van de precieze vraagstelling en het niveau van de 
vraag (op organisatieniveau, op regionaal niveau, op landelijk niveau), kan de inhoud 
en de omvang van de indicatorenset variëren.
Bij het ontwerp en de adoptie van alternatieve bekostigingsmodellen is het valide meten 
van waarde van groot belang. Alleen dan kunnen de prikkels van de bekostigingsmodellen 
zo vormgegeven worden dat ze ook daadwerkelijk tot meer waarde leiden, en kunnen 
de effecten van de alternatieve bekostigingsmodellen op waarde daadwerkelijk worden 
gemeten. Daarnaast is het belangrijk dat er eenduidigheid komt in het gebruik van 
taal om de typologie van bekostigingsmodellen te duiden. Een gemeenschappelijke 
taal kan de adoptie van alternatieve bekostigingsmodellen helpen te bevorderen, door 
het vergroten van begrip van de complexe modellen die opereren in een complex 
zorgsysteem. Verder is het verstandig om de alternatieve bekostigingsmodellen steeds 
af te stemmen naar de situatie in de praktijk, waarbij rekening wordt gehouden met het 
financiële risico dat zorgaanbieders willen en kunnen dragen. Daarbij is het belangrijk 
om transparant te zijn over de elementen in het model, wat het bewijs is voor de effecten 
van het model, en realistische verwachtingen te hebben over wat de uitkomsten kunnen 
zijn. Voordat het concept van waarde optimaal gebruikt kan worden in een PM-context 
moeten er nog veel stappen gezet worden. Dit proefschrift hoopt hieraan een bijdrage 
te hebben geleverd.
541371-L-bw-deVries




Processed on: 24-2-2020 PDF page: 26
1
541371-L-bw-deVries




Processed on: 24-2-2020 PDF page: 28
28
Chapter 1
Sustainability of health care systems in Western countries under pressure
Over the past decades, the sustainability of health care systems in Western countries is 
increasingly pressured. One of the main reasons was the reduction of the incidence of 
infectious diseases that resulted in an enormous increase in the average life expectancy 
[1]. In combination with problematic health factors such as obesity and smoking, this 
emerged in an era of chronic diseases after the 1950s. These chronic diseases, among 
which diabetes, chronic kidney disease, chronic vascular diseases, cancer and psychiatric 
disorders, are not only the main causes of death, but also have an enormous impact on 
the quality of life for an increasing amount of life years. Consequently, the demand 
for health care has changed from acute diseases requiring timely care from a single 
provider to chronic diseases requiring highly coordinated care from providers over the 
entire continuum of care, cure and prevention [2, 3]. Together with a decreasing birth 
rate, emerging technological innovations such as expensive innovative cancer therapies 
and high-tech diagnostic technologies, the changing demand for health care resulted 
in European spending levels of about 9.6% of the Gross Domestic Product (GDP) 
in 2017 (see Figure 1), with further growth expected in the future [4]. Therefore, 
countries are increasingly challenged to improve the value of their health systems by 
improving populations’ health through meeting the changed demand for health care, 
while containing the spending levels [4, 5]. If these goals are not sufficiently achieved 
countries will need to increase taxes, shift resources from other public domains (e.g. 
infrastructure or education) or increase use of out-of-pocket payments [6].
Current health systems are fragmented and inefficient
Many health care systems are still largely organized to facilitate acute care delivery 
[2, 4]. Acute diseases, such as infectious diseases or fractured arms, require high-
responsive timely care from single providers, meaning that care is organized, financed 
and delivered in specific and separate domains (e.g. primary care, specialty care, long-
term care, social care, home care, pharmaceutical care; all separate). However, people 
with one or multiple chronic diseases need careful calibrated care from multiple providers 
that is guided by patient goals [2]. Both patients and providers struggle with the level 
of collaboration that is required for addressing their needs [7]. In daily practice, the 
current organization of care in sectors and domains require patients to explain their 
situation multiple times, to continuously communicate changes in treatment plans and to 
continuously keep each provider aligned to personal goals. Therefore, the fragmentation 
of care leads to high-pressure on the organizational capacity of patients. Additionally, 
the fragmentation of care may result in miscommunications that lead to medical errors 
or overutilization and payment models that incentivize production instead of value and 
high administrative burdens and other types of inefficiently organized, financed and 
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Chapter 1
delivered care [4]. Recent estimates show that up to 20% of health spending in Europe 
[4, 5] and up to 30% of health spending in the United States is wasteful [8-10]. At 
the same time, there is growing evidence that low-value services (e.g. non-medically 
indicated caesarean sections or the use of antibiotics in viral infections) are increasingly 
performed (e.g. [11-15], while high-value services (e.g. addressing health-related social 
needs and targeting subpopulations that are being underserved) are underutilized [5]. 
Consequently, countries are increasingly searching for ways to improve the value of 
their health systems.
Population health management initiatives to achieve value
One of the responses to the sustainability problems health systems of Western countries 
are facing, is to improve health care delivery by integration of services across medical 
care, social care and public health within the region, which is called population 
health management (PHM) [16]. The ultimate goal for most PHM initiatives is to, 
simultaneously, attain better population health and experienced quality of care and a 
reduction of the per capita costs [9].
In a number of countries, networks of providers, payers and municipalities, within specific 
regions have adopted the PHM approach. Generally, PHM regions try to close the gap 
between health care and community services by addressing a number of themes. Common 
themes include building trust and increasing collaboration between all stakeholders and 
implementing interventions tailored for specific subgroups. Additionally, PHM regions 
try setting up data-infrastructure to share patient information between multiple care 
providers and make efforts to shift the financial accountability from payers towards 
groups of providers [17]. A well-known PHM initiative is Gesundes Kinzigtal (GK) in 
Germany [18, 19], which implemented a long-term shared savings contract to organize 
care across all domains for people of all ages and needs [20]. In the contract was specified 
that one organization (GK) is accountable for the care delivery and spending for the 
entire (insured) population [21]. GK has developed many interventions, which include 
evidence-based preventive programs that target common chronic diseases and supporting 
patients’ self-management activities [20]. For example, if patients are identified to be 
at risk for a certain disease, individual treatment plans are developed by doctors and 
patients together. GK invests in training physicians in how to improve case management 
and shared-decision making. In addition, substantial investments were made to develop 
data-infrastructure to improve the collaboration between providers.
Other examples include Accountable Health Communities in the USA [22] and Dutch 
PHM initiatives [23]. These PHM initiatives employ interventions that, for instance, 
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aim to develop data-infrastructure for data sharing among providers. Other interventions 
include the substitution of low-complex hospital-based cardiovascular management care 
towards the primary care setting and implementing alternative payment models (e.g. 
shared savings in pharmaceutical care or bundled payments for maternity care) [22-28]. 
Although these PHM initiatives make efforts to experiment with payment reform, they 
struggle on how to successfully develop and implement alternative payment models [22, 
23]. As such, Accountable Health Communities search how payment model incentives 
should be set to enhance social determinants, while improving financial sustainability 
[29] and the Dutch PHM initiatives are in search for the most appropriate payment 
model that is aligned with the PHM goals.
Research on population health management is starting to emerge
As research on PHM initiatives is just starting to emerge, evidence of the effects of 
PHM initiatives is scarce. Until thus far, two studies [19, 20] showed beneficial outcomes 
of Gesundes Kinzigtal; savings and a lower mortality rate compared to the control group. 
Additionally, patient and provider experiences were found to be positive in Gesundes 
Kinzigtal [30, 31]. Up until now, research in PHM has focused on defining the concept 
of PHM [16] and how to evaluate PHM initiatives [32]. Struijs and colleagues (2015) 
developed an analytical framework to evaluate PHM (Figure 2), that was based on the 
Care Continuum Alliance model [33]. The essence of this framework is that through 
a deep understanding of the needs of the population and continuously monitoring on 
PHM goals, resources may be allocated in such a way, that those needs are met in an 
efficient way. Based on Struijs’ analytical framework, Hendrikx and colleagues worked 
on operationalizing PHM goals such as population health [34-36] and experienced 
quality of care [37]. Yet, the link between the interdependent PHM goals (i.e. population 
health, quality of care and spending) and the overarching goal of ‘value’ is currently 
lacking. This link is important to be able to monitor interventions and make informed 
budget allocation decisions in PHM regions. Therefore, the first aim of this thesis 
is to contribute to the existing PHM literature by exploring how to measure and 
operationalize ‘value’ in a PHM context.
Other research in PHM concentrated on how to successfully implement interventions, 
such as Steenkamer and colleagues [38] who proposed a set of guiding principles 
for how collaboration can be improved in pharmaceutical care, or whether existing 
prediction models are helpful to identify the needs of the population to optimally target 
interventions [39]. In addition, a few PHM interventions were studied, as for example 
the substitution of care from hospital to primary care [40, 41]. Although many PHM 
initiatives are experimenting with payment reforms, research on the implementation and 
1
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Source: Struijs et al 2015 [32]
Figure 2: Analytical framework for population health management
the effects of these models on value in PHM is still lacking [42]. Therefore, the second 
aim of this thesis is to gain insight into experiences with, and the types and effects of, 
alternative payment models in PHM.
The following section elaborates on the background of the two thesis aims.
Theoretical considerations
Since the introduction of Porters’ book ‘Redefining health care’ in 2006 [43] and the 
development of concepts such as ‘value-based payment models’ (or as is further referred 
to in this thesis: alternative payment models (APMs)), the concept of ‘value’ gained 
popularity, in particular in the health care domain. Porters’ definition of value is health 
outcomes that matter to patients relative to its spending, where outcomes are patient 
reported and disease-specific and spending comprises the total spending for the full 
cycle of care for the disease [44]. Based on this concept, the Value-Based Health Care 
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model (Figure 3) was developed, and consists of six steps to transform care pathways 
such that the ratio between patients’ health and euro’s spent, increases [45]. The model 
was applied in many initiatives (mainly in hospitals) and can be compared to PHM in 
the sense that it aims to integrate services across (groups of) providers by using aligned 
and supportive payment models and data-infrastructure in order to improve overall 
value, but particularly designed for the health care domain.
Conceptually, it is important to acknowledge the difference between value - which seeks 
to optimally increase the ratio between inputs (i.e. spending, or other inputs such as 
utilization or labor) and outputs (i.e. health outcomes that matter to the patient), and 
cost containment, which only limits the inputs with no regard to changes in the output 
[46]. This implies that value is, partly, about reducing inefficiencies, such as reducing 
administrative excess, inefficient and duplicate use of resources and low-value care [5, 
47]. Low-value care is generally defined as health services that provide no benefit or may 
even cause harm [5, 13]. Low-value services can be found at the entire care continuum 
of care [48, 49] and are, per definition, services for which the costs outweigh the benefits 
[50]. For example, overtesting with overdiagnosis as a result may seem harmless but have 
undesired effects when diagnoses causes stress among patients and family members and 
may even lead to more invasive procedures or medication, that, in turn, may have serious 
Source: Porter and Lee 2013 [45]
Figure 3: The value agenda
1
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adverse outcomes or adverse effects [50]). Note that whether services are of high- or 
low-value may differ between groups of patients [51], e.g., the use of propranolol is of 
low-value for patients using it for anxiety issues, but is of high-value in the management 
of high blood pressure.
As is discussed in previous sections, PHM initiatives employ interventions that introduce 
mechanisms to reduce the utilization of low-value services and stimulate the utilization 
of high-value services. Examples of such interventions are substituting low-complex 
care to the primary care setting and implementing APMs. Commonly, PHM initiatives 
search to improve value of care, both at the level of individuals and the system. Therefore, 
it is important to move beyond the disease-specific definition from Porter. This thesis 
defines value as the ratio between outputs and inputs of health services specifically at 
the regional level and irrespective of domain (e.g. medical care, social care, prevention).
Alternative payment models in population health management
Theoretically, a precondition for improving value is to shift away from the traditional 
fragmented fee-for-service (FFS) payment models to more value-based payment models 
[2, 52, 53]. That is because FFS models are known to incentivize each provider to 
increase the amount of services produced (as long as price is above marginal cost) and 
they are designed for acute care specifically [54]. Therefore, FFS models seem to be 
misaligned with the PHM strategy that aims to integrate services over medical care, 
social care and prevention [55]. APMs such as shared savings arrangements, bundled 
payments or global payments may fit PHM better.
The promise is that APMs incentivize care coordination, stimulate high-value services 
utilization and discourage low-value services utilization through increased financial 
accountability for (groups of) providers [56]. Figure 4 shows the theoretical effects of 
APMs on the allocation of financial risks between provider and payer that have been 
discussed extensively in the literature [57-60]. In FFS, the financial risks are largely 
born by the payer. Because providers do not run financial risks in terms of volume and 
value of care, FFS incentivizes providers to increase volume, even when the services 
are of low value [52, 57-59]. APMs aim to shift a part of the financial risks for value 
(i.e. health outcomes and spending) towards providers [57]. The increased financial risk 
for providers incentivizes them to increase efficiency by avoiding low-value services 
utilization and overutilization [61], in addition to downward substitution of care, task 
reallocation and increased coordination of care. Also, APMs encourage the utilization of 
services for which the benefits exceed the costs (high-value services) [56]. The allocation 
of financial risk between provider and payer is determined by the scope and type of 
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APM. Ideally, only performance risk, which is the risk related to what the provider is 
able to influence [52], is allocated with the provider, and insurance risk, which is the risk 
related to patient case-mix [52], is allocated with the payer. The optimal allocation of risk 
is where provider risk is maximized and insurance risk is minimized for providers [60]. 
In search for the optimum allocation of risks, APMs may be augmented with bonuses 
and penalties for meeting certain (quality) targets (for example in shared savings) and 
strategies that mitigate the level of risk for providers (e.g. high-risk population exclusions, 
risk-adjustments, or a stop-loss provision, which is a threshold that caps the maximum 
for which the provider is at risk [62]).
In practice, many PHM initiatives struggle on how to successfully design and implement 
APMs [17, 22, 23] both at the intervention level and at the PHM region level.
Thesis objectives
This thesis aims to contribute to the existing literature on PHM in two ways. First, it 
explores how to measure the concept of value in PHM for monitoring and allocation 
decision-making purposes in PHM regions (Part A). Specifically, this part explores how 
to measure the concept of value by reviewing the potential of low-value care indicators 
in PHM and how to operationalize value within observational datasets. The second part 
(Part B) aims to gain insight into experiences with, and the types and effects of, APMs 
Source: Frakt and Mayes 2012
Figure 4: (alternative) payment methods and provider/payer risk
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in order to assess its possible role in PHM. Part B questions what types of APMs are 
currently implemented and what evidence is available on spending and health outcomes. 
It also investigates experiences with the implementation of APMs in PHM. To answer 
these questions, this thesis uses several types of data sources: international literature, 
nationwide datasets containing information from multiple data sources and interviews 
with various stakeholders from PHM regions.
Thesis context
This thesis uses the context of PHM initiatives within the Dutch health care system, 
which has a Bismarckian history of social health insurance. In 2006, managed 
competition was introduced in which the government adopted a more distant role as 
supervisor and facilitator of the health care markets (i.e. between patients and providers, 
between patients and insurers and between insurers and providers) [63]. In this context, 
the trend of increasing decentralization of medical care and social care had created 
a larger role for regions and municipalities. In 2013, the Dutch Ministry of Health, 
Welfare and Sport, designated nine regional partnerships to be monitored by the Dutch 
National Institute for Public Health and the Environment (RIVM) [23]. In the period 
2013 through 2018, the RIVM monitored these regions using both qualitative and 
quantitative research approaches in the National Monitor Population management. 
This thesis uses interviews that were held periodically with both payers (insurers and 
municipalities) and providers (among which GPs, care groups, hospitals). In addition, this 
thesis uses existing nationwide linked dataset (claims data, health data and municipality 
registration data) that were acquired for the purpose of the National Monitor Population 
management. In the Netherlands, 19 PHM regions have been identified [64].
Along with the developments that led to Dutch PHM initiatives being emerged, 
the Dutch government actively stimulated the integration of care for subpopulations 
including both episodes of care and chronic disease. For instance, since January 2017 
it is possible for maternity care providers to implement bundled payment contracts 
[27, 28, 65]. The adoption of these bundled payment contracts are interventions for 
subpopulations that are suitable (and may be adopted) in a PHM setting. The RIVM 
was asked to monitor and evaluate the implementation of the bundled payment model 
in maternity care. This thesis uses the individual level nationwide dataset that linked 
claims data with maternal and infant health outcomes and quality of care and multiple 
datasets containing case-mix.
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The remainder of this thesis is outlined as follows. Part A explores how to measure 
the concept of value in PHM using scientific literature and extensive nationwide 
observational data. Chapter 2 assesses whether low-value care indicators are suitable 
for use in PHM by reviewing the presence and the validity of indicators in the scientific 
literature that measure low-value care across the entire continuum of care in the 
international literature. Chapter 3 investigates how to relieve population heterogeneity 
in its effort to identify areas on where to improve value, by assessing differences across 
subgroups across Dutch PHM regions. The study uses a nationwide linked dataset from 
the National Monitor Population management. Chapter 4 explores how to measure 
value by using the association between the utilization of low-value care and maternal 
and neonatal health outcomes across Dutch Maternity Care Networks using nationwide 
observational data at the individual level that combined multiple data sources from the 
Monitor Bundled Payments for Maternity Care.
Part B gains in-depth insight into the current state of payment reform across PHM 
regions using international literature and the experiences of actual stakeholders. Chapter 
5 reviews what types and key elements of APMs are currently implemented in one 
specific PHM intervention, maternity care, and what their effects are on health outcomes 
and spending. Chapter 6 identifies which APMs are currently implemented in Dutch 
PHM regions and what experiences are with implementing the APMs.
Finally, the main findings are discussed and reflected on in chapter 7.
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Background: Reducing low-value care is a core component of healthcare reforms in many 
Western countries. A comprehensive and sound set of low-value care measures is needed 
in order to monitor low-value care use in general and in provider-payer contracts. Our 
objective was to review the scientific literature on low-value care measurement, aiming 
to assess the scope and quality of current measures.
Methods: A systematic review was performed for the period 2010 - 2015. We assessed 
the scope of low-value care recommendations and measures by categorizing them 
according to the Classification of Health Care Functions. Additionally, we assessed 
the quality of the measures by 1) analysing their development process and the level of 
evidence underlying the measures, and 2) analysing the evidence regarding the validity 
of a selected subset of the measures.
Results: Our search yielded 292 potentially relevant articles. After screening, we selected 
23 articles eligible for review. We obtained 115 low-value care measures, of which 87 
were concentrated in the cure sector, 25 in prevention and 3 in long-term care. No 
measures were found in rehabilitative care and health promotion. We found 62 measures 
from articles that translated low-value care recommendations into measures, while 53 
measures were previously developed by institutions as the National Quality Forum. 
Three measures were assigned the highest level of evidence, as they were underpinned by 
both guidelines and literature evidence. Our search yielded no information on coding/
criterion validity and construct validity for the included measures. Despite this, most 
measures were already used in practice.
Conclusion: This systematic review provides insight into the current state of low-value 
care measures. It shows that more attention is needed for the evidential underpinning 
and quality of these measures. Clear information about the level of evidence and validity 
helps to identify measures that truly represent low-value care and are sufficiently 
qualified to fulfil their aims through quality monitoring and in innovative payer-provider 
contracts. This will contribute to creating and maintaining the support of providers, 
payers, policy makers and citizens, who are all aiming to improve value in health care.
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BACKGROUND
The concept of low-value care, defined as services that provide no benefit to patients or can 
even cause harm [1, 2], has received much attention in recent years in Western countries. 
Reducing the use of low-value care is expected to contribute to cost containment and 
more efficiency in health care [3-5]. It leads to a reduction in medical spending without 
harming health outcomes and it may stimulate a reallocation of resources to high-value 
services [4]. In this way, measuring low-value care for which the non-effectiveness is 
proven provides information on a specific type of inefficiency, i.e. spending with no 
benefit, which can be used besides other, more indirect, types of efficiency analysis such 
as traditional cost-effectiveness studies or analyses of practice variation.
Internationally, several initiatives have been launched to reduce low-value service 
utilization, among which the Choosing Wisely (CW) campaign in the US. Similar 
initiatives have originated in 12 other countries including the United Kingdom, 
Canada, Australia and the Netherlands [4, 6]. In the CW campaign, participating 
specialty societies produce lists of recommendations that are to be discussed in the 
doctor’s office, as for example, ‘don’t order diagnostic tests at regular intervals (such as 
every day), but rather in response to specific clinical questions’ [7]. Ideally, these lists 
of recommendations would meet the CW criteria: 1) each of the services is within 
the specialty’s purview, 2) each of the services is frequently used or costly, 3) each 
recommendation is based on sufficient evidence, and 4) the process for developing the 
recommendation list is documented and is made available to the public if requested [8]. 
In general, the recommendations aim to increase awareness among both doctors and 
patients [5] and subsequently influence the decision whether or not to use a specific 
service.
Besides these rather generic recommendations, studies have tried to assess the prevalence 
and geographic or practice variation in low-value care utilization (e.g. [9-12]) using 
direct measures of low-value care. The aim of the direct measures differs from the aim of 
recommendations. Where recommendations aim to create awareness among physicians 
and patients, low-value care measures may be widely used, for example in payer-provider 
contracts [13, 14] and for monitoring low-value care initiatives [4, 15].
To meet these aims, low-value care measures need to be methodologically sound [2, 
16, 17]. Otherwise, using these measures might create misinterpretation, underuse 
of indicated services, patient selection or damage the patient-physician relationship 
[18]. To date, only one study [19] reviewed the state of low-value care measurement by 
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performing a scan of the published and grey literature. They found 37 specified measures 
and 123 services that may be developed into measures, covering mainly diagnostic or 
therapeutic areas. Furthermore, another study [20] identified a set of low-value services 
and demonstrated significant variance in its utilization between hospital referral regions 
in the US.
Still, major knowledge gaps exist in the literature on measuring low-value care. First, 
there is lack of knowledge regarding the validity of current low-value care measures 
[2, 16, 17]. As Baker et al. [15] pointed out earlier, low-value care measures must at 
least be rigorously evidence-based. In addition, they must be able to detect variation 
between providers, regions or countries, reflect actual cases of the concept of interest, 
be supported by correlations to other measures indicating the same concept, and not 
be subject to substantive systemic bias (i.e. importance, coding or criterion validity, 
construct validity and risk adjustment) [21]. Therefore, specific standards for how to 
develop and assess low-value care measures should be developed [15, 18]. Second, it is 
unclear whether current low-value care measures cover the whole continuum of care. 
This is important, because it was argued that low-value care use is present in all sectors 
along the care continuum [15, 22]. However, the low-value service recommendations 
from the CW initiative cover mainly specialist care in the cure sector [8].
In this study, we aimed to start filling these gaps by performing a systematic review 
of the recent scientific literature on low value care measurement. Our objective was 
twofold. Firstly, to assess the scope of low-value care recommendations and measures in the 
literature by categorizing them according to health care function (such as curative care, 
long-term care and rehabilitation). Secondly, to assess the quality of the measures by 1) 
analysing their development process and the evidence that underlies the measures and 
2) analysing the evidence regarding the validity of a selection of the included measures.
METHODS
Study design and search strategy
A systematic review of the literature was performed, focusing on English-language 
articles published between January 2010 and January 2015. As recommended by 
Cochrane [23], we performed our search in multiple databases including EMBASE, 
Medline, SciSearch, BIOSIS Previews and GLOBAL Health. We developed a search 
strategy to identify articles matching a variation of the following search terms: 1) 
initiatives, design, measuring, indicators, instrument, identifying, index; 2) waste, 
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overuse, overutilization, misuse, low-value; and 3) health care, cure, care, prevention. 
Additional file 1 gives a detailed description of the search strategy.
Article selection
Two researchers (EFdV & RJPH) independently reviewed the relevance of the articles by 
screening titles and abstracts. As recommended by Cochrane [23], we included articles 
from peer-reviewed journals only. The full-text was retrieved when both researchers 
considered the paper relevant. Articles were eligible for review when they met the 
following predefined criteria: 1) the low-value service recommendation or measure in 
the paper matched the definition ‘services that provide no benefit to patients or may even 
cause harm [1, 2]; 2) the low-value service recommendation or measure was described 
using clinical details such as diagnosis, patient population and treatment. We removed 
duplicate articles and replies or commentaries and theoretical or discussion articles that 
did not present any low-value service recommendations or measures. Any disagreement 
between the reviewers was resolved by discussion and consensus.
Data extraction
We extracted general characteristics of the articles (i.e. name of first author, year of 
publication, country, aim of the paper, methods) and the measures (i.e. the name of the 
measure, the numerator, the denominator, exclusion criteria and direction). In addition, 
we retrieved the original source or reference of the measure.
Recommendations versus measures
The literature search yielded both recommendations and measures for low-value care. 
We considered a description of low-value care as ‘measure’ when at least a numerator and 
denominator were specified as such. We identified the scope of both recommendations 
and measures, while the quality assessment was performed for the measures only.
Categorizing low-value care recommendations and measures by function in 
health care
All recommendations and measures were categorized using the Classification of Health 
Care Functions (ICHA-HC) as defined by the Organization for Economic Co-operation 
and Development (OECD), the World Health Organization (WHO) and Eurostat [24]. 
The ICHA-HC provides a framework to classify services according to their purpose or 
function and is commonly used to compare medical services internationally. It covers the 
entire continuum of the health system, i.e. curative care, rehabilitative care, long-term 
care and preventive care. We subcategorized curative care into general (i.e. primary) 
care and specialized care. General care involves basic care such as routine examinations, 
2
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basic maternity care, routine diagnosis and follow-up, prescriptions and vaccinations 
(unless they are covered under a preventive program) [24]. Specialized care involves more 
complex technology and is often a breakdown from the basic fields (e.g. neurosurgery 
or allergology) [24]. In addition, the measures were categorized according to the non-
functional categories ancillary services (i.e. laboratory, imaging, transport), and medical 
goods (i.e. pharmaceutical and therapeutic appliances).
Assessing the quality of low-value care measures
We assessed the quality of the measures by 1) analysing their development process and 
the level of evidence underlying the measures, and 2) analyse the validity of a selection 
of the measures.
Development process and level of evidence
We distinguished two groups: A) articles that translated low-value service 
recommendations into low-value care measures, and B) articles that used measures 
previously developed by institutions. For both groups we reviewed how the measures 
were developed.
For group A, we searched for evidence underlying the recommendations. We categorized 
each measure based on the evidence, distinguishing three levels of evidence: 1) a 
combination of evidence from the literature (trial or review), guidelines and from CW, 
United States Preventive Services Task Force (USPSTF) or National Institute of Clinical 
Excellence (NICE) recommendations, 2) evidence from the literature (trial or review) or 
guidelines, and 3) evidence not found. As criteria for developing CW recommendations 
do not prescribe the level of evidence required [8] we labelled measures with CW, 
USPSTF or NICE evidence only, as ‘unknown’. We valued the first level highest, and 
the third level lowest.
For group B, we distinguished the same levels of evidence. However, here we specifically 
searched for elements of a quality label indicating the soundness of the measure. A 
National Quality Forum (NQF) endorsement corresponds with the qualification of 
‘minor or no evidence gaps’ [21]. Measures with such qualification have the strongest 
evidence base regarding importance, face validity, criterion validity, construct validity 
and risk adjustment [21]. Therefore, NQF endorsed measures were valued highest. The 
Agency of Healthcare Research and Quality (AHRQ ) and the Centers of Medicare 
and Medicaid Services’ (CMS) Quality provide information on the level of evidence 
by specifying the literature underpinning the measure. Therefore, measures from these 
sources were valued second best.
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For both groups, our assessment was limited to the evidence provided in the reviewed 
article and the first document retrieved by reference tracking.
Validity
We selected a subset of five unique measures in order to gain insight in the quality of the 
low value care measures. Ideally, we would extensively assess each measure regarding 
their validity. However, for 115 measures this was beyond the scope of this review. 
Therefore, we chose five unique measures that appeared most frequently in the reviewed 
articles, assuming more information on validity to be available for these measures. 
For these five measures, we searched for evidence regarding the measures’ validity 
by reviewing the original source and reference tracking. In addition, we performed 
a PubMed search using key words from the name of the measures (i.e. diagnosis and 
procedure) and “low-value” or “overuse”, augmented with “validity”. Specifically, we 
searched for studies that aimed to assess the validity of the selected low-value care 
measures. Hereby, we distinguished between the most commonly used types of validity 
(as seen in e.g. [21, 25, 26]): face validity, coding/criterion validity (i.e. reflect actual cases 
low-value care) and construct validity (i.e. supported by correlations to other measures 
indicating low-value care) [21]. Face validity refers to the empirical or clinical rationale 
of the measure, and therefore we used the information from Table 2 for this criterion.
RESULTS
Article retrieval
Our literature search yielded 292 potentially relevant articles (Figure 1). Based on titles 
and abstracts, 108 articles were selected for full-text retrieval and thorough screening. 
This screening process generated 23 articles that were eligible for review. Main reasons 
for exclusion were using a different definition of low-value care (n=138), for example 
articles on garbage, patient safety or drug abuse, or not providing clinical details (n=49). 
Figure 1 shows all reasons for exclusion.
Article characteristics
All articles were published after 2011 and the vast majority of the 23 included articles 
originated from the United States (n=22) (Table 1). Seven articles explicitly focused 
on low-value care measures. One of these reviewed the literature on low-value care 
measurement [19], and six were empirical studies measuring low-value care utilization 
[3, 9, 11, 12, 20, 27]. Low-value care recommendations were presented in 17 articles of 
which most were related to the CW campaign (n=12).
2
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Our search yielded 115 low-value care measures and 412 low-value care recommendations. 
Additional file 2 shows the characteristics of the 115 low-value care measures (i.e. 
containing a numerator and denominator). Out of these 115 measures, 42 contained 
exclusion criteria. For one of these measures (measure no. 72, Additional file 2), the 
direction of the measure was specified.
Figure 1: Flow chart summarizing article selection
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Low-value care recommendations and measures by function in health care
Figure 2 displays an overview of low-value care recommendations and measures 
categorized by health care function [24]. Here, we combined recommendations and 
measures covering the same combination of diagnosis and procedure. For instance, we 
found 8 measures for imaging in low back pain (measure no. 2-9, Additional file 2) using 
slightly varying exclusion criteria regarding e.g. age category (18-50 years versus 18-55 
years) or intervention (imaging in general versus specific MRI). These eight measures 
were combined into a single group. In this manner, we found that 115 measures and 101 
low-value care recommendations corresponded with 65 measure groups. The remaining 
recommendations (n=412-101=311) were aggregated into 241 new recommendation 
groups.
In the cure dimension we found 87 measures, which we further subdivided in general 
care (n=85) and specialized care (n=2). Most measures in the cure dimension were 
in imaging (n=50) or pharmaceutical goods (n=15). The remaining measures were 
categorized in long-term care (n=3) and secondary prevention (n=25).
Quality of low-value care measures
Development process
Approximately half of the measures (n=62) originated from low-value care 
recommendations (group A). Although the authors of the articles [3, 9, 12, 20, 27] 
described the methods to operationalize the low-value care measures, it was not 
specifically described how each specific low-value care recommendation was translated 
into a measure, i.e. how the denominator, numerator, exclusion and direction were 
determined for the purpose of the study. We did find that the measures developed 
by clinicians (n=18) [9, 20] used (a combination of) International Classification of 
Diseases (ICD-9) and/or current procedural terminology (CPT) codes to construct the 
denominator [2, 9, 20, 27]. The other half of the measures (n=54) were developed by 
institutions (group B), including the NQF (n=25) [9, 19, 20], the AHRQ (n=10) [19, 
20, 27], CMS QualityNet (n=16) [11, 19, 20] and Blue Cross Blue Shield (n=2) [20].
Level of evidence
Table 2 shows the level of evidence provided in the referenced sources for each measure. 
In group A, the recommendations were mainly derived from CW, USPSTF, and NICE 
(n=45). Other group A measures originated from guidelines, peer-reviewed literature 
or sources that summarized low-value services [43].
2
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Three measures (measure no. 39, 40, 46; Additional file 2) were assigned the highest level 
of evidence (1), as they were underpinned by guidelines and literature (trial or review) and 
recommendations. For most measures (n=33), however, we found guideline or literature 
evidence solely. For one measure (measure no. 101) the USPSTF considered the evidence 
for the underlying recommendation insufficient to assess the benefits and harms of the 
procedure, which we therefore assigned with the lowest level of evidence. At the time of 
our review, for 24 measures, we considered the level of evidence to be unknown. In group 
B, we found 19 measures [9, 19] supported by a quality label (NQF). For six measures 
the NQF endorsement was removed (n=4) or not found (n=2). Although the AHRQ 
website provides detailed information on the measures, we found no quality label, such 
as the NQF endorsement. We found seven measures (measure no. 1, 4, 55, 60, 69, 70, 
86) displaying measurement characteristics (e.g. domain (process/outcome), description 
of denominator and numerator and target population) and evidence supporting the 
measure. The measures derived from QualityNet [44] were described in detail, however, 
no evidence supporting the description was provided.
Validity
Table 3 shows the validity of the five measures that were found most frequently (n=26). 
Two measures had the highest level of evidence. Our search yielded no information on 
coding/criterion validity and construct validity for the included measures, while four 
out of five measures are currently used in practice.
DISCUSSION
To the best of our knowledge, this is the first systematic literature review identifying, 
categorizing and assessing the scope and quality of low-value care measures. We obtained 
115 low-value care measures from the literature. Out of these 115 measures, 87 focused 
on the cure sector (primary and specialized care), 25 on secondary prevention and 3 on 
long-term care. Most measures (n=62) originated from low-value care recommendations, 
while 53 were previously developed by institutions as the National Quality Forum. Three 
measures were assigned the highest level of evidence, as they were underpinned by both 
guidelines and literature evidence. For other measures, such a level of evidence was not 
transparently apparent. We do not conclude that these measures are invalid, because 
validity tests may not have been performed at all. Nevertheless, a lack of evidence is 
present at least. Our search yielded no information on coding/criterion validity and 
construct validity for the included subset of measures in this emerging field. Despite 
this, most measures are currently used in practice.
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Low-value care measures have received increased attention and are now used for 
monitoring purposes, alignment of financial incentives [14, 47] and, in the foreseeable 
future, in shared saving programs such as the Alternative Quality Contract (AQC) [48]. 
In this manner, low-value care measurement may incentivize providers and insurers to 
shift resources from low-value services to high-value services [49]. Our findings show 
that more attention is needed for the evidential underpinning and quality of these 
measures. Otherwise, the lack of transparency and evidence will reduce acceptance of 
low-value care measures by its users. Additionally, using measures of low quality, might 
lead to negative consequences including underuse of indicated services, cost-shifting, 
damages to the patient-physician relationship, provider dissatisfaction, adverse health 
effects, or patient selection [18].
Our review showed that more than half of the low-value care measures originated 
from low-value service recommendations (i.e. CW, NICE, USPSTF). This implies 
that the empirical evidence of many low-value care measures is based on the evidence 
supporting the underlying low-value service recommendations. However, criteria for the 
development of recommendation lists remains rather vague in the CW initiative, as well 
as in other similar campaigns [8]. Therefore, more transparency regarding the evidential 
underpinning of the recommendations is needed. Next to the importance of evidence 
underlying both low-value service recommendations and measures, one should be aware 
that the aim of low-value service recommendations differs from the aim of low-value 
care measures. The aim of CW recommendations is patient and physician awareness, 
while the aim of low-value care measures in turn may be to inform decisions on several 
levels. Consequently, requirements for the quality and development of recommendations 
and measures approaches vary accordingly.
We found that most current low-value care measures are concentrated in the cure 
sector even though it was argued that low-value services are provided and used along 
the entire continuum of care [22]. For example, we only found four low-value care 
recommendations (that could possibly be transformed into low-value care measures) in 
rehabilitative care and none in the health promotion domain. This is probably the result 
of most measures originating from the CW initiative, which has its origin in the cure 
sector. While we acknowledge the emerging state of the field of research, we emphasize 
that similar consensus-based efforts are needed to stimulate the development of measures 
in other settings to broaden the scope and impact of the low-value care concept.
Given the potential impact of using low-value care measures, it is essential that guidelines 
for developing them be created by combined efforts of the involved parties: physicians, 
2
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citizens, government and insurers [18, 50]. We do not suggest creating an evidence 
base for each health care intervention demonstrating all circumstances in which it is not 
effective. This will prove an undoable exercise. Expert judgement by the clinician will 
always remain necessary to some degree. Therefore, other types of information, e.g. 
from studies on practice variation in procedure rates or cost-effectiveness studies, will 
remain necessary to identify inefficiencies in healthcare, especially when high quality 
low-value care measures are not available. We do propose using expert opinion from 
initiatives such as Choosing Wisely as a starting point for monitoring low-value care. 
These qualitative information sources can be complemented with new scientific insights. 
For example, the insight that certain genes predict the development of breast cancer, 
must be used to prevent a considerable amount of low-value care utilization. Still, as 
soon as we start measuring and monitoring low-value care in such areas, it will be of 
particular interest to fully specify and define all measurement information, such as 
exclusion criteria, direction and evidence supporting the measure, and to make this 
publicly available. Furthermore, low-value care measures should be extensively tested 
regarding their level of evidence and validity before implementing them for use in 
practice, and specifically for the measures that are already in use. Recently, articles 
started studying aspects that are closely related to validity. As for example, Schwartz et 
al. [3] who found that the sensitivity and specificity strongly depends on the definition of 
the measures. Notwithstanding the efforts already been made, we stress the importance 
of the validity of the measures specifically being studied. Another area of research 
would be to further standardize low-value care measures, which ideally would result in 
alignment of the low-value care metrics and determining specifically for what subgroup 
or population a service is of low-value [3, 51]. Moreover, the guidelines should take into 
account any differences between countries in terms of the availability and provision of 
healthcare services that are likely to occur due to cultural or economic differences.
Another important issue to pay further attention to is the data requirements. Measuring 
low-value care utilization requires information on services provided to patients in 
combination with diagnosis and possibly additional patient characteristics. It is not 
clear to which extent current data sources can provide this information [3, 4], since rather 
detailed data need to be registered and data sources, such as claims data and detailed 
(hospital) registration data need to be connected in order to retrieve the necessary 
information.
Limitations
Our study has two main limitations. First, we did not evaluate the quality of each 
individual measure. Ideally, we would extensively assess each measure regarding their 
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validity. To perform this task for 115 measures was, however, beyond the scope of this 
review. Nonetheless, we performed a first attempt in assessing the validity for the five 
measures that appeared most often in the literature and highlight several important 
general quality issues. Second, we did not include grey literature in our search. Therefore, 
we may have missed relevant measures. Nevertheless, for the purpose of our review, 
namely to systematically map the state of affairs of low-value care measurement, we are 
confident that the publications we did use provided sufficient evidence.
Conclusions
To conclude, our systematic review provides insight in the current state of low-value 
care measures. It shows that current low-value care measures only cover a selective 
part of the health care system. To achieve their full potential, future research should 
be focused on generating clear information about the level of evidence and validity to 
identify measures that truly represent low-value care in this emerging field of research. 
This will contribute to creating and maintaining the support of stakeholders who will 
use these measures for monitoring purposes and innovative insurer-provider contracts, 
all aiming to improve efficiency in health care with better health outcomes.
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ADDITIONAL FILES
A1. Search strategy




1 *health services/ or *adolescent health services/ or *community health services/ or *child 
health services/ or *community health nursing/ or *community mental health services/ or 
*community pharmacy services/ or *community health centers/ or *home care services/ or 
*maternal health services/ or *occupational health services/ or *preventive health services/ 
or *preventive medicine/ or *dental health services/ or *emergency medical services/ or 
*emergency service, hospital/ or *hospitals/ or *health services for the aged/ or *mental 
health services/ or *nursing services/ or *personal health services/ or *pharmaceutical 
services/ or *rehabilitation/ or *reproductive health services/ or *rural health services/ 
or *suburban health services/ or *women’s health services/ or *mass screening/ (295687)
2 *primary health care/ or *general practice/ or *family practice/ or *physicians, family/ 
or *professional practice/ or *physicians practice patterns/ or *comprehensive health 
care/ or *managed care programs/ or *delivery of health care/ or *delivery of health care, 
integrated/ or *patient care management/ or *nursing process/ or *nursing/ or *nurse 
practitioners/ or *telemedicine/ or *health services administration/ or *health services 
research/ or *translational medical research/ or *health facility administration/ or *health 
facilities/ or *health maintenance organizations/ or *health planning/ or *regional 
health planning/ or *community health planning/ or *regional medical programs/ or 
*health policy/ or *national health programs/ or *social work/ or *social welfare/ or 
*child welfare/ or *infant welfare/ or *maternal welfare/ or *government regulation/ or 
*government programs/ or *multi-institutional systems/ (344106)
3 (health system* or healthcare or health service* or care or (health and services) or 
health planning or health policy or health reform or welfare or preventive service* or 
screening).ti. (523842)
4 (family practic* or family physician* or general practi* or “gps” or “gp’s” or nurse 
practitioners or community health center* or community health centre* or municipal 
health center* or municipal health centre* or health center* or health centre*).ti. (47193)
5 “quality of health care”/ or “quality indicators, health care”/ or health care costs/ 
(93908)
6 1 or 2 or 3 or 4 or 5 (1008916)
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7 ((identif* or indicator* or correlat* or pattern* or predictor* or measur* or assess* or 
examin* or classify* or categoriz* or characterization or quantif * or variation*) adj5 
(low value or “no value” or overuse or overutilization or overused or misuse or disuse or 
(wasteful adj3 “use”) or (wasteful adj3 services))).tw. (1541)
8 ((estimat* or evaluat* or distinguishing or labe?ling or compar* or potential* or factors 
or prevalence or rate* or degree or evidence or understanding) adj5 (low value or “no 
value” or overuse or overutilization or overused or misuse or disuse or (wasteful adj3 
“use”) or (wasteful adj3 services))).tw. (2408)
9 ((identif * or indicator* or correlate* or pattern* or predictor* or measur* or assess* 
or examin* or classify* or categoriz* or characterization or quantif * or variation*) 
adj5 ((unsafe adj3 practice*) or (ineffective adj3 practice*) or (ineffective adj3 care) or 
(ineffective adj3 healthcare) or (inappropriat* adj3 practice*) or (inappropriat* adj3 “use”) 
or (harmful adj3 practice*))).tw. (490)
10 ((estimat* or evaluat* or distinguishing or labe?ling or compar* or potential* or factors 
or prevalence or rate* or degree or evidence or understanding) adj5 ((unsafe adj3 practice*) 
or (ineffective adj3 practice*) or (ineffective adj3 care) or (ineffective adj3 healthcare) or 
(inappropriat* adj3 practice*) or (inappropriat* adj3 “use”) or (harmful adj3 practice*))).
tw. (810)
11 ((identif* or indicator* or correlate* or pattern* or predictor* or measur* or assess* 
or examin* or classify* or categoriz* or characterization or quantif* or variation) adj5 
waste).tw. (2127)
12 ((estimat* or evaluat* or distinguishing or labe?ling or compar* or potential* or factors 
or prevalence or rate or degree or evidence or understanding) adj5 waste).tw. (2833)
13 ((index or instrument) and (low value or “no value” or overuse or overutilization or 
overused or misuse or disuse or (wasteful adj3 “use”) or (wasteful adj3 services))).ti. (21)
14 (“choosing wisely” or “do not do recommendations”).tw. (134)
15 6 and (7 or 8 or 9 or 10 or 11 or 12 or 13 or 14) (1126)
16 prescription drug misuse/ or (prescription misuse or substance misuse or drug misuse 
or alcohol or hazardous drinking or substance).ti. (100941)
17 (hospital waste or medical waste or biomedical waste or bio-medical waste or 
healthcare waste or health-care waste or care waste or genotoxic waste or plate waste 
or waste anesthetic gases or infectious waste or pharmaceutical waste or solid waste or 
liquid waste or aeration or waste disposal or waste treatment or electronic waste or waste 
waster* or waste materials or aeration).ti. (4893)
18 15 not (16 or 17) (927)
19 (practice* or low value or value or “no value” or overuse or misuse or overutilization 
or overused or inappropr* or ineffective or unsafe or “use” or waste).ti. or (“choosing 
wisely” or “do not do recommendations”).tw. (664168)
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20 18 and 19 (487)
21 20 and english.lg. (452)
22 limit 21 to yr=2010-2015 (227)
23 22 not (letter or comment or news).pt. (205)
24 remove duplicates from 23 (201)
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Alternative - - Elshaug Acupuncture for Bell’s palsy
Alternative - - Elshaug Acupuncture for depression
Alternative - - Elshaug Acupuncture for induction of labor
Alternative - - Elshaug Acupuncture for irritable bowel syndrome 
(IBS)
Alternative - - Elshaug Acupuncture for lower urinary tract 
symptoms (LUTS) in men
Alternative - - Elshaug Acupuncture for peripheral joint 
osteoarthritis
Alternative - - Elshaug Acupuncture for the management of otitis 
media with effusion (OME)
Alternative - - Elshaug Acupuncture for uterine fibroids
Alternative - - Elshaug Acupuncture to treat hyperbilirubinemia
Alternative - - Elshaug Acupuncture, acupressure and hypnosis for 
women in labour
Alternative - - Elshaug Laser acupuncture for carpal tunnel 
syndrome
Cure Dental - Elshaug Emergency pulpectomy
Cure Dental - Elshaug Porcelain dental crowns
Cure Dental - Elshaug Occlusal adjustment for temporomandibular 
joint dysfunction
Cure General - Chan More than one ED visit in the last 30 days 
of life.
Cure General - Chan Routine labor induction
Cure General - Chan Referring OME early in the course of the 
problem.
Cure General - Chan Potentially preventable ED visits.
Cure General - Chan Routine epidural analgesia.
Cure General - Chan Routine fetal movement counting.
Cure General - Chan Routine vaginal examination to assess 
gestational age, predict preterm birth, or 
estimate tight passage during birth.
Cure General - Chan Rupturing membranes (amniotomy) after 
the start of spontaneous labor whether labor 
is progressing well or prolonged.
Cure General - Elshaug Caesarean section without medical 
indication
Cure General - Elshaug Vertebroplasty for painful osteoporotic 
vertebral factures
Cure General - Elshaug Open surgery for carotid occlusive disease
Cure General - Elshaug Vena Caval Filters for the prevention of 
pulmonary embolism
541371-L-bw-deVries
Processed on: 24-2-2020 PDF page: 105
ICHA-HC First author Low-value care recommendation
Cure General - Elshaug Endovascular repair of infrarenal abdominal 
aortic aneurysms
Cure General - Elshaug Routine episiotomy associated with 
spontaneous vaginal birth
Cure General - Elshaug Routine episiotomy associated with vaginal 
birth following previous third- or fourth 
degree trauma
Cure General - Elshaug Routine dilation and curettage for missed 
abortion
Cure General - Elshaug Dilatation and curettage as a diagnostic tool 
OR therapeutic treatment
Cure General - Elshaug Amnioinfusion for the treatment of women 
with meconiumstained liquor
Cure General - Elshaug Chest physiotherapy as an adjunctive 
treatment for adults with pneumonia
Cure General - Elshaug Hospitalization for bed rest in multiple 
pregnancy
Cure General - Elshaug Neonatal circumcision
Cure General - Elshaug Urinary flow-rate measurement in men with 
lower urinary tract symptoms (LUTS).
Cure General - Hicks Do not use inferior vena cava filters 
routinely in patients with acute venous 
thromboembolism
Cure General - Keyhani Carotid endarterectomy for all indications
Cure General - Korenstein Carotid endarterectomy for carotid stenosis
Cure General - Korenstein IVC filter
Cure General - Korenstein Chiropractic for low back pain
Cure General - Korenstein Nasopharyngeal washings
Cure General Imaging Chan Imaging studies in patients with nonspecific 
low back pain and no red flags.
Cure General Imaging Chan Performing an imaging stress test as the 
initial diagnostic test in patients with 
known or suspected CAD who are able 
to exercise and have no resting ECG 
abnormalities that may interfere with 
interpretation of test results.
Cure General Imaging Chan Coronary angiography in patients with 
chronic stable angina with well-controlled 
symptoms on medical therapy or who lack 
specific high-risk criteria on exercise testing.
Cure General Imaging Chan Obtaining diagnostic images for minor head 
injuries without loss of consciousness or 
other risk factors.
Cure General Imaging Chan Imaging for uncomplicated head ache.
Cure General Imaging Chan Imaging studies in patients with recurrent, 
classic migraine headache and normal 
findings on neurological examination.
2
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Cure General Imaging Chan Repeat CT scans in patients with functional 
abdominal pain syndrome if no major 
changes in clinical findings or symptoms.
Cure General Imaging Chan Sinus imaging for patients with acute 
rhinosinusitis in absence of predisposing 
factors for atypical microbial causes.
Cure General Imaging Chan CT or MRI to evaluate simple syncope in 
patients with normal findings on neurologic 
examination.
Cure General Imaging Chan Routinely performing ECHO in the 
evaluation of syncope, unless the history, 
physical examination, and ECG do not 
provide a diagnosis or underlying heart 
disease is suspected.
Cure General Imaging Chan Pre-op chest radiography in the absence 
of a clinical suspicion for intrathoracic 
pathology.
Cure General Imaging Chan Performing radionuclide imaging as part of 
routine follow-up in asymptomatic patients.
Cure General Imaging Chan Routine periodic ECHO in asymptomatic 
patients with mild aortic stenosis for more 
frequently than every 3-5 years.
Cure General Imaging Chan Routinely repeat ECHO in asymptomatic 
patients with mild mitral regurgitation and 
normal left ventricular size and function.
Cure General Imaging Chan Performing ECHO in asymptomatic 
patients with innocent-sounding heart 
murmurs.
Cure General Imaging Chan Electronical fetal monitoring during labor 
without access to fetal scalp sampling or 
continuous electronic fetal monitoring.
Cure General Imaging Chan Follow-up imaging for clinically 
inconsequential adnexal cysts.
Cure General Imaging Chan Home uterine activity monitoring to 
prevent preterm birth.
Cure General Imaging Chan Routine ultrasound after 24 weeks.
Cure General Imaging Chan Routine ultrasound to estimate fetal size if 
large baby is suspected.
Cure General Imaging Elshaug Imaging in cases of low back pain*
Cure General Imaging Elshaug Exercise electrocardiogram (ECG) for 
angina
Cure General Imaging Elshaug Plan x-rays of the skull for diagnosing 
significant brain injury
Cure General Imaging Elshaug Routine monitoring of bone mineral density 
after starting bisphosphonate treatment
Cure General Imaging Elshaug Cardiac stress testing on low risk patients 
before major surgery
Cure General Imaging Elshaug Preoperative chest x-ray
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Cure General Imaging Elshaug Cardiotocography for antepartum fetal 
assessment / antenatal cardiotocography for 
fetal assessment
Cure General Imaging Elshaug The routine anomaly scan (at 18 weeks 
0 days to 20 weeks 6 days) for Down’s 
syndrome screening using soft markers
Cure General Imaging Korenstein Imaging for low back pain
Cure General Imaging Korenstein PT for low back pain
Cure General Imaging Korenstein Preoperative pulmonary function testing
Cure General Imaging Onuoha Preoperative baseline diagnostic cardiac 
testing (TTE or TEE) or cardiac stress test 
in asymptomatic stable patients with known 
cardiac disease (e.g. CAD, vulvular disease) 
undergoing low-risk or moderate-risk non-
cardiac surgery
Cure General Imaging Schuur Do not order magnetic resonance imaging 
of the lumbar spine for patients with lower 
back pain without high-risk features.
Cure General Imaging Schuur Do not order CT of the head for patients 
with mild traumatic head injury who do not 
meet New Orleans Criteria or Canadian CT 
Head Rule.
Cure General Imaging Schuur Do not order CT to diagnose pulmonary 
embolism without first risk stratifying for 
pulmonary embolism (pretest probability 
and D-dimer tests if low probability).
Cure General Imaging Wood Patients Who Have No Cardiac History 
and Good Functional Status Do Not 
Require Preoperative Stress Testing Before 
Non-cardiac Thoracic Surgery
Cure General Imaging Wood Before Cardiac Surgery There Is No Need 
for Pulmonary Function Testing in the 
Absence of Respiratory Symptoms
Cure General Lab Bulger Do not perform repetitive complete blood 
count (CBC) and chemistry testing in the 
face of clinical and lab stability.
Cure General Lab Chan Routine chlamydia screening.
Cure General Lab Chan Routine hepatitis C screening.
Cure General Lab Chan Annual lipid screening for patients without 
lipid-lowering drug, diet therapy, or reasons 
for changing lipid profiles.
Cure General Lab Chan Broad spectrum testing rather than focus on 
likely source.
Cure General Lab Chan Repeat blood tests - creatinine within 10 
days.
Cure General Lab Chan Repeat blood tests - ferritin within 6 weeks.
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Cure General Lab Chan Repeat blood tests - hemoglobin A1c within 
12 weeks
Cure General Lab Chan Repeat blood tests - hemoglobin within 
10 days.
Cure General Lab Chan Repeat blood tests - liver function tests 
(ALT/AST) within 6 weeks.
Cure General Lab Chan Repeat blood tests - sodium within 10 days.
Cure General Lab Chan Repeat blood tests - Thyroid stimulating 
hormone within 6 weeks.
Cure General Lab Chan Repeat blood tests - total cholesterol within 
6 weeks.
Cure General Lab Chan Routine bacterial vaginosis screening.
Cure General Lab Chan Routine preterm labor screening.
Cure General Lab Chan Routine toxoplasmosis screening.
Cure General Lab Chan Serologic testing for Lyme disease in 
patients with chronic nonspecific symptoms 
and no clinical evidence of disseminated 
Lyme disease.
Cure General Lab Chan Serologic testing for suspected early Lyme 
disease.
Cure General Lab Chan Unnecessary laboratory tests, targeting 
panels (e.g. thyroid, SMA 20).
Cure General Lab Chan Unnecessary laboratory tests, targeting 
special testing (e.g. Lyme disease with 
regional considerations).
Cure General Lab Elshaug Measurement of parathyroid hormone 
(PTH) levels in people with stage 1, 2, 3A 
or 3B chronic kidney disease (CKD)
Cure General Lab Elshaug Chlamydia screening in routine antenatal 
care
Cure General Lab Elshaug Screening for hepatitis C virus in pregnant 
women
Cure General Lab Elshaug Biochemical tests of placental function for 
assessment in pregnancy
Cure General Lab Elshaug Blood biochemical testing in children with 
dehydration
Cure General Lab Elshaug C-reactive protein tests
Cure General Lab Elshaug Factor V Leiden, thrombophilia genetic 
mutations
Cure General Lab Elshaug Female hormone testing in women with 
heavy menstrual bleeding (HMB)
Cure General Lab Elshaug Fetal blood sample (FBS) with evidence of 
acute fetal compromise
Cure General Lab Elshaug Genetic testing of fragile X syndrome - 
population screen
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Cure General Lab Elshaug Human leukocyte antigen (HLA) DQ2/
DQ8 testing in the initial diagnosis of 
coeliac disease
Cure General Lab Elshaug Immunoglobulin G / A (IgG/IgA) 
anti-gliadin antibody (AGA) test in the 
diagnosis of coeliac disease.
Cure General Lab Elshaug Liver function tests - Statin therapy
Cure General Lab Elshaug Measurement of calcium levels in people 
with stage 1, 2, 3A or 3B chronic kidney 
disease (CKD)
Cure General Lab Elshaug Measurement of phosphate levels in people 
with stage 1, 2, 3A or 3B chronic kidney 
disease (CKD)
Cure General Lab Elshaug Microscopy for testing for the presence of 
hematuria
Cure General Lab Elshaug Nucleic acid amplification tests for 
diagnosis of Neisseria gonorrhea and 
Chlamydia trachomatis rectal infections
Cure General Lab Elshaug Preimplantation genetic screening for 
aneuploidy
Cure General Lab Elshaug Rectal biopsy in suspected Hirschsprungs 
disease
Cure General Lab Elshaug Routine blood tests in children with fever
Cure General Lab Elshaug Routine screening for preterm labour
Cure General Lab Elshaug Screening for gestational diabetes using 
fasting plasma glucose, random blood 
glucose, glucose challenge test and 
urinalysis for glucose.
Cure General Lab Elshaug Serum cholesterol concentrations in 
pregnancy
Cure General Lab Elshaug Serum ferritin tests in adults (in patients 
with chronic fatigue syndrome)
Cure General Lab Elshaug Serum ferritin tests in women with heavy 
menstrual bleeding
Cure General Lab Elshaug Testing for diarrhea in children
Cure General Lab Elshaug Tests for folate levels in patients with 
chronic fatigue syndrome
Cure General Lab Elshaug Tests for vitamin B12 deficiency in patients 
with chronic fatigue syndrome
Cure General Lab Elshaug Troponin levels in acute pulmonary 
embolism patients
Cure General Lab Elshaug Umbilical cord blood direct antiglobulin 
test (DAT) (Coombs’ test) to predict 
significant hyperbilirubinemia
Cure General Lab Elshaug Urinary protein measurement in pregnant 
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Cure General Lab Elshaug Urine testing in infants and children for 
urinary tract infection (UTI)
Cure General Lab Elshaug Vertebral biopsy
Cure General Lab Rouster-
Stevens
Do not test for Lyme disease as a cause 
of musculoskeletal symptoms without 
an exposure history and appropriate 
examination findings.
Cure General Lab Schuur Do not order coagulation studies for 
patients without hemorrhage or suspected 
coagulopathy (e.g., with anticoagulation 
therapy, clinical coagulopathy).




Don’t use antimicrobials to treat bacteriuria 
in older adults unless specific urinary tract 
symptoms are present.
Cure General Pharmaceuticals Bulger Do not prescribe medications for stress ulcer 
prophylaxis to medical inpatients unless at 
high risk for GI complications.
Cure General Pharmaceuticals Chan Routinely prescribe antibiotics for acute 
mild to moderate sinusitis unless symptoms 
last for 7 or more days OR symptoms 
worsen after initial clinical improvement.
Cure General Pharmaceuticals Chan Using non-generic statins when initiating 
lipid-lowering drug therapy.
Cure General Pharmaceuticals Chan Use of brand over generic Rx for bronchitis, 
hyperlipidemia, hypo-functioning thyroid 
gland, ischemic heart disease.
Cure General Pharmaceuticals Chan Diethylstilbestrol to prevent miscarriage.
Cure General Pharmaceuticals Chan Fenfluramine plus phentermine to treat 
obesity.
Cure General Pharmaceuticals Chan Long-term acid suppression therapy (proton 
pump inhibitors or histamine-2 receptor 
antagonists) should be titrated to the lowest 
effective dose needed to achieve therapeutic 
goals.
Cure General Pharmaceuticals Chan Routine iron supplementation.
Cure General Pharmaceuticals Chan SSRIs in patients with migraine or tension-
type headaches..
Cure General Pharmaceuticals Chan Thalidomide for sedation in pregnant 
women.
Cure General Pharmaceuticals Chan Triparanol (MER-29) for cholesterol 
reduction.
Cure General Pharmaceuticals Chan NSAIDS in individuals with HTN or heart 
failure or CKD of all causes, including 
diabetes.
Cure General Pharmaceuticals Keyhani Antibiotics for acute respiratory tract 
infections
Cure General Pharmaceuticals Keyhani Antibiotics for URI use of diagnostic tests
Cure General Pharmaceuticals Korenstein Antibiotics for URI, acute bronchitis
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Cure General Pharmaceuticals Korenstein Acid blockers
Cure General Pharmaceuticals Korenstein Bronchodilators for bronchiolitis 
obstructive diseases
Cure General Pharmaceuticals Quinonez Do not use bronchodilators in children with 
bronchiolitis.
Cure General Pharmaceuticals Quinonez Do not use systemic corticosteroids in 
children under 2 years of age with a lower 
respiratory tract infection.
Cure General Pharmaceuticals Quinonez Do not treat gastroesophageal reflux in 
infants routinely with acid suppression 
therapy.
Cure General Pharmaceuticals Wiener Do not routinely offer pharmacologic 
treatment with advanced vasoactive agents 
approved only for the management of 
pulmonary arterial hypertension to patients 
with PH resulting from left heart disease 
or hypoxemic lung diseases (group II or 
III PH).
Cure General Pharmaceuticals Williams Avoid nonsteroidal anti-inflammatory 
drugs (NSAIDS) in individuals with 
hypertension, heart failure, or CKD of all 
causes, including diabetes.
Cure Specialized - Bulger Avoid transfusions of red blood cells 
for arbitrary hemoglobin or hematocrit 
thresholds and in the absence of symptoms 
or active coronary disease, heart failure, or 
stroke.
Cure Specialized - Bulger Do not place, or leave in place, urinary 
catheters for incontinence or convenience 
or monitoring of output for non–critically 
ill patients (acceptable indications: 
critical illness, obstruction, hospice, 
peri-operatively for <2 days for urologic 
procedures; use weights instead to monitor 
diuresis).
Cure Specialized - Chan Chemotherapy in the last 14 days of life.
Cure Specialized - Chan Cancer-directed therapy for solid tumor 
patients with the following characteristics: 
low performance status (3 or 4), no benefit 
from prior evidence-based interventions, 
not eligible for a clinical trial, and no strong 
evidence supporting the clinical value of 
further anticancer treatment.
Cure Specialized - Chan Traction to treat low back pain.
Cure Specialized - Chan Administering ESAs to CKD patients 
with hemoglobin levels ≥ 10 g/dL without 
symptoms of anemia.
Cure Specialized - Chan Aggressive interventional procedures.
Cure Specialized - Chan Autologous bone marrow transplant with 
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Cure Specialized - Chan Extracranial-intracranial bypass to reduce 
the risk of ischemic stroke.
Cure Specialized - Chan Gastric bubble for morbid obesity.
Cure Specialized - Chan Gastric freezing for peptic ulcer disease.
Cure Specialized - Chan Mammary artery ligation for CAD
Cure Specialized - Chan Optic nerve decompression surgery for 
NAION.
Cure Specialized - Chan Potentially preventable hospital admissions 
lasting < 24 hours.
Cure Specialized - Chan Radiation therapy for acne
Cure Specialized - Chan Recommending replacement immunoglobin 
therapy for recurrent infections unless 
impaired antibody responses to vaccines are 
demonstrated.
Cure Specialized - Chan Spinal manipulation for treatikng migraine 
or cluster headaches.
Cure Specialized - Chan Subcutaneous interferon alfa-2a to treat 
age-related macular degeneration.
Cure Specialized - Chan Supplemental oxygen for healthy premature 
babies.
Cure Specialized - Chan Unwarranted procedures, targeting knee/
hip replacement.
Cure Specialized - Chan White cell stimulating factors for primary 
prevention of febrile neutropenia for 
patients < 20% risk for this complication.
Cure Specialized - Elshaug Hysterectomy as a first-line treatment solely 
for heavy menstrual bleeding
Cure Specialized - Elshaug Surgical approach to hysterectomy for 
benign gynecological disease, abdominal 
hysterectomy (AH), vaginal hysterectomy 
(VH) and laparoscopic hysterectomy (LH)
Cure Specialized - Elshaug Radical prostatectomy
Cure Specialized - Elshaug Radical prostatectomy and external beam 
radiation therapy
Cure Specialized - Elshaug Upper airway surgery for obstructive sleep 
apnea syndrome
Cure Specialized - Elshaug Radiotherapy for patients with metastatic 
spinal cord disease
Cure Specialized - Elshaug Radiotherapy with the intention of 
preventing metastatic spinal cord 
compression (MSCC) in patients with 
asymptomatic spinal metastases.
Cure Specialized - Elshaug Spinal surgery with the intention 
of preventing metastatic spinal cord 
compression (MSCC)
Cure Specialized - Elshaug Prostatectomy for early stage prostate cancer
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Cure Specialized - Elshaug Active surveillance for men with high-risk 
localized prostate cancer (active surveillance 
includes PSA testing and prostate biopsy)
Cure Specialized - Elshaug Surgery for obstructive sleep apnea
Cure Specialized - Elshaug Radiotherapy for patients with metastatic 
spinal cord compression (MSCC) and 
planned surgery
Cure Specialized - Elshaug Posterior decompression alone in patients 
with metastatic spinal cord compression 
(MSCC).
Cure Specialized - Elshaug Adjuvant radiotherapy with surgery for 
endometrial cancer
Cure Specialized - Elshaug Anal fistula surgery in patients with 
inflammatory bowel disease
Cure Specialized - Elshaug Complementary therapies for 
chronic fatigue syndrome/myalgic 
encephalomyelitis.
Cure Specialized - Elshaug Conventional photon irradiation in 
treatment of chordoma
Cure Specialized - Elshaug Coronary stenting (angioplasty) for stable 
angina and in diabetic patients with multi-
vessel disease
Cure Specialized - Elshaug Diagnosis of primary tumor site in 
metastatic cancer
Cure Specialized - Elshaug Dicectomy
Cure Specialized - Elshaug External fixation versus conservative 
treatment for distal radial fractures in adults
Cure Specialized - Elshaug Extracorporeal shock wave lithotripsy 
(ESWL) versus percutaneous 
nephrolithotomy (PCNL) or retrograde 
intrarenal surgery (RIRS) for kidney stones
Cure Specialized - Elshaug Extrapleural pneumonectomy for 
mesothelioma
Cure Specialized - Elshaug Femoral central vein catherization
Cure Specialized - Elshaug Hypothermia for traumatic head injury
Cure Specialized - Elshaug Implantable cardioverter defibrillators
Cure Specialized - Elshaug Interventions for treating acute Achilles 
tendon ruptures
Cure Specialized - Elshaug Intracavity lavage to reduce the risk of 
surgical site infection
Cure Specialized - Elshaug IVU for urothelial tumors
Cure Specialized - Elshaug Laparoscopic vs open colposuspension for 
urinary incontinence in women
Cure Specialized - Elshaug Medial pinning of supracondylar humeral 
fractures
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Cure Specialized - Elshaug Neurosurgical clipping for patients with 
aneurysmal subarachnoid hemorrhage
Cure Specialized - Elshaug Off-pump heart bypass
Cure Specialized - Elshaug Open total mesorectal excision for rectal 
cancer
Cure Specialized - Elshaug Pelvic lymphadenectomy for the 
management of endometrial cancer
Cure Specialized - Elshaug Postoperative radiotherapy for non-small 
cell lung cancer
Cure Specialized - Elshaug Prophylactic surgical litigation of patent 
ductus arteriosus for prevention of mortality 
and morbidity in extremely low birth weight 
infants
Cure Specialized - Elshaug Radiofrequency facet joint denervation
Cure Specialized - Elshaug Radiotherapy following mastectomy to 
patients with early invasive breast cancer at 
low risk of local recurrence
Cure Specialized - Elshaug Radiotherpay for neovascular age-related 
macular degeneration
Cure Specialized - Elshaug Removal of adenoids
Cure Specialized - Elshaug Rhinomanometry and acoustic rhinometry
Cure Specialized - Elshaug Rubber band ligation versus excisional 
haemorrhoidectomy for haemorrhoids
Cure Specialized - Elshaug Scalpel versus no-scalpel incision for 
vasectomy
Cure Specialized - Elshaug Sentinel lymph node biopsy (SLNB) in 
patients with a preoperative diagnosis of 
ductal carcinoma in situ (DCIS).
Cure Specialized - Elshaug Standard central venous catheters
Cure Specialized - Elshaug Stem Cell transplantation for AML
Cure Specialized - Elshaug Suprapubic urinary catheter
Cure Specialized - Elshaug Temporary defunctioning stoma in people 
undergoing anal sphincter repair
Cure Specialized - Elshaug Tension free repair for asymptomatic 
inguinal hernia
Cure Specialized - Elshaug Total fundoplication for gastroesophageal 
reflux disease
Cure Specialized - Elshaug Transit studies to diagnose idiopathic 
constipation
Cure Specialized - Elshaug Transurethral resection of the prostate for 
symptomatic benign prostatic obstruction
Cure Specialized - Elshaug Tube thoracostomy (TT) in thoracic surgery 
clinics
Cure Specialized - Elshaug Ultrasound-guided internal jugular (USIJ) 
versus the subclavian (SC) vein approach for 
central venous cannulation (CVC)
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Cure Specialized - Elshaug UVB therapy for vitiligo
Cure Specialized - Elshaug Whole brain radiotherapy for the treatment 
of multiple brain metastases
Cure Specialized - Halpern Don’t transfuse red blood cells in 
hemodynamically stable, non-bleeding 
ICU-patients with a hemoglobin 
concentration greater than 7 mg/dL.
Cure Specialized - Halpern Don’t use parenteral nutrition in adequately 
nourished critically ill patients within the 
first seven days of an ICU stay.
Cure Specialized - Halpern Don’t deeply sedate mechanically ventilated 
patients without a specific indication and 
without daily attempts to lighten sedation.
Cure Specialized - Halpern Don’t continue life support for patients at 
high risk for death or severely impaired 
functional recovery without offering 
patients and their families the alternative of 
care focused entirely on comfort.
Cure Specialized - Hicks In situations where transfusion of RBCs is 
necessary, transfuse the minimum number 
of units required to relieve symptoms of 
anemia or to return the patient to a safe 
hemoglobin range (7-8 g/dL in stable, non-
cardiac in-patients)
Cure Specialized - Hicks Do not administer plasma or prothrombin 
complex concentrates for non-emergent 
reversal of vitamin K antagonists (ie, outside 
of the setting of major bleeding, intracranial 
hemorrhage, or anticipated emergent 
surgery)
Cure Specialized - Korenstein Hysterectomy
Cure Specialized - Korenstein Transfusion
Cure Specialized - Korenstein Chemotherapy (colon cancer)
Cure Specialized - Korenstein Coronary artery bypass graft
Cure Specialized - Korenstein Coronary revascularization for coronary 
artery disease
Cure Specialized - Korenstein Oxygen therapy
Cure Specialized - Korenstein PTCA
Cure Specialized - Korenstein Tympanostomy tubes
Cure Specialized - Onuoha Intraoperative administration of packed 
red blood cells in a young healthy 
patient without ongoing blood loss and 
hemoglobin concentration of >6 g/dL unless 
symptomatic or hemodynamically unstable
2
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Cure Specialized - Onuoha Intraoperative routine administration of 
colloid (dextrans, hydroxyethyl starches, 
albumin) for volume resuscitation without 
appropriate indications; clinicians should 
refer to current data for its use in specific 
populations
Cure Specialized - Onuoha Intraoperative routine use of pulmonary 
arterial catheter for cardiac surgery in 
patients with low risk of hemodynamic 
complications (especially with concomitant 
use of alternative diagnostic tools, e.g., 
TTE or TEE)
Cure Specialized - Quinonez Do not use continuous pulse oximetry 
routinely in children with acute respiratory 
illness unless they are on supplemental 
oxygen.
Cure Specialized - Wiener For patients recently discharged on 
supplemental home oxygen following 
hospitalization for an acute illness, do not 
renew the prescription without assessing the 
patient for ongoing hypoxemia.
Cure Specialized - Williams Don’t administer erythropoiesis-stimulating 
agents (ESAs) to CKD patients with 
hemoglobin levels ≥ 10 g/dl without 
symptoms of anemia.
Cure Specialized - Williams Don’t place peripherally inserted central 
catheters (PICCs) in stage 3–5 CKD 
patients without consulting nephrology.
Cure Specialized Imaging Bulger Do not order continuous telemetry 
monitoring outside of the ICU without 
using a protocol that governs continuation.
Cure Specialized Imaging Chan Unwarranted diagnostic procedures, 
targeting uncomplicated chest/thorax CT 
screening.
Cure Specialized Imaging Chan Performing DEXA screening for 
osteoporosis in women < 65 years or men 
<70 years with no risk factors.
Cure Specialized Imaging Chan Performing follow-up imaging studies for 
incidentally discovered pulmonary nodules 
≤ 4 mm in low-risk individuals.
Cure Specialized Imaging Chan Obtaining CT scans in a patient with 
pneumonia that is confirmed by chest 
radiography in the absence of complicating 
clinical or radiographic features.
Cure Specialized Imaging Chan Antinuclear antibody test in patients with 
nonspecific symptoms or in patients with 
fibromyalgia.
Cure Specialized Imaging Chan CT for the evaluation of suspected 
appendicitis in children until after 
ultrasound has been considered as an 
option.
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Cure Specialized Imaging Chan Performing follow-up surveillance 
examination in < 3 years if patient had a 
second endoscopy that confirms the absence 
of dysplasia on biopsy.
Cure Specialized Imaging Chan Performing imaging studies as the initial 
diagnostic test in patients with low pretest 
of VTE.
Cure Specialized Imaging Chan Performing pre-discharge chest radiography 
for hospitalized patients with community-
acquired pneumonia who are making 
satisfactory clinical recovery.
Cure Specialized Imaging Chan Repeat imaging studies (< 60 days since 
prior test).
Cure Specialized Imaging Chan Repeating screening ultrasonography for 
following a negative study.
Cure Specialized Imaging Chan Unwarranted diagnostic procedures, 
targeting bone or joint x-ray prior to 
conservative therapy, without red flags.
Cure Specialized Imaging Chan Unwarranted diagnostic procedures, 
targeting endoscopy.
Cure Specialized Imaging Chan Unwarranted diagnostic procedures, 
targeting chest x-ray, preoperative, on 
admission or routine monitoring.
Cure Specialized Imaging Elshaug Chest radiograph in acute respiratory 
infections
Cure Specialized Imaging Elshaug Routine chest x-rays on children with fever 
(without features of serious illness)
Cure Specialized Imaging Elshaug Halter monitoring (24 hour ECG) in young 
patients with palpitations and history 
indicating ectopic beats
Cure Specialized Imaging Elshaug Computerized tomography (CT) of the 
pelvis in men with low- or intermediate-risk 
localized prostate cancer
Cure Specialized Imaging Elshaug Chest x-ray in children with symptoms and 
signs suggesting pneumonia
Cure Specialized Imaging Elshaug Abdominal ultrasound to diagnose 
idiopathic constipation
Cure Specialized Imaging Elshaug Angiography in lower limb vascular trauma 
patients
Cure Specialized Imaging Elshaug Auditory brainstem responses for 
diagnosing CFS
Cure Specialized Imaging Elshaug Chest x-ray for diagnosis of acute coronary 
syndrome
Cure Specialized Imaging Elshaug CT or MRI in primary aldosteronism
Cure Specialized Imaging Elshaug CT or ultrasound to diagnose appendicitis
Cure Specialized Imaging Elshaug CT scans (head) in children with low risk 
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Cure Specialized Imaging Elshaug Cystoscopy for men with uncomplicated 
lower urinary tract symptoms (LUTS).
Cure Specialized Imaging Elshaug Endoscopic retrograde 
cholangiopancreatiography in acute 
gallstone pancreatitis without cholangitis
Cure Specialized Imaging Elshaug Fluorimetry or endoscopy to assess 
dysphasia
Cure Specialized Imaging Elshaug Imaging of the upper urinary tract in men 
with uncomplicated lower urinary tract 
symptoms (LUTS)>
Cure Specialized Imaging Elshaug Inappropriate indication for upper 
endoscopy
Cure Specialized Imaging Elshaug Mammography of the ipsilateral soft tissues 
after mastectomy
Cure Specialized Imaging Elshaug Plain abdominal radiograph to diagnose 
idiopathic constipation in children and 
young people
Cure Specialized Imaging Elshaug Plain radiographs of the spine to make or to 
exclude the diagnosis of spinal metastases 
or metastatic spinal cord compression 
(MSCC).
Cure Specialized Imaging Elshaug Routine daily chest radiographs in intensive 
care
Cure Specialized Imaging Elshaug Routine imaging of the spine in patients 
with a previous diagnosis of malignancy
Cure Specialized Imaging Elshaug Routine screening for cardiac anomalies 
using nuchal translucency
Cure Specialized Imaging Elshaug Routine spinal magnetic resonance imaging 
(MRI) for all men with hormone-refractory 
prostate cancer and known bone metastases
Cure Specialized Imaging Elshaug Routine ultrasound in infants or children 
for (UTI)
Cure Specialized Imaging Elshaug Saline infusion sonography as a first-line 
diagnostic tool
Cure Specialized Imaging Hicks Limit surveillance CT scans in 
asymptomatic patients after curative-intent 
treatment for aggressive lymphoma
Cure Specialized Imaging Keyhani Coronary angiography for acute myocardial 
infarction
Cure Specialized Imaging Keyhani Coronary angiography - for all indications
Cure Specialized Imaging Keyhani Radionuclide myocardial perfusion imaging
Cure Specialized Imaging Korenstein Coronary angiography for myocardial 
infarction, coronary artery disease
Cure Specialized Imaging Korenstein Radiographs in acute respiratory illnesses 
for bronchiolitis or croup, asthma
Cure Specialized Imaging Korenstein CT scan for epilepsy
Cure Specialized Imaging Korenstein Endoscopy (upper) for bleeding (upper), 
peptic ulcer disease
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Cure Specialized Imaging Quinonez Do not order chest radiographs in children 
with asthma or bronchiolitis.
Cure Specialized Imaging Rouster-
Stevens
Do not routinely perform surveillance joint 
radiographs to monitor JIA disease activity.
Cure Specialized Imaging Schuur Do not order computed tomography (CT) of 
the cervical spine for patients after trauma 
who do not meet the National Emergency 
X-ray Utilization Study (NEXUS) low-risk 
criteria9 or the Canadian C-Spine Rule.
Cure Specialized Imaging Wiener Do not perform CT scan surveillance for 
evaluation of indeterminate pulmonary 
nodules at more frequent intervals or for a 
longer period of time than recommended by 
established guidelines.
Cure Specialized Imaging Wiener Do not perform chest CT angiography to 
evaluate for possible PE in patients with a 
low clinical probability and negative results 
of a highly sensitive D -dimer assay.
Cure Specialized Imaging Wood Do Not Initiate Routine Evaluation of 
Carotid Artery Disease Before Cardiac 
Surgery in the Absence of Symptoms or 
Other High-Risk Criteria
Cure Specialized Imaging Wood Do Not Perform a Routine Pre-discharge 
Echocardiogram After Cardiac Valve 
Replacement Surgery
Cure Specialized Imaging Wood Patients With Suspected or Biopsy Proven 
Stage I NSCLC Do Not Require Brain 
Imaging Before Definitive Care in the 
Absence of Neurologic Symptoms
Cure Specialized Lab Chan Performing unproven diagnostic tests (e.g. 
IgG or IGE) in the evaluation of allergy
Cure Specialized Lab Chan Performing follow-up complete blood 
counts, blood chemistry studies, tumor 
marker studies, chest radiography, or 
imaging studies other than appropriate 
breast imaging in asymptomatic women 
with previously treated breast cancer
Cure Specialized Lab Chan Measuring brain natriuretic peptide in the 
initial evaluation of patients with typical 
findings of heart failure.
Cure Specialized Lab Chan Pre-op coagulation tests when risk or 
predisposing factors for bleeding and 
history of abnormal bleeding are absent.
Cure Specialized Lab Chan Routine pre-op laboratory tests in otherwise 
healthy patients undergoing elective 
surgery.
Cure Specialized Lab Chan Routinely do diagnostic testing in patients 
with chronic urticaria
Cure Specialized Lab Elshaug Tissue biopsy to reassess HER2 status
Cure Specialized Lab Elshaug Tissue biopsy to reassess ER status
2
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Cure Specialized Lab Elshaug Assessing progesterone receptor status of 
tumors in patients with invasive breast 
cancer
Cure Specialized Lab Elshaug Inflammatory markers for prediction of 
recurrent stroke
Cure Specialized Lab Elshaug Measurement of alfa-fetoprotein in alpha-
fetoprotein producing gastric cancers
Cure Specialized Lab Elshaug Measurement of bilirubin levels in babies 
who are not visibly jaundiced
Cure Specialized Lab Elshaug Mortality markers in end stage renal disease
Cure Specialized Lab Elshaug Troponin Tests for evaluation of heart 
attack/heart injury
Cure Specialized Lab Elshaug Uro4 HB&L system for the rapid diagnosis 
of lower respiratory tract infections in 
intensive care units
Cure Specialized Lab Halpern Don’t order diagnostic tests at regular 
intervals (such as every day), but rather in 
response to specific clinical questions.
Cure Specialized Lab Hicks Do not test for thrombophilia in adult 
patients with venous thromboembolism 
occurring in the setting of major transient 
risk factors (surgery, trauma, or prolonged 
immobility)
Cure Specialized Lab Korenstein Tumor markers
Cure Specialized Lab Onuoha Preoperative baseline laboratory studies 
(CBC, BMP or CMP, coagulation studies) 
in healthy patients without significant 
systemic disease (ASA I or II), when 
blood loss (or fluid shifts) is expected to be 
minimal
Cure Specialized Lab Rouster-
Stevens
Do not order autoantibody panels unless 
positive ANAs and evidence of rheumatic 
disease
Cure Specialized Lab Rouster-
Stevens
Do not repeat a confirmed positive ANA in 
patients with established JIA or SLE.
Cure Specialized Lab Rouster-
Stevens
Do not perform methotrexate toxicity 
labs more often than every 12 weeks when 
patients are on stable doses.
Cure Specialized Lab/Im Korenstein Post-cancer surveillance
Cure Specialized Pharmaceuticals Chan Chelation therapy to prevent or reverse 
atherosclerosis.
Cure Specialized Pharmaceuticals Chan Hydralazine for CHF.
Cure Specialized Pharmaceuticals Chan Lidocaine to prevent arrhythmia and 
sudden death in AMI.
Cure Specialized Pharmaceuticals Chan Quinidine for suppressing recurrences of 
atrial fibrillation.
LTC Day - Elshaug Lower-extremity arteriovenous access for 
hemodialysis
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LTC Day - Williams Don’t initiate chronic dialysis without 
ensuring a shared decision-making process 
between patients, their families, and their 
physicians.




Don’t recommend percutaneous feeding 
tubes in patients with advanced dementia; 
instead, offer oral assisted feeding.




Avoid using physical restraints to manage 
behavioral symptoms of hospitalized older 
adults with delirium




Don’t use benzodiazepines or other 
sedative–hypnotics in older adults as first 
choice for insomnia, agitation, or delirium.




Avoid using prescription appetite stimulates 
or high-calorie supplements for treatment of 
anorexia or cachexia in older adults; instead 
optimize social supports, providing feeding 
assistance, and clarify patient goals and 
expectations




Don’t prescribe a medication without 
conducting a drug regimen review




Don’t prescribe cholinesterase inhibitors 
for dementia without periodic assessment 
for perceived cognitive benefits and adverse 
gastrointestinal effects.




Don’t use antipsychotics as first choice 
to treat behavioral and psychological 
symptoms of dementia.
LTC Outpatient - Chan Monitoring patients with asthma or COPD 
by using full pulmonary function testing 
that includes lung volumes and diffusing 
capacity, rather than spirometry alone (or 
peak expiratory flow rate monitoring in 
asthma).
LTC Outpatient - Elshaug Spirometry during COPD exacerbation and 
treatment monitoring
LTC Outpatient Lab Elshaug Frequent monitoring HbA1C levels in 
adults with diabetes




Avoid using medications to achieve 
hemoglobin A1c <7.5% in most adults age 
65 and older; moderate control is generally 
better.
LTC Outpatient Pharmaceuticals Amos Amitryptiline in ≥65 year olds
LTC Outpatient Pharmaceuticals Amos Chlorpropamide in ≥65 year olds
LTC Outpatient Pharmaceuticals Amos Citalopram > 20 mg / day in ≥65 year olds
2
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LTC Outpatient Pharmaceuticals Amos Clonidine (oral) in ≥65 year olds
LTC Outpatient Pharmaceuticals Amos Disopyramide in ≥65 year olds
LTC Outpatient Pharmaceuticals Amos Escitalopram >10 mg/day in ≥65 year olds
LTC Outpatient Pharmaceuticals Amos Indomethacin in ≥65 year olds
LTC Outpatient Pharmaceuticals Amos Ketorolac max 2 days in ≥65 year olds
LTC Outpatient Pharmaceuticals Amos Methyldopa in ≥65 year olds
LTC Outpatient Pharmaceuticals Amos Nifedipine (short acting) in ≥65 year olds
LTC Outpatient Pharmaceuticals Amos NSAID’s > 15 days in ≥65 year olds
LTC Outpatient Pharmaceuticals Amos Oestrogen in ≥65 year olds
LTC Outpatient Pharmaceuticals Amos Orphenadrine in ≥65 year olds
LTC Outpatient Pharmaceuticals Amos Pentazocine in ≥65 year olds
LTC Outpatient Pharmaceuticals Amos Spironolactone >25 mg/day in ≥65 year olds
LTC Outpatient Pharmaceuticals Amos Testosterone in ≥65 year olds
LTC Outpatient Pharmaceuticals Chan Inappropriate medication use, targeting 
polypharmacy (for multiple chronic 
conditions; of antipsychotics).
LTC Outpatient Pharmaceuticals Chan Overuse or early use of third-line treatment, 
for example Avandia for diabetes.
Preventive - - Chan Screening for COPD with spirometry in 
individuals without respiratory symptoms
Preventive - - Elshaug Spirometry for COPD screening




Don’t recommend screening for breast or 
colectoral cancer, nor prostate cancer (with 
the prostate-specific antigen test) without 
considering life expectancy and the risks of 
testing, over-diagnosis and overtreatment
Preventive - Imaging Chan Coronary heart disease screening using 
ECG, exercise treadmill test (ETT), 
electron beam CT in low-risk adults
Preventive - Imaging Chan Obtaining ECGs to screen for cardiac 
disease in patients at low to average risk for 
CAD.
Preventive - Imaging Chan Obtaining exercise ECG for screening in 
low-risk asymptomatic adults.
Preventive - Imaging Chan Ordering annual ECG or any other cardiac 
screening for asymptomatic, low-risk 
patients.
Preventive - Imaging Chan Screening for colectoral cancer in adults 
older than 75 years or in adults with a life 
expectancy of less than 10 years.
Preventive - Imaging Chan Repeating colonoscopy within 5 years in: 
(a) asymptomatic patients with low-risk 
adenomas, (b) patients with one or two 
small (< 1 cm) adenomatous polyps, without 
high-grade dysplasia, completely removed 
via high-quality colonoscopy.
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Preventive - Imaging Chan Carotid artery stenosis screening in general 
adult population
Preventive - Imaging Chan Repeat cardiac studies within a 3-month 
period.
Preventive - Imaging Chan Using MRI rather than mammography as 
the breast cancer screening test of choice for 
average-risk women.
Preventive - Imaging Elshaug Fecal occult blood screening for colorectal 
cancer
Preventive - Imaging Keyhani Surveillance endoscopy
Preventive - Imaging Korenstein Cardiac stress test
Preventive - Imaging Korenstein Fecal occult blood screening for colorectal 
cancer
Preventive - Imaging Korenstein Echocardiogram
Preventive - Imaging Korenstein Periodic health examination: 
electrocardiogram
Preventive - Imaging Korenstein Colonoscopy for colon cancer screening and 
follow-up
Preventive - Imaging Korenstein Periodic health examination: chest 
radiography
Preventive - Imaging Wiener Do not perform CT scan screening for lung 
cancer among patients at low risk for lung 
cancer.
Preventive - Lab Chan Prostate cancer screening in males ≥ 75 
years or with a life expectancy of < 10 years.
Preventive - Lab Chan Pap tests in females <21 years or post-
hysterectomy for benign disease; cervical 
cancer screening in average in average 
to low-risk females ≥ 65 years or post-
hysterectomy for benign disease.
Preventive - Lab Chan Using CA-125 antigen levels to screen 
woman for ovarian cancer in the absence of 
increased risk.
Preventive - Lab Chan Blood chemistry panels or urinalyses for 
screening in asymptomatic, healthy adults.
Preventive - Lab Chan BRCA mutation testing for breast and 
ovarian cancer in low-risk females.
Preventive - Lab Chan Screening low-risk individuals for hepatitis 
B virus infection.
Preventive - Lab Elshaug Prostate specific antigen (PSA) testing
Preventive - Lab Elshaug The routine measurement of vitamin D 
levels in stage 1, 2, 3A or 3B chronic kidney 
disease (CKD) is not recommended
Preventive - Lab Elshaug Chlamydia screening in under 25 year olds
Preventive - Lab Korenstein Prostate-specific antigen :prostate cancer 
screening
Preventive - Lab Korenstein Papanicolaou test: cervical cancer screening
2
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Preventive - Lab Korenstein Periodic health examination: urinalysis
Preventive - Lab/Im Chan Routine cancer screening for dialysis 
patients with limited life expectancies 
without signs or symptoms.
Preventive - Lab/Im Williams Don’t perform routine cancer screening 
for dialysis patients with limited life 
expectancies without signs or symptoms.
Rehabilitative - - Elshaug CBT for schizophrenia, bipolar disorder 
and major depression
Rehabilitative - - Elshaug Electroconvulsive therapy (ECT) for people 
with moderate depression
Rehabilitative - - Elshaug Social skills training (as a specific 
intervention) to people with schizophrenia
Rehabilitative - - Elshaug Structural neuroimaging techniques (either 
magnetic resonance imaging (MRI) or 
computed axial tomography (CT) scanning) 
for the management of first-episode 
psychosis
Lab.: Laboratory; Im.: Imaging
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Background: To indicate inefficiencies in health systems, previous studies examined 
regional variation in healthcare spending by analyzing the entire population. As a result, 
population heterogeneity is taken into account to a limited extent only. Furthermore, it 
clouds a detailed interpretation which could be used to inform regional budget allocation 
decisions to improve quality of care of one chronic disease over another. Therefore, we 
aimed to gain insight into the drivers of regional variation in healthcare spending by 
studying prevalent chronic diseases.
Methods: We used 2012 secondary health survey data linked with claims data, healthcare 
supply data and demographics at the individual level for 18 Dutch regions. We studied 
patients with diabetes (n=10,767) and depression (n=3,735), in addition to the general 
population (n=44,694). For all samples, we estimated the cross-sectional relationship 
between spending, supply and demand variables and region effects using linear mixed 
models.
Results: Regions with above (below) average spending for the general population mostly 
showed above (below) average spending for diabetes and depression as well. Less than 
1% of the a-priori total variation in spending was attributed to the regions. For all 
samples, we found that individual-level demand variables explained 62-63% of the 
total variance. Self-reported health status was the most prominent predictor (28%) of 
healthcare spending. Supply variables also explained, although a small part, of regional 
variation in spending in the general population and depression. Demand variables 
explained nearly 100% of regional variation in spending for depression and 88% for 
diabetes, leaving 12% of the regional variation left unexplained indicating differences 
between regions due to inefficiencies.
Conclusions: The extent to which regional variation in healthcare spending can be 
considered as inefficiency may differ between regions and disease-groups. Therefore, 
analyzing chronic diseases, in addition to the traditional approach where the general 
population is studied, provides more insight into the causes of regional variation in 
healthcare spending, and identifies potential areas for efficiency improvement and budget 
allocation decisions.
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BACKGROUND
The sustainability of healthcare systems is a common challenge for Western countries. 
One of the main responses is to improve population health and quality of care, while 
slowing down the expenditure growth by population health management (PHM). PHM 
aims to integrate services across healthcare, prevention, social care, welfare and public 
health for a pre-specified population within the region [1]. Commonly, these initiatives 
are set-up by a network of health insurers, health care providers and other health 
organizations that together develop interventions. These interventions include so-called 
citizen-centered interventions, which targets citizens at risk and are tailored for pre-
defined subpopulations such as citizens who smoke, diabetes patients or multi-morbid 
patients. In a number of countries, stakeholders within specific regions have adopted the 
PHM approach. Examples are Gesundes Kinzigtal in Germany [2], Accountable Health 
Communities in the USA [3] and Dutch PHM initiatives [4, 5]. In order to develop 
policy to improve efficiency and to make budget allocation decisions, these initiatives 
require insight into the performance of (the organization of) their health services. One 
way to inform these decisions is to study the drivers of variation in healthcare spending 
between regions, as regional variation in healthcare spending, not caused by differences 
in medical need, is said to indicate inefficiency [6, 7].
Research has shown that regional variation in healthcare spending is determined by 
the interplay of demand and supply factors under the influence of system factors [8, 9]. 
Demand factors labeled as medical need, such as demographics and health status, are 
generally considered justifiable causes of variation in healthcare spending. Empirical 
research has shown that such factors explain a large part of the regional variation in 
healthcare spending (e.g. [8, 10, 11]). Regional variation as a result of supply factors (e.g. 
competition, capacity or physician beliefs) is considered to be generally undesirable. In 
empirical studies, those factors have been found to be of varying impact, depending on 
the study context, or system factors (e.g. [11, 12]). System factors such as (insurance) 
regulation, price setting or payment methods influence the dynamics of demand and 
supply.
Previous studies (e.g. [6, 10, 13]) generally examined regional variation in healthcare 
spending studying sources of variation that affect spending for the entire population in 
a region, such as local price levels or general economic circumstances. However, there 
is substantial population heterogeneity that clouds a more detailed interpretation, as 
other causes of variation might differ between disease groups across regions. Population 
heterogeneity between regions exists, for example in terms of the prevalence of (chronic) 
3
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diseases and multi-morbidities; a region may have a relatively high prevalence for certain 
disease groups and lower prevalence for others. Furthermore, the extent to which 
regional differences are caused by disease severity or other patient characteristics or 
the level of treatment standardization may vary between disease groups [14, 15]. These 
more detailed explanations remain undetected when studying the general population 
only. Also, because of lack of knowledge and data, it is complicated to control for all 
relevant sources of variation in healthcare spending. In order to inform, for instance, 
budget allocation decisions for quality improvements or care standardization efforts of 
one chronic disease over another, a more detailed approach may be needed.
Therefore, this study aimed to gain further insight into the sources of regional variation 
in healthcare spending by zooming in on prevalent chronic diseases (disease-approach). 
We applied this to the context of 18 Dutch PHM regions. We expected variation 
patterns to differ between disease-groups within the population. This is in part 
intrinsically to the disease and in part in line with the degree to which consensus is 
reached on how to treat a certain disease [8, 15]. We selected two types of prevalent 
disease groups: patients with diabetes and patients with depression. We chose patients 
with diabetes as treatments for diabetes are known to be highly standardized due 
to provider approved general treatment decisions in the Dutch Diabetes Federation 
Health Care Standard (DFHCS) and as a consequence of the bundled payment model 
that was introduced in 2010 [16]. We chose patients with depression as treatments for 
depression are expected to be less standardized, considering the variety of treatment 
options and lack of healthcare standards at a national level. Assuming that treatment 
options vary in costs, we expected the group of patients with depression to reflect more 
variation in healthcare spending as compared to the group of patients with diabetes. We 
showed the results of the disease-approach in addition to the results of the traditional 
approach (where the general population is studied) for each step taken in the analysis of 
regional variation in spending, which is to 1) describe the unadjusted regional variation 
in healthcare spending, and 2) explore the extent to which demand and supply factors 
explain regional variation in healthcare spending.
METHODS
Data sources
We used data from the Dutch Public Health Monitor (DPHM) for the year 2012 
[17]. We merged these data at the individual level with demographic variables from 
Statistics Netherlands and nationwide claims data which we obtained from Vektis [18]. 
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The claims data included all health care use in 2012 that was covered by the basic 
health insurance. The records were linked using a pseudonymized personal identification 
code. Furthermore, at the regional level, we added health care supply data from the 
Netherlands Institute for Health Services Research (NIVEL), the National Institute of 
Public Health and the Environment (RIVM) and the Health Care Inspectorate (IGZ). 
We used 2012 as reference year for all data sources. For an overview of data and variables 
used, see Supplementary File 1.
Study population
To define the regions, we used the geographical demarcation of 18 Dutch PHM 
initiatives [4]. We analyzed the variation in healthcare spending across these regions, 
focusing on three (sub)populations: 1) the general population, 2) patients with diabetes, 
and 3) patients with depression. For a detailed description of the sample selection, see 
Supplementary File 2.
The first sample (general population) was based on participation in the DPHM survey 
(n=138,000), since we aimed to include health status information from that survey. 
We excluded individuals with missings on self-reported health status (n=82,455) and 
missings on the health spending variable (n=10,298). In addition, to correct for errors 
and costs in the data that are not linked to Diagnosis Treatment Groups (DTGs) in the 
previous year, we removed 1% outliers in terms of spending (above €29,468) (n=1,284) 
and negative values for health spending (n=1). As a result, 44,694 individuals from the 
general population were included in the sample. The second study sample consisted of 
diabetes patients. We selected them by their participation in a bundled payment program 
for diabetes care, the Pharmacy-based Cost Group (PCG) or the DTGs referring to 
diabetes type II (n=10,767), which is known to include nearly all diabetes type II patients 
[19]. The PCGs are – among other variables - used in the Dutch risk equalization system 
to identify risk-profiles that predict healthcare spending in the following year [20]. 
PCGs aim to identify persons with chronic diseases based on claims data of the previous 
year for medication for which it is known that they are used for that particular disease. 
The third study sample was created by selecting patients with depression (n=3,735) in a 
similar way as the diabetes patients. We used PCGs and DTGs referring to depression.
Econometric specification
To allow for the complex structure of the data, i.e. individuals nested within regions 
and the skewed distribution of healthcare costs as dependent variable, we performed 
multilevel analyses using linear mixed models (LMM) with a random intercept for 
region effects. We applied LMM to the log-transformed dependent variable. We 
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considered other methods and distributions: see Supplementary File 3 for details on 
the model selection. We specified the following equation (1):
   (1)
where  is the healthcare spending of individual i in region j,  are the fixed effects 
of individual level characteristics;  is the vector of variables at the individual level; 
 are the fixed effects of the region level characteristics;  is the vector of variables 
at the region level;  is the random intercept at the region level with 
, and  is the residual error at the individual level with .
The outcome variable was the natural log of total curative healthcare spending in 2012 at 
the individual level (see Supplementary File 4). It was calculated by summing spending 
on general practitioner (GP)-care, hospital and specialist care, pharmaceutical care, 
physical therapy, mental health care and other types of care (i.e. patient transport, 
maternity care, medical aids and care abroad). It comprised all spending within the 
basic health insurance package [18].
Similar to previous studies, individual characteristics (age, gender, SES and health 
status) were included in the model. These variables reflect justified causes of variation 
in healthcare spending, which is also referred to as medical need (e.g. [6]). The self-
reported health status variable was derived from the DPHM survey consisting of three 
levels from bad to very good [17]. Self-reported health status is generally considered to 
be a good predictor for future health as it encompasses more than standard objective 
measure of health (e.g. blood pressure, presence of disease) and reflects preclinical 
diseases or worsening of diseases [21]. In addition, using the self-reported health status 
in addition to using claims data derived health status alone, resolves the bias resulting 
from claims data derived health status, which is not independent from the supply-side 
and therefore may also reflect supplier-induced utilization. We used 2008 and 2012 
Diagnosis-based Cost Groups (DCGs), which are cost-profiles of the diseases based 
on diagnosis information [22] and PCGs from the Dutch risk equalization model [20], 
each referring to data from previous years. Using claims data from previous years may 
tackle the endogeneity issues that arise when using spending and health data from the 
same year [23]. The DCG variable ranged from 0 to 13 or 15 (13 clusters for 2008 and 
15 for 2012) where a higher DCG number is equal to being in a higher cost cluster. 
We transformed the DCG into dummy variables, reflecting being in either a specific 
DCG or not. The PCG variable ranged from 0 to 20 or 25 (20 clusters for 2008 and 
25 for 2012), where a higher number means being in a higher cost cluster. As it was 
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possible for an individual to be in more PCGs at the same time (i.e. reflecting multiple 
diseases), we constructed an aggregate score from the PCG by summing the PCGs for 
each individual.
Supply variables, in this study mainly about the access to healthcare, reflecting generally 
unjustified variation, were included at the individual and at the regional level. At the 
individual level, we added distance to provider in meters from Statistics Netherlands. 
At the regional level, we used number of providers per 1000 population, which we 
constructed using the four-digit postal codes of providers in the Netherlands using 
information from NIVEL, RIVM and IGZ.
The random intercept at the regional level in the full model is considered to indicate 
variation in efficiency between regions, as it reflects regional variation which is not due 
to the demand and supply variables and the random error at the individual level in the 
model.
Statistical analyses
First, in order to gain insight in the a-priori variation of the three samples, we showed 
the deviation from the mean in percentages per region and the overall coefficient of 
variation (CoV; ratio of the standard deviation and the mean) at the regional level. The 
a-priori regional variation includes all justified and unjustified variation in healthcare 
spending between regions.
Second, we studied the extent to which demand and supply factors explained variation 
in healthcare spending at the individual and regional level. For all samples separately, 
to identify the contribution of the variables to the model, we fitted LMM models by 
gradually adding groups of variables to a null model without covariates. This strategy is 
common in analyzing regional variation in healthcare spending and is previously used 
by e.g. Gopffarth et al [11] and Newhouse et al [6]. We started with demographics (age 
and gender), followed by health status variables (first self-reported health status and 
then the DCGs and PCGs). Consecutively, we added the supply variables one by one. 
Finally, we selected the best-fit model based on subsequent nested fits for each sample 
using the likelihood ratio test (LRT), Akaike Information Criteria (AIC) and Bayesian 
Information Criterion (BIC). We chose the more expanded model when the p-value for 
the LRT < 0.01, and checked whether the AIC and BIC corresponded accordingly. After 
fitting the model, we calculated Pearson’s correlation coefficients for the observed and 
predicted means of natural log of the curative healthcare spending to estimate how the 
3
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predicted means changed by adding the covariates. In addition, we plotted the variance 
at each level for all samples.
Data management and analyses were performed using SPSS Version 20 and Stata/MP 
14.0.
RESULTS
Unadjusted regional variation in healthcare spending
Figure 1 displays the unadjusted regional variation shown as deviation from the mean 
in percentages per sample per region. It includes both justified and unjustified variation 
in healthcare spending. For the diabetes sample, region 13 and 4 ranked highest in 
spending per capita (pc). The two lowest spending regions were 15 and 9. The depression 
sample had highest spending pc in regions 17 and 11; lowest in region 15 and 9 (see 
Supplementary File 4 for more details and for the exact levels of spending per region). 
Regions with above (below) average spending for the general population mostly showed 
above (below) average spending for diabetes and depression as well. The disease-groups 
showed less variability compared to the general population (CoV of 1.21). The diabetes 
sample showed less variation than the depression sample, which is reflected in the CoV 
of 1.03 for diabetes and 1.16 for depression.
CoV: Coefficient of Variation (ratio of standard deviation and mean); data label: region identification number 
Figure 1: Unadjusted regional variation in healthcare spending in the general population and 
the disease-approach
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Variance (un)explained by demand and supply factors
Table 1 shows the model estimates for the null and the best-fitted model for all samples. 
The results are shown on the log-transformed scale. For all samples, the best-fitted 
model included demand variables as demographic variables and health status variables 
(both self-reported and claims data derived). Supplementary File 5 illustrates that 
self-reported health status explains a substantial part of healthcare spending; the total 
variance decreased approximately 28% on the log-scale. Supply variables were found 
to add small but significantly on the log-scale, to the models for depression and the 
general population (not for diabetes). The best-fitted depression model included distance 
in meters to a physical therapist. For the general population, distance in meters to GP, 
hospital and pharmacy were additionally included. The Pearson’s correlations (Table 
1) between the overall mean in the null models and predicted mean in the full models 
confirmed the influence of the covariates by showing coefficients of 0.12 (diabetes), 0.14 
(general population) and 0.16 (depression), which was largely due to the influence of 
the demand variables.
Figure 2 demonstrates the proportion of the variance that is explained after fitting the 
models. A-priori, more than 99% of the total variance was attributed to the individual 
level (also see Table 1), leaving less than 1% attributed to the regional level. At the 
individual level, 62-63% of the variance on the log-scale was explained by demand 
variables. At the regional level, the covariates explained relatively more variation for 
the general population and the depression sample (96% and 100% respectively) than for 
the diabetes sample (88%).
DISCUSSION
The aim of this study was to gain more in-depth insight into regional variation in 
healthcare spending using prevalent chronic diseases. We used samples of patients 
with diabetes and depression, as we expected more homogeneity due to treatment 
standardization in the first compared to the latter. To our knowledge, we were the first 
to apply such an approach. We found indications that levels and sources of variation 
in healthcare spending seem to differ between disease-groups. The results showed that 
unadjusted regional variation in healthcare spending was smaller for the sample of 
patients with diabetes, than for patients with depression and the general population. 
Regions with above (below) average spending for the general population mostly showed 
above (below) average spending for diabetes and depression as well. A-priori, more than 
99% of the total variance was concentrated at the individual level, leaving less than 1% 
3
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at the regional level. We found that demand variables explained 62-63% of the total 
variance in healthcare spending. Self-reported health status was the most prominent 
variable in the model, explaining 28% of the variation. Supply variables added nearly 
0%, but significantly to the model in the general population sample (distance to GP, 
hospital, pharmacy and physical therapy) and the depression sample (distance to physical 
therapy). For the general population and the depression sample, the covariates in the 
model explained 96-100% of the variation at the regional level as opposed to 88% for 
the diabetes sample.
The finding that variation in healthcare spending is largely explained by demand factors 
and that the variation at the regional level is limited, is in accordance with work from 
e.g. Lavergne, Barer [24] and Gopffarth, Kopetsch [11]. Both studies were performed 
Figure 2: Variance in healthcare spending explained by covariates in the general population and 
the disease-approach
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using a traditional population-based approach and performed their studies in similar 
health systems as the Netherlands. Based on their results, both authors concluded that 
regional differences in healthcare spending do not clearly reflect inefficiencies. Therefore, 
Lavergne, Barer [24] suggests that policy reforms should be rather targeted at system 
wide efficiency improvements, than at high-spending regions. Although the results of 
our study similarly showed a small amount of variation that was left at the regional level, 
we think that unexplained variance that might indicate inefficiency cannot be ruled out 
based on two findings. First, at the regional level, the diabetes sample showed relatively 
more unexplained variance than the other samples. This indicates that variance at the 
regional level was caused by factors outside of the model, as for example differences 
in efficiency in organizations that were influenced by the disease standardization. In 
contrast, the other study samples showed less variability. For the depression sample, all 
of the variation was explained at the regional level. This might be caused by variability in 
disease severity or treatment differences between individuals within regions, rather than 
across regions. Second, at the individual level, supply variables were small, but significant 
in the general population and depression sample and not in the diabetes sample. Even 
though we found small regional effects, we believe this insight is useful, as more efforts 
at the regional level are expected in the near future, and therefore more variability at 
the regional level may be encountered in analyses of disease-groups.
Our study has several limitations. First and most important, by using the self-reported 
health status variable which we derived from the Dutch Public Health Monitor 
survey, we were limited to a subsample of the nationwide patient-level claims data. 
Consequently, we encountered loss of precision in our analyses as the region sample sizes 
were less than 30 for a maximum of three regions in the disease-groups. Additionally, 
the external validity of this study depends directly on that of the Dutch Public Health 
Monitor, which shows selection bias that was corrected for by using a weighing factor 
(unpublished work of Carolien vd Brink submitted to TSG). Nevertheless, we believe 
that for the purpose of this study, namely to show a method on how to gain insight into 
differences between disease-groups within and across regions, this had no substantial 
impact on our conclusions. Second, controlling for supply and demand factors in the 
analyses should be improved. For example, we were not able to capture variables that 
inform cultural differences between physician treatments or the level of standardization 
of treatments per region. Third, due to computational issues in STATA we could not 
retransform the log-transformed healthcare spending variable and calculate variance 
measures on the linear scale (see Supplementary File 3). Interpretation of the results is 
therefore more difficult and less precise. Consequently, the extent to which variance is 
explained might differ when measured on the linear scale. However, and in extension 
3
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to previous work [11, 25], we used a more complex hierarchical structure to account for 
the nested structure of individuals into regions and therefore avoided the disadvantages 
(i.e. ecological fallacy) of an aggregate design. As this study has a descriptive character 
and we did not aim to infer causally, we are confident our conclusions hold up in a 
qualitative sense.
Despite these limitations, this study contributes to the literature that aims to investigate 
the role of demand and supply factors in explaining geographical variation in health care 
spending. First, this study benefits from the homogenous Dutch healthcare system. In 
contrast to, for example, the US, financing structures and schemes are defined at the 
country level in the Netherlands. Therefore, they do not influence regional variation in 
healthcare spending. In addition, as opposed to studies from the U.S., Dutch claims 
data cover roughly 95% of the population, as private health insurance is mandatory. 
Second, we were able to reduce bias that results from using claims data derived health 
status, which was encountered in e.g. Lavergne, Barer [24] and Wennberg, Sharp [26], 
by including a self-reported health status variable from a large health survey. Finally, by 
using a disease-approach, we were able to create a more homogenous study population in 
advance, which enriches the understanding of causes of regional variation in spending 
between groups within the population. To our knowledge, we are the first to apply such 
an approach. It provides a novel process of modeling regional variation in healthcare 
spending that may be followed in similar future studies. The notion that regional 
variation in healthcare spending might be a composition of different variation patterns 
of several disease-groups is important when developing regional healthcare policies. 
We suggest further research to investigate whether regions are consistent over a larger 
set of disease-groups and specific cost data to better interpret the results research has 
shown this far. Moreover, in the coming years data will become available to analyze the 
effects of the PHM regions. Additionally, more research is needed to fill in the gaps of 
regional variation that remains unexplained. A suggestion is to operationalize cultural 
differences to include in the analysis (previously mentioned by Kopetsch and Schmitz 
[25]). At the individual level, cultural differences might influence healthcare utilization 
on the demand side and at the organizational level or physician level cultural differences 
may influence the supply side. In addition, a longitudinal analysis of regional variation 
in healthcare spending using disease-groups might be interesting to start unraveling the 
causal relationship instead of a more descriptive analysis as used in this study.
Conclusion
The extent to which regional variation in healthcare spending can be considered as 
inefficiency may differ between regions and disease-groups. Therefore, an approach 
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analyzing chronic diseases, in addition to the traditional approach, where the general 
population is studied, provides more detailed insight into the causes of regional variation 
in healthcare spending and identifies potential areas for efficiency improvement and 
budget allocation decisions.
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S3. Statistical analyses: model selection
The selection of a method for the analysis of healthcare spending data is not 
straightforward, as difficulties arise due the distribution of healthcare spending, 
which is known to be non-negative, skewed and heavy-tailed. However, in general, 
generalized linear models (GLM) are used as it deals with the skewed distribution of 
healthcare spending [1, 2]. GLM requires a mean function and a variance function to 
be specified beforehand based on the probability distribution of the dependent variable. 
The mean function relates the mean to some function of covariates and the variance 
function relates the mean to the variance on the raw scale. For spending data, options 
for distributions typically include (Generalized) Gamma, Poisson, inverse Gaussian 
and Gaussian distributions. Link functions include identity, inverse square or power. A 
major advantage of GLM over Ordinary Least Squares (OLS) using a log-transformed 
response is that the expected value of the response on the original response scale can be 
retrieved straightforwardly, without the need for a specific retransformation.
As the gamma family and log link is often used in previous literature for handling data 
on healthcare spending (e.g. [3, 4]), we used this distribution and link as a starting 
point. For the gamma distribution the variance is a square function of the mean, which 
can be checked by performing the modified Park test [2]. We performed the modified 
Park test by fitting the GLMM for the log of the squared residuals using the log of the 
predicted y. The coefficient of the log of the predicted y indicates the functional form of 
the underlying distribution: beta ≈ 0 indicates Gaussian distribution; beta ≈ 1 Poisson; 
beta ≈ 2 gamma; and beta ≈ 3 indicates inverse Gaussian or Wald distribution. However, 
due to computational problems, STATA was not able to fit the GLMM with gamma 
family and log link for the large number of observations and variables in addition to 
the nested structure. However, in much smaller samples the model with gamma family 
and log link did converge. Therefore, we consecutively tried fitting Poisson, inverse 
Gaussian and Gaussian distributions. Due to aforementioned computational problems, 
STATA was only able to fit the model using the Gaussian distribution. These sorts of 
computational problems are seen before in e.g. Tsiachristas and Rutten-van Mölken [5] 
and Mohnen, Molema [4]. In order to refrain from losing too much statistical power 
we chose a different model instead; he only link option in combination with Gaussian 
distribution is identity (i.e. Linear Mixed Models (LMM))
A disadvantage of using the Gaussian distribution is that the results are sensitive to 
extreme values, can produce out-of-range values as negative predicted spending, and is 
likely to be inefficient for small to medium sample sizes since the underlying distribution 
in reality is not normal [6]. To accommodate a Gaussian distribution, we decided to 
3
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log-transform the outcome variable. Modeling the log-transformed variable instead 
of the raw cost variable may solve the problem of skewness and allows for comparison 
on the log-transformed scale. Although the results are more precise and robust by 
the transformation, a major drawback is that the interpretation of the results are not 
straightforward. The comparison of the means of the log-transformed scale cannot be 
translated directly to comparison of means on the raw scale by inverting the log, as the 
log of the expected value does not equal the expected value of the log (i.e. ln(E[y|x]) ≠ 
E[ln(y|x)]). Appropriate solutions for this problem (e.g. Duan’s non-parametric smearing 
factor [7]) may be applied to transform the contribution of the covariates. However, 
variance estimates remain on the log-scale. As the results of this study focuses on the 
variances and therefore still had to be displayed on the log-scale, we decided not to 
retransform the covariates.
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Objective: To explore whether Dutch Maternity Care Networks (MCNs) show differences 
in value using observational data.
Data sources/study setting: We linked data from three nationwide administrative registers; 
data on maternal and neonatal health, quality of maternity care and case-mix variables, 
claims data and municipality registry data for low-risk pregnancies in the Netherlands in 
2011 through 2016 (n=297,960).
Study design: The variation of six value-indicators, defined as the rate of adverse health 
outcomes (outputs) relative to the rate of services (inputs), was measured across 91 MCNs. 
To explore the extent to which the value-indicators are able to reflect the actual value, 
additional analyses were performed. We assessed the association between inputs and 
outputs, the consistency across inputs and across outputs and the persistence of inputs 
and outputs over time. All estimates were modeled through multilevel modeling with 
adjustments for mother, father and child demographics, pregnancy related clinical factors, 
previous health spending and time.
Principal findings: We observed substantial variation in all six value-indicators, comprising 
combinations of inputs (caesarean sections, epidural analgesia and labor induction) and 
outputs (Apgar score lower than 7 after 5 minutes, hemorrhage post-partum and serious 
perineal damage), across MCNs after adjusting for case-mix. Additional analyses showed 
that MCNs with more (less) low-value services did not show more (less) adverse outcomes, 
except for ‘caesarean section’ and ‘epidural’ with ‘low Apgar score’, which were weakly 
negatively correlated. Furthermore, positive correlations emerged for: 1) low Apgar score 
after caesarean section, after epidural and after labor induction, 2) hemorrhage postpartum 
after labor induction and after caesarean section (consistency). Persistence over time was 
found for all inputs (caesarean section, epidural, labor induction).
Conclusions: We found substantial variation across MCNs for the six value-indicators. 
The additional analyses indicated that some of the outputs may have measured a similar 
concept (consistency), and that the inputs (i.e. low-value care indicators) may have captured 
a part of value (persistence). Yet, despite access to extensive set of case-mix variables, 
population heterogeneity clouded our results. Future research should further deal with 
the limitations of observational data and refine outcome measures that matter to the 
population of pregnant women in order to truly capture value at the MCN level and 
contribute to value-based maternity care.
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INTRODUCTION
As a reaction to sustainability issues of health systems in Western countries, regional 
networks of payers and professionals [1, 2] increasingly seek to improve value. Higher-
value care means that the ratio between health outcomes and spending increases [3]. An 
example of such networks are the Dutch maternity care networks (MCNs), generally 
consisting of obstetricians (organized in medical specialist partnerships) in hospitals, 
several independent midwife organizations and community maternity caregivers [4]. 
Insight into the performance, with respect to value, within and across MCNs, can 
assist these networks in monitoring progress towards value, in developing policies and 
interventions, and in making budget allocation decisions [5].
A common method to analyze the performance of regional networks is to study the 
variation of outcomes across regions. The reasoning is that variation, which is not 
caused by medical need, is unwarranted and, therefore, points at inefficiencies [6, 7]. 
To date, most studies have examined the variation in health spending (e.g. [8-10]), 
utilization (e.g. [6, 11-13]) or health outcomes (e.g. [14]), separately. However, despite the 
increasing attention for the concept of value, studies that aim to measure performance 
of organizations with respect to value (i.e. comprising both outcomes and inputs), are 
scarce [15-22]. A few studies assessed the value of care, implicitly, by specifying outputs 
and inputs relative to each other, or explicitly by using a production function framework 
to develop a value-indicator [16]. Those studies assessed the value of care across hospitals 
[16, 20, 22], mental care providers [17], diabetes care groups [18] or physical therapists 
[19]. We found one study assessing the value of care across regional provider networks 
for high-cost seniors [21]. As far as we know, an analysis of the performance of maternity 
care networks (MCNs) with respect to the value of care has not been performed before.
Moreover, previous studies that, explicitly or implicitly, analyzed the variation in value 
used health spending as input, which result in endogeneity problems [20]. Endogeneity 
occurs because health spending, as is registered by insurers and alike, includes spending 
on the initial treatment as well as on the complications that may be caused by the 
treatment itself. Moreover, healthcare spending may also reflect the health status of the 
patients next to the intensity with which patients are treated by health care providers, 
even when an attempt to adjust for case-mix has been made. This affects not only value 
analyses, but also studies analyzing the variation in healthcare spending separately. 
Although most studies using health spending acknowledge endogeneity bias in the 
limitations section of their papers (e.g. [5, 18, 22]), only a few studies actively attempt 
to deal with this problem.
4
541371-L-bw-deVries
Processed on: 24-2-2020 PDF page: 160
160
Chapter 4
This study aims to explore value in Dutch maternity care, by (1) selecting several 
maternal care services, of which the utilization reflects the intensity with which patients 
are treated (inputs), (2) selecting several neonatal or maternal health outcomes that may 
be affected by those services (outputs), and (3) assessing to what extent Dutch MCNs 
show variations in the relationship between the services and outcomes. In the remainder 
of this article, we define ‘value-indicators’ as specific combinations of input and output as 
derived from Dutch observational data, that potentially reflect how more input will affect 
the output. In this study, we propose six value-indicators across MCNs. By selecting the 
utilization of low-value services, we can largely avoid problems with endogeneity that 
would have come with considering health care spending as an input. Low-value services 
are services that provide little to no benefits, or even cause harm. Previous studies (e.g. 
[23, 24]) have demonstrated the benefits of using low-value services over aggregate 
measures such as spending [12]. Not only do they allow for pinpointing exact sources 
of overuse, but they also provide a sense of how much health care resources can be saved 
or redirected, by comparing the most efficient and least efficient regions.
We further examine the extent to which our proposed value-indicators reflect actual 
value, by a series of additional analyses regarding the underlying inputs and outputs 
of the value-indicators. First, we assessed the association between the inputs and the 
outputs per value-indicator to explore their relation. When this relationship is highly 
variable and/or noisy, the proposed value-indicator and the observational data may 
perhaps not be suitable. Second, we measure the consistency across inputs and outputs 
in order to assess whether they measure the same concept. If the consistency is low, 
it indicates that underlying value is multifaceted and not easily measured by just one 
indicator. Third, we study the persistence of the inputs and outputs over time. The 
presence of persistency over time would suggest that we might capture (a part of) value 
across MCNs, as we do not expect ‘true value’ at the MCN level to change drastically 
over one year in the majority of the cases.
METHODS
Data sources
We linked data from three nationwide administrative registers; Perined (maternal and 
neonatal health, quality of maternity care and case-mix variables), Vektis (claims data) 
and Statistics Netherlands (case-mix variables) for births in 2011 through 2016.
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Perined is a perinatal registration center that collects data from independent midwifes, 
obstetricians, obstetric active general practitioners, and neonatologists. Perined collects 
information on pregnant women (e.g. age, parity, medical history) and information 
on the pregnancy, labor and quality of care (e.g. gestational age, way of delivery, pain 
relief, maternal and infant health outcomes). Perined covers information on 99.7% of 
all pregnancies with births >22 weeks gestational age in the Netherlands [25]. We used 
data from pregnancies that led to a live birth or stillbirth of >22 weeks gestational age 
in 2011 through 2016.
Vektis collects individual claims data from all Dutch health insurers under the Health 
Insurance Act. The dataset of Vektis covers all claims data of more than 99% of the 
Dutch citizens [26]. We used detailed claims data of mothers for whom any claims on 
maternity care were made during 2011-2016. In addition, we used claims data of children 
with birth dates in 2011-2016.
Statistics Netherlands gave access to several case-mix variables: month and year of birth 
of the mother, father and child, gender of the child, ethnicity, household income and 
highest attained educational level.
Data linkage and sample
Statistics Netherlands provided a highly secured remote access platform on which we 
were able to safely link the data at the individual level using a pseudonimized linkage 
number to adhere to privacy legislation [27]. Each dataset contained unique encoded 
identifiers at the level of the mother, father or child. In order to link the data at the 
pregnancy level, data on both mothers and children needed to be assigned a pregnancy 
identification number. The Appendix elaborates on the specifics of the data linkage 
process.
We included pregnancies with date of birth in 2011 through 2016. Only low-risk 
pregnancies, defined as nulliparous term singleton vertex (NTSV1) with live births or 
stillbirths were included to limit bias due to population heterogeneity [28]. We excluded 
pregnancies with a Neonatal Intensive Care Unit (NICU)-admission, because these 
pregnancies were solely attributed to the nine MCNs with such a unit. In addition, we 
excluded pregnancies that could not be attributed to a MCN, and pregnancies that were 
1 Pregnancies of the first born child with gestational age between 37 weeks and 42 weeks being a single 
birth (no twins) in head presentation.
4
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attributed to a MCN for which the total number of pregnancies was too low (threshold 
<2000 pregnancies attributed to one MCN in 2011-2016).
Measuring the value of maternity care
As we aimed to measure value validly, we chose inputs and outputs based on the 
following conditions: 1) the input has to reflect one health service that occurs before 
the output, 2) the input has to be a low-value service with literature evidence showing 
wide variations across care providers, 3) there must be a possibility for the input to have 
a clinical relationship with the output (i.e. the utilized service could possibly prevent 
the adverse outcome, if used appropriately, or could possibly induce the adverse outcome 
if not used appropriately), which is supported with literature evidence and obstetrics 
gynecologist expert opinion. Only indicators for which it is not possible for the input 
to have a clinical relationship with the output are removed. 4) the output has to be a 
primary neonatal or maternal outcome in integrated maternity care.
Table 1 shows an overview of the value-indicators that we use in this study, specifying 
the numerator (output) and denominator (input) and the rationale of an association 
between input and output. Below, we briefly discuss the rationale of the inputs and 
outputs separately.
Inputs: low-value services in low-risk pregnancies
Several studies showed that wide variations of rates of caesarean sections (c-sections) 
exist across practitioners and hospitals, which cannot be explained by differences in 
medical need (e.g. [28, 34, 42-44]). Other low-value services in low-risk pregnancies 
for which wide variations exist are (routine) epidural analgesia (epidural) [28, 45] and 
non-medically induced induction of labor (induction) [44-47].
Outputs: neonatal and maternal health outcomes
In the absence of Patient Reported Outcome Measures (PROMS) in our dataset, we 
selected neonatal and maternal health outcomes as deemed relevant in integrated care 
by the Dutch Working Group on Indicators for Integrated Care [48] that were present 
in our observational dataset. The outcomes that we selected are generally referred to as 
the Adverse Outcome Index-5 (AOI-5) [49, 50]. Three of these five indicators reflect 
neonatal health outcomes; perinatal mortality between 22 weeks of gestational age 
and seven days after birth, NICU-admission and Apgar score <7 after 5 minutes (low 
Apgar score). The other two indicators reflect maternal health outcomes: hemorrhage 
post-partum (hemorrhage) ≥1000 ml and 3rd and 4th degree perineal tear for vaginal 
births (perineal damage).
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Case-mix variables
Based on previous research (e.g. [5, 18, 28, 42, 44, 51]), and depending on the specific 
input or output, we adjusted for a combination of the following case-mix variables. We 
included age of the mother at the time of birth, highest attained educational level, ethnic 
background, degree of urbanization based on the 4-digit postal code of the mother, 
household income, gestational age, birth weight, gestational hypertension and diabetes, 
history of miscarriages, maternal health spending in the second year before pregnancy, 
paternal age >45 years [52] and gender of the child.
Statistical analyses
First, we summarized unadjusted descriptive statistics for the inputs, outputs and 
case-mix variables at the MCN level (mean, minimum and maximum per pregnancy 
per MCN). Second, we fitted generalized mixed effects logistic models to estimate 
the variation at the MCN level, that is adjusted for case-mix and random errors at 
the pregnancy level. Because of nonrandom attributing of pregnancies to MCNs, 
the unadjusted variation would reflect differences in case-mix rather than MCN 
performance. Allowing for random effects instead of fixed effects is more efficient and 
limits the consequences of overfitting as smaller MCNs will shrink to zero (i.e., the 
average). The random effects at the MCN level are considered to reflect performances 
across MCNs, as it shows the variation between MCNs that is not due to the case-mix 
variables and the random error at the pregnancy level [53]. We specified the following 
equation for the probability that an input or an output occurs:
 
  (1),
where  is the binary-valued input or output of pregnancy i in MCN j,  is the m-th 
fixed effect of pregnancy level characteristics;  is the m-th case-mix variables at the 
pregnancy level including fixed effects for year of birth;  is the parameter of our 
interest, the random intercept at the MCN level with , and  is the 
residual error at the pregnancy level, which is distributed as logistic with mean 0 and 
variance π2/3 and is independent from . All inputs and outputs were fitted separately 
using backward elimination. That means that we first fitted all variables, one at the time. 
Variables for which the p-value was <0.3, were selected for the most extensive model. 
Then, the least significant variable (for alpha <0.05) was dropped until all variables 
contributed significantly to the model. The outputs were fitted on the study sample for 
which the input applied to (e.g. low Apgar score only after a c-section was performed, 
low Apgar score only after epidural was used, low Apgar score only after labor induction, 
and so on). Third, we described the variance in value across MCNs by plotting the inputs 
4
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against the outputs at the logit link scale (random MCN effects only). To increase 
interpretability we showed the adjusted rates (mean, minimum and maximum) on the 
response scale (which are essentially percentages derived through taking the inverse 
logit of the linear predictor function, as described between brackets in (1)). We further 
assessed whether the MCNs exhibit distinct profiles of value by calculating whether the 
random effects differed from zero for the inputs and the outputs and/or both, through 
studying the Empirical Bayes estimates of the random effects and their variances. Data 
management and analyses were performed using Stata software version 15.1.
Additional analyses
To explore whether we truly grasped the concept of value, we performed three additional 
analyses. First, to gain insight into the extent to whether high (or low) performing 
MCNs on a specific input also performed high (or low) on a specific output, the graphs 
were inspected and Spearmans’ correlation coefficient (rho) was calculated between 
each input and output. Second, to assess whether the value-indicators might measure 
the same concept, we checked the consistency across each possible combination of 
inputs, and across each possible combination of outputs, using Spearmans’ correlation 
coefficient (rho). Third, we assessed the persistence of the inputs and outputs over time. 
The presence of persistency over time would suggest that we may have captured (a part 
of) the concept of value across MCNs, as we do not expect ‘true value’ at the MCN level 
to change drastically over one year. In order to do so, we fitted new models. We repeated 
the procedure for the estimation of the random effects, but this time, we estimated the 
models for each year separately. Per indicator, the association between sequent years 
was calculated using Spearmans’ correlation coefficient (rho) and assessed to what extent 
they persisted over the years.
All observed Spearman correlation coefficients (rho) were interpreted as negligible 
(0.00 – 0.10), weak (0.10-0.39), moderate (0.40-0.69), strong (0.70-0.89) or very strong 
(0.90-1.00) [54]. 95% confidence intervals were bootstrapped with 1000 replications. 
Statistically significant correlations that were moderate, strong or very strong were 
interpreted to point towards consistency or persistence.
RESULTS
Study characteristics
Our original dataset contained 834,234 pregnancies over 2011 through 2016. We 
excluded pregnancies with a NICU-admission (n=2,871), pregnancies that were not 
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low-risk (n= 533,403), pregnancies that could not be attributed to a MCN (n=5,936), or 
were attributed to a MCN for which the numbers of pregnancies were too low (threshold 
2,000 pregnancies per MCN) (n=4,222).
Table 2 shows unadjusted descriptive statistics (mean/%, minimum and maximum value) 
at the MCN-level for outputs, inputs and case-mix variables. From 2011 through 2016, 
91 distinct MCNs served a total of 297,960 low-risk pregnancies. That comes down 
to an average of 4,054 pregnancies per MCN during the whole study period, where 
the smallest MCN had 764 pregnancies and the largest MCN had 7,861 pregnancies. 
Unadjusted rates of low-value services varied widely, with c-sections ranging from 6% 
through 21%, epidural ranging from 5% through 58% and induction ranging from 20% 
through 69%, depending on the MCN. Rates for neonatal and maternal health outcomes 
also varied across MCNs. For example, rates of low Apgar score varied between 0.2% 
and 2.3%. Subsequent to the utilization of low-value services, the rates of low Apgar 
score ranged from 0.0% through 6.8% (after c-sections), from 0.4% through 3.6% (after 
epidural) and from 0.3% through 3.3% (after induction). Case-mix characteristics of the 
mother, father, pregnancy, and child also varied across MCNs.
Variation of value-indicators across MCNs
After we adjusted for case-mix, variation across MCNs persisted for all inputs and 
outputs (Table 3). Most variation was observed for the inputs indicators. For example, 
labor induction showed rates of 21.0% through 67.7% depending on the MCN, and 66 
out of 91 MCNs showed statistically significant differences from the average. Variation 
also persisted for the outcomes. For example, ‘low Apgar score after c-section’ ranged 
from 1.6% through 5.2%, and 5 out of the 91 MCNs differed statistically significant 
from the average, for both the input (c-section) and the output (low Apgar score). 
The output with the largest number of MCNs (20 out of 91) that differed statistically 
significant from the average is ‘hemorrhage after labor induction’ and varied between 
4.9% and 11.7%, depending on the MCN.
4
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Figure 1 shows the random effects at the log scale for the value-indicator ‘hemorrhage 
after labor induction’ at the MCN level. Each point in the quadrants represents one 
MCN and confidence intervals are shown around the points. MCNs at the bottom left 
show higher value as they perform relatively less low-value services and have less adverse 
outcomes (relative to other MCNs). MCNs at the top right show lower value as they 
perform relatively more low-value services and have more adverse outcomes (relative 
to other MCNs). Figure 1a shows the MCNs (n=66) that differed from the average 
regarding labor inductions (input) (i.e. no overlapping confidence interval with Y-axis), 
figure 1b shows the MCNs (n=26) that differed with respect to hemorrhages (output) 
(i.e. no overlapping confidence interval with the X-axis), and figure 1c depicts the MCNs 
(n=20) that differed on both labor inductions (input) and hemorrhages (output), thus 
value, for alpha <0.05 (no overlapping of both Y- and X-axis). Eight MCNs were found 
to be of higher value, depicted in the lower left part of the quadrant, meaning that they 
performed relatively less inductions and had relatively less hemorrhages, corrected for 
case-mix. Five MCNs were found of lower value, meaning that they performed relatively 
more inductions and had relatively more hemorrhages, depicted at the higher right 
part of the quadrant. The Appendix contains the figures for all value-indicators. The 
Appendix also contains the regression results that yielded the MCN effects.
Additional analyses
Correlations between inputs and outputs: relation between input and output?
In order to gain insight into the relation between the inputs and outputs, we assessed 
Spearmans’ correlation coefficient between each input and output. Five value-indicators 
did not show statistically significant correlations between input and output performances 
(see Appendix for the full table). This means that MCNs performing relatively more 
low-value services did not show relatively more adverse outcomes and vice versa. Instead, 
most MCNs performing relatively more low-value services had showed no differences in 
outcomes. The exceptions were correlations between the relative performance of MCNs 
regarding ‘c-sections’ and ‘low Apgar score, and ‘epidural’ and ‘low Apgar score’, which 
were weakly negatively correlated (rho, -0.37; 95 percent CI -0.53; -0,20 and rho, -0.20*; 
95 percent CI -0.39; -0.01 respectively). This indicates that MCNs performing relatively 
more c-sections or epidurals had relatively less low Apgar scores. Yet, visual inspection of 
the graph (see Appendix) shows that there are no MCNs that had statistically significant 
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Figure 1: Maternity 
Care Network (MCN) 
perf ormances on the 
value-indicator ‘hem-
orrhage after labor in-
duction’: a) MCNs that 
differed from the aver-
age on labor inductions 
(input), b) MCNs that 
differed from the av-
erage on hemorrhages 
(output), c) MCNs that 
differed on both labor 
induction (input) and 
hemorrhages (output)
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Consistency across inputs and outputs: do they measure the same concept?
In order to gain insight into whether the value-indicators might grasp the same concept, 
we assessed the consistency across inputs and outputs. The consistency of the relative 
performance of the MCNs across adjusted inputs and adjusted outputs was positively 
correlated for 6 out of 18 pairs (Table 4). Correlations were positive and statistically 
significant for 2 out of 3 input pairs, and for 4 out of 15 pairs of output/input. Statistically 
significant correlation coefficients ranged from weak (in red) to strong (in green) 
(rho: 0.24 with 95 percent CI, 0.05-0.42 to rho: 0.77 with 95 percent CI, 0.68-0.87). 
Consistency was found across all ‘low Apgar score’ outputs, irrespective of the inputs 
(labor induction, caesarean section, epidural), which indicates that MCNs showing high 
(or low) scores on low Apgar score after caesarean section, also showed low Apgar scores 
after labor induction and after epidural analgesia. This mostly indicated that the same 
persons were measured (low Apgar score after induction ánd a c-section, for instance). 
Across different outcomes, for example, across low Apgar score and hemorrhage we 
found low correlation coefficients.
Persistence over time: do they measure possibly the concept of value?
The persistence over two consecutive years indicates whether the inputs and outputs 
could possibly reflect the concept of value as we expected true value not to change much 
over one year. For inputs, the correlations were positive and statistically significant for 
all subsequent years (except for ‘labor induction’ between 2015 and 2016). The strongest 
correlation coefficients for the subsequent years were found for ‘epidural’ (ranging from 
rho: 0.84 with 95 percent CI, 0.71-0.97 to rho: 0.93 with 95 percent CI, 0.89-0.98). 
All inputs were considered to persist over time as they had four or more (out of five) 
statistically significant correlations of rho >0.40 (orange or green) in subsequent years. 
For outputs, 18 out of 30 subsequent years showed positive and statistically significant 
correlations. Statistically significant correlation coefficients ranged from weak to 
moderate (rho: 0,23 with 95 percent CI, [0.01,0.44] (‘low Apgar score after epidural’ 
between 2011 and 2012) to rho: 0,52 with 95 percent CI, [0.35,0.69] (‘hemorrhage after 
c-section’ between 2011 and 2012)). The output that showed the most persistence over 
time was ‘hemorrhage after labor induction’, which had two statistically significant 
correlations of >0.40 in subsequent years.
4
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This study aimed to explore whether it is possible to demonstrate difference in 
value across Dutch MCNs by studying six proposed value-indicators that could be 
operationalized in Dutch nationwide linked observational data from 2011 through 
2016. We observed substantial variation in all six value-indicators across MCNs after 
adjusting for characteristics of mothers, fathers, pregnancies and children in low-risk 
pregnancies. Additional analyses showed no correlations between inputs and outputs, 
except between ‘low Apgar score’ and ‘caesarean section’ and between ‘low Apgar score’ 
and ‘epidural analgesia’, which were weakly negatively correlated. Additionally, we found 
that MCNs showing relatively high (or low) ‘low Apgar score after caesarean section’, 
also showed relatively high (or low) ‘low Apgar scores after labor induction’ and after 
epidural analgesia (consistency). We also found consistency between ‘hemorrhage after 
induction’ and ‘hemorrhage after c-section’. Persistence over time was found for all 
inputs, i.e. the low-value care indicators (labor indication, caesarean section, epidural), 
for at least four out of five sequential years.
Our findings suggest that the inputs (which are known as low-value care indicators) 
may, in part, reflect the concept of value, because they showed variation across MCNs 
and persistence over time. The performance of MCNs regarding ‘low Apgar score’ and 
‘hemorrhage post-partum’ seems invariant to the rate of low-value services in low-risk 
pregnancies (i.e. whatever treatment rate, MCNs seem to have fixed health outcome 
rates). This points at overuse of those services, because it seems that a reduction of the 
utilization of caesarean sections, epidural analgesia and labor induction is not associated 
with a deterioration in maternal and neonatal health outcomes at the MCN level. 
Therefore, policies aiming at reducing these services would improve value.
Although the low-value care indicators that we have used in this study may have captured 
a part of value, we considered the low-value care indicators not to be consistent. Our 
results showed that the use of labor inductions was weakly positively correlated with the 
use of caesarean sections and the use of epidural analgesia. That means that if an MCN 
has relatively high rates for one low-value care indicator, it may have relatively low rates 
for another. This indicates that value likely is multi-faceted, and not easily measured 
by just one indicator. Our results somewhat contrast previous research of Schwartz 
and colleagues, who found (moderate) consistency between different clinical disciplines 
within organizations [13, 24]. Possibly, some aspects of obstetrics are less influenced by 
practice patterns than others [13], or areas of expertise vary across MCNs.
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Despite our efforts to bypass endogeneity issues by using low-value utilization indicators 
instead of health spending and using many case-mix variables, we still detected 
population heterogeneity that may have clouded our results. We found that high 
variability of value-indicators, both inputs and outputs, in addition to wide confidence 
intervals, which suggests we were not able to control sufficiently for all factors that play 
a role in predicting the inputs and outputs. Variances between MCNs may be driven 
by unobserved or unavailable characteristics of the population or care professionals 
that we were not able to capture, such as preferences of pregnant women, training of 
midwifes and obstetricians and level and history of collaboration within an MCN [13]. 
Nevertheless, whatever the cause of the variation may be, we did observe persistent 
and wide variations for the low-value care indicators across MCNs, which is consistent 
with previous literature [28, 34] and suggests that there is room for improvement at the 
MCN level [13].
The most important limitation to our study was that we had no access to patient reported 
outcome measures (PROMs) or patient reported experience measures (PREMs). These 
indicators are important for capturing the concept of value as they potentially reflect 
what matters to women, which is essential as it is part of the definition of value [3]. By 
lack of patient reported indicators, we used observational outcomes, which did not show 
persistence over time. In addition, we excluded pregnancies with a NICU-admission, 
because all these pregnancies were attributed to the nine MCNs that had such a unit, 
and would have resulted unfair high rates of negative outcomes for those MCNs. The 
drawback is that we excluded the pregnancies with outcomes of interest, which may have 
had an important impact on the variation of the outcomes across MCNs.
Future research should investigate possibilities to include PROMs and PREMs on a 
large scale in observational data, without putting an administrative burden on (pregnant) 
women and providers, for example by using mobile phone applications. Subsequently, the 
marginal effects of low-value services on PROMs and PREMs should be investigated, 
in addition to exploring other (types of) outcomes that directly reflect the value of 
the services delivered in terms of experiences of women. Furthermore, future research 
should focus on dealing with limitations of observational data, for example that it still 
is difficult to deal with endogeneity problems and population heterogeneity, and be 
transparent about it.
Conclusions
Our findings suggested differences between MCNs with respect to the selected value-
indicators. In addition, our results indicated that some outputs may have measured a 
4
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similar concept (consistency), and that the inputs (i.e. low-value care indicators) may have 
captured a part of value (persistence). Yet, despite access to many case-mix variables from 
multiple datasets, we detected population heterogeneity which might have clouded our 
results. Future research should further deal with the limitations of observational data 
and refine outcome measures that matter to the population of pregnant women in order 
to truly capture value at the MCN level and contribute to value-based maternity care.
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S1. Data linkage process
The linkage of the datasets and the analyses of this study were performed in the highly 
secured remote access platform from Statistics Netherlands (SN). Vektis and Perined 
uploaded their data to the secured platform from SN. To adhere to the privacy legislation, 
SN pseudonomized the social security numbers in the Vektis data using pseudonomized 
identification numbers (PINs). The linkage percentage for the Vektis-data was 99.9% 
for each year. Subsequently, SN linked the Perined data, which do not include social 
security numbers, to the municipality registration data in order to obtain PINs for 
mother and child. The linkage key comprised out of: the date of birth of the mother, 
date of birth of the child, gender of the child, single births or twins, live- or stillbirth 
and 4-digit zip code. The linkage percentage for the Perined-data varied between 92 
and 98% depending on the year. After the linkage and pseudonomization by SN, the 
data was accessible for the authors.
The datasets were linked in three subsequent steps. First, we combined nationwide 
individual level all-payer claims data (containing total spending per year) for 2009 
through 2016. Then, we linked datasets containing municipality registration data (i.e. 
year of birth, month of birth, gender, ethnicity), highest attained educational level and 
standardized household income using the unique PINs. Finally, we used Perined data, 
which showed one pregnancy per record, to link the father, mother and child data 
separately to.
In order to include the detailed claims data from Vektis on maternity spending, we 
additionally performed the following steps and applied the following assumptions. First, 
we created pregnancy-id’s that could end in both a birth or a miscarriage. Therefore, we 
first created a list of all unique mothers (in the Vektis-data) and used the SN data to link 
parents to their children. We identified multiple gestations based on mothers’ PIN and 
month of birth using the community registration set from SN. We assumed that mothers 
for whom no child was found in the community registration set, have had a miscarriage. 
A number was assigned to each pregnancy based on chronological order. In this manner, 
we made a distinction between births and miscarriages. Second, we linked claims data 
to a singular pregnancy based on the date the claim was made and the date of birth of 
the child based on the community registration set. A claim was linked to a pregnancy 
when the date fell between 9 months prior to the date of birth and two months after 
the date of birth. The remaining claims were labeled as miscarriage claims. We assumed 
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that claims in concurrent months belonged to the same miscarriage. Third, we linked 
the mother and child combinations to the Perined data using the pregnancy-id.
The created linked dataset could now be augmented with several SN datasets, such as 
datasets containing municipality registrations (age, ethnicity, gender), highest attained 
educational level and level of urbanization.
S2. Endogeneity of health spending
As discussed in the introduction section, healthcare spending may not be ideal for 
analyses of the variation of value as endogeneity problems may occur. We wanted 
to confirm that this endogeneity issue also applies to our dataset by inspecting the 
relationship between maternity spending and maternal/infant health outcomes at the 
individual level. In order to do so, we created a subsample (n=268,893) of our data for 
which detailed claims data on maternity care were available (2015-2016). To define 
the spending on maternity care, we categorized a single claim into a prenatal, natal 
and postnatal phase and summed those categories. In order to inspect the relationship 
between maternal and infant health outcomes, we modelled each of the health outcomes 
as a function of maternity spending (in 10 bins), case-mix and MCNs, where case-mix 
and MCNs were kept constant. We fitted logistic models using the covariates from the 
main analysis (age mother, educational level, household income, ethnicity, urbanity, 
gestational age, birth weight, gestational hypertension, gestational diabetes, healthcare 
spending in the previous year, gender of the child and age of the father). The marginal 
contributions of maternity spending on health outcomes with their confidence intervals 
(95%) were plotted (see Figure A1). There seems to be a positive association (i.e. the 
higher the adverse health outcome, the higher the maternity spending) between the 
adverse outcomes components separately and maternity care spending. This suggests that 
the spending level seems to be associated with the type of treatment (which is necessary 
in order to deal with the health status the mother and child are presented with), rather 
than quality of care, even when adjusted for case-mix.
4
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Figure A1: adjusted 
predictions of ma-
ternity spending on 
adverse neonatal and 
maternal outcomes 
(a: low Apgar score; 
b) hemorrhage; c) 
perineal damage)
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S3. Graphics of the six value-indicators
The figures show the random effects at the log scale for the five additional value-indicators 
at the MCN level. In each plot, each point represents one MCN and confidence intervals 
are shown around the points. MCNs at the bottom left part of the quadrant show higher 
value as they perform relatively less low-value services and have less adverse outcomes 
(relative to other MCNs). MCNs depicted at the top right part of the quadrant show 
lower value as they perform relatively more low-value services and have more adverse 
outcomes (relative to other MCNs). For each value-indicator, the figures a show the 
MCNs that differed from the average regarding inputs. The figures b show the MCNs 
with respect to the outputs. And the figures c depict the MCNs that differed from the 
average on both inputs and outputs (i.e. value), for alpha < 0.05.
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S6. Correlations between inputs and outputs
Output
Input Low Apgar Score Hemorrhage Perineal Damage




Labor Induction -0.07 [-0.27; 0.13] 0,01 [-0.20; 0.21] -0.12 [-0.31; 0.07]
Estimates are Spearman correlation coefficient (rho) and bootstrapped 95% confidence interval for 1000 
replications in brackets. N = 91. * p < 0.05, ** p < 0.01, *** p <0.001
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Although effects of alternative payment models (APM) on health and spending are 
unclear, they are increasingly implemented across countries. This study provides an 
overview of APMs in maternity care, describing key elements and empirical evidence. 
A scoping review was performed in PubMed, Embase and Scopus for articles published 
from January 2007 through November 2018. Key elements (status, type of APM and 
risk mitigation strategies) were collected and evidence regarding health and spending 
was examined. We identified seventeen initiatives that employed pay-for-performance 
(n=2), shared savings (n=7) and bundled payments (n=8). Key terms (e.g. shared savings 
and bundled payments) were used interchangeably. APMs that shifted more financial 
accountability towards providers included more strategies that mitigated risks. Four 
studies evaluated effects of APMs; two found associated improved outcomes and two 
associated reduced spending. Clear definitions of key elements and understanding of 
how they operate into different settings is required to interpret future evidence and 
shape payment reform.
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INTRODUCTION
Policies in both US and Europe aim for the reduction of avoidable infant mortality, 
pre-term rates and maternal mortality. Previous reports show that improvements can 
be made by optimizing the delivery of health services [1, 2]. For instance, low-value 
services, such as non-medically indicated caesarean sections, are increasingly performed, 
while high-value services, such as screening for gestational diabetes or educating women 
on what to expect during and after birth, are underutilized [2, 3]. To achieve optimally 
organized care, more coordination of care delivery is needed.
The promise of alternative payment models (APMs) is that they incentivize care 
coordination, and stimulate the use of high-value care and discourage the use of low-
value care by increased provider accountability. In the literature, theoretical effects 
of APMs have been discussed [4-8] in comparison to effects of fee-for-service (FFS) 
models, which are commonly used in daily practice. The financial risks in the FFS 
models are borne largely by the payers. Since health care providers thereby run no 
financial risk in terms of the volume and the value of care they deliver, a FFS system 
inadvertently encourages providers to deliver larger volumes of care and low-value care 
[4-7, 9]. APMs aim to remove these incentives by shifting the accountability, for health 
outcomes and health spending, towards providers [4]. This serves as an incentive to 
avoid unnecessary care as well as encourages other cost-conscious behaviors such as 
downward substitution of care, task reallocation and more efficient coordination between 
practitioners within care. The scope of the APM determines the allocation of financial 
risk between provider and payer. Ideally, the performance risk (i.e. risks that are related 
to the providers own share in providing high quality and efficient care [7]) is allocated 
with the provider and the insurers risk (i.e. risks that stem from patients and their 
respective needs [7]) with the payer. Performance risk increases the incentives to create 
value, whereas insurance risk increases a providers’ level of financial risk without the 
provider being able to control it. Therefore, the optimal allocation of risks is where, for 
providers, insurance risk is minimized and the performance risk is maximized [8]. To 
optimize the financial risk for providers, APMs may be refined by adding components 
such as bonuses or penalties when certain quality targets are met (e.g. in shared savings), 
or adding risk adjustments or stop loss provisions (i.e. risk mitigation strategies).
New contribution
Based on the promises of better quality of care, APMs are increasingly implemented 
in maternity care, for example in Arkansas [10-12] and in the Netherlands [13]. All 
adopted a different strategy for which there is currently no strong empirical evidence. 
5
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Yet, further implementation of APMs is likely to continue for maternity care [14, 15]. 
However, to understand (future) empirical evidence, there is a need to gain insight 
into the key design elements of the APMs. As far as we are aware, such an overview of 
APMs in maternity care and their effects on health and spending, is currently lacking. 
Therefore, this study focused on the following research questions:
1) What are the key elements of APMs currently implemented in maternity care?
2) What evidence is available with regard to the empirical effects of such payment 
models on the maternal and neonatal health outcomes and perinatal spending?
Conceptual framework
Based on previous research [4, 8, 16, 17], we developed a framework in which the key 
elements of APMs gain insight into their level of integration of financial accountability 
and the level of integration of providers over domains of care. We defined APMs as 
initiatives that include changing the financing of care delivery that aimed to improve 
maternal and/or infant health outcomes and reduce utilization and/or health spending. 
Our definitions of the types of APMs are shown in Table 1. Frakt and Mayes (2012) 
showed that the level of financial risk varies with the payment model For example, under 
FFS, payers bear more risk than providers and under global payment providers bear 
more risk than payers (Frakt and Mayes 2012). This creates an incentive to collaborate 
with providers in other domains in order to reallocate and coordinate care efficiently. 
Yet, the level of financial risk a provider is bearing can be mitigated by ‘risk mitigation 
strategies’. Such risk mitigation strategies prevent providers from bearing too much risk 
(i.e. insurers’ risk) and include high-risk population exclusions and/or risk adjustment to 
account for the severity of the population in the episode price or benchmarks for shared 
savings. Another example of a risk mitigation strategie is a ‘stop-loss provision’, which 
is a threshold that caps the maximum amount to which the provider is at risk [18] and 
can be used at the individual level to limit the risk of e.g. high-cost Neonatal Intensive 
Care Unit (NICU) care or at the aggregate level [19].
METHODS
Search strategy and information sources
To identify as many initiatives as possible that implemented APMs for maternity care, we 
reviewed the international literature. The process was guided by the Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis (PRISMA) to ensure validity and 
reliability [22]. In collaboration with a librarian, we developed a search strategy for 
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PubMed, Embase and Scopus databases for articles published from January 2007 
through November 2018. Search key words included ‘payment’, ‘funding’, ‘alternative 
payment’, ‘value based payment’, ‘maternity ward’, ‘obstetric’, etc. The full search strategy 
is displayed in the Appendix.
Eligibility criteria
English or Dutch language articles were found eligible if they described and/or 
empirically evaluated, APMs in maternity care in high-income countries. Additional 
relevant articles and grey literature (e.g. government reports, white papers) were 
Table 1: APM types and definitions (based on De Vries et al. [17])
APM type Definition
Pay-for-performance In pay-for-performance, a bonus/malus is paid for attaining 
certainty quality thresholds on top of the base FFS payment. 
Under FFS, providers are paid a fee for each service delivered 
[4]. The additional payments can be employed for improving 
coordination, care efficiency, quality of care or accessibility of care 
[20].
Shared savings In a shared savings model, individual providers are each paid on 
a FFS basis and then there is reconciliation between the target 
episode price and the actual episode average price after a period 
of time across all the episodes attributed to a provider. Based on a 
specific formula, which is either negotiated or established by the 
payer, the accountable provider can share in gains and/or losses 
with the payer. Shared saving models that only share in gains are 
called one-sided. In two-sided models also risks are shared.
Bundled payments Bundled payments are defined for a specific set of activities tied to 
an episode of care, such as maternity care, that includes more than 
one provider or organization. The entity receiving the bundled 
payment earns a higher margin if a patient has utilized less care, 
but also bears the financial risk of complications. In our definition, 
the main difference with shared savings is that savings or losses 
are not shared with the payer. There are two types of bundled 
payments, retrospective and prospective. In retrospective bundled 
payment, there is a virtual budget negotiated upfront, providers are 
paid by FFS and retrospectively, the target price is reconciled [21]. 
Prospective bundled payment pays a prospectively defined prize 
that is paid as one payment to the accountable entity that in turn 
pays the individual providers [16].
Global payments In global payments the entire population and the entire continuum 
of care is included. The accountable provider is paid a fixed fee per 
head of the population.
APM: Alternative Payment Model; FFS: fee-for-service
5
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identified through reference tracking and recommendations from experts. Articles were 
excluded if they were commentary articles.
Study selection
First, duplicates were removed. Based on title and abstract, the remaining articles were 
screened for eligibility by two researchers (EdV and MdBK) independently. Differences 
were discussed and, if there remained any doubt, the full-texts were retrieved to reach 
consensus on whether or not to include the article.
Data extraction and synthesis
From the full-text articles, the following information was extracted: first author, year 
of publication, country, publication type, name of initiative and key elements of the 
implemented APMs:
 – Type of APM
 – Care providers that participated in the model
 – Accountable entity
 – Care activities that are covered by the model
 – Link of the model with quality of care.
From studies that empirically evaluated APMs, we additionally extracted information 
on the research method, data collection period and results of the payment model on 
health outcomes and healthcare spending. We assessed the quality of the evidence using 
the Effective Public Health Practice Project Quality Assessment Tool for Quantitative 
Studies [23]. This tool provides an overall methodological rating of the article: strong, 
moderate or weak based on assessment of six components (selection bias, study design, 
confounders, blinding, data collection methods and withdrawals and dropouts). The 
quality appraisal was performed by EdV and MdBK, independently. Discrepancies 
were resolved by discussion until consensus was reached. The evidence of the studies 
was not pooled.
If blanks or uncertainty remained, the authors of the articles were requested to provide 
additional information through e-mail. EdV subtracted the data. JS and MdBK checked 
this randomly.
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RESULTS
Study selection and characteristics
Figure 1 shows the study selection flow diagram. We identified 149 articles through 
a search in the peer-reviewed international literature. Reference tracking yielded an 
additional 31 documents of which also non-scientific articles, white papers, government 
documents and blogs. After removal of duplicates and non-eligible articles, our final 
sample consisted of six articles from peer-reviewed journals and 30 government 
documents, white articles or other documents. Four peer-reviewed articles performed 
an empirical evaluation of the APM on health outcomes and health spending. The 
documents and document types included in this review are fully listed in the Appendix.
Figure 1: Study selection flow diagram according to Preferred Reporting Items for Systematic 
Review and Meta-Analysis (PRISMA)
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Key elements of APMs in maternity care
General characteristics
In the 36 articles, we identified 17 initiatives that had implemented an APM (Table 
2). Most of them are from the United States (n=13) and further initiatives are found in 
the United Kingdom (n=2), New Zealand (n=1) and the Netherlands (n=1). The earliest 
APMs were implemented in 2007 (GHS (16) and LMC (17)) and the most recent in 
2017 (Dutch BP (13)). Most initiatives are established on a permanent basis (n=11); five 
others were pilots, and for one the status is unknown.
Type of APM
Table 2 also shows the type of APM of the 17 initiatives. The APMs are classified into 
three categories: pay-for-performance (n=2), shared-savings models (n=7) and bundled 
payment models (n=8). For a detailed overview, see Appendix B.
Pay-for-performance is applied in two initiatives (1,2). In the CQUIN initiative in 
England (1), hospitals are paid bonuses if they satisfy specified scores on a set of quality 
indicators pertaining to elective and emergency Caesarean sections. This pay-for-
performance system is superimposed onto the existing FFS model, hence not replacing 
the existing payment structure. In the Texas Medicaid Program (2) there is a penalty 
for hospitals that delivered neonatal deliveries before 37 weeks gestation that are not 
medically necessary; these billing codes are ineligible for reimbursement.
Shared savings models are implemented in seven initiatives (Horizon (3), Baby+Company 
(4), TennCare (5), Arkansas (6), Ohio (7), CHC (8) and New York (9)). Those are 
contracts whereby any achieved savings is shared between providers and payers. Such 
savings are calculated by comparing the health care spending for the risk adjusted 
population included in the payment model either with the spending for a predefined 
control group (i.e. concurrent accountable providers) (TennCare (5), Arkansas (6), 
Ohio (7)) or with the spending for the intervention population in years preceding the 
implementation of the APM (historical benchmark) (Horizon (3), CHC (8)). If savings 
are achieved for the intervention population in comparison with the control group or the 
historical benchmark, those savings are partially distributed to the providers, resulting 
in for example 50% for the providers and 50% for the payers (TennCare (5)).
The shared-savings contracts vary in the degree to which health care providers bore 
financial risks in the event of spending overruns. Two initiatives, Horizon (3) and 
Baby+Company (4), operated a one-sided shared-savings model, whereby providers 
bear no downside risks if budgets are exceeded but share in any savings achieved. Five 
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initiatives, TennCare (5), Arkansas (6), Ohio (7), CHC (8) and New York (9), agreed 
in their contracts that the providers must reconcile any spending overruns (two-sided 
models). In the more recently launched initiatives CHC (8) and New York (9), the 
shared-savings contracts employed one-sided models in the first year but were converted 
to two-sided contracts in the second year, thus gradually shifting more financial risks 
towards the providers. Four of the shared saving models (Horizon (3), TennCare (5), 
Arkansas (6) and Ohio (7)) appoint the provider (group) that delivers the baby as the 
accountable entity. In the shared-savings models, the distribution of savings is contingent 
on achieved improvements in quality. In the New York scheme (9), provider penalties 
for exceeding budgeted spending are reduced or eliminated for those scoring high on 
the quality indicators.
Eight initiatives (10, 11, 12, 13, 14, 15, 16, 17) implemented variants of bundled payment 
models that vary highly in terms of shifting the accountability. Two initiatives (Pacific 
(10) and Minnesota BP (11)) only cover care in the delivery phase for which the hospital 
is accountable. A fixed fee is negotiated for deliveries, irrespective of whether vaginal 
or Caesarean. In the Minnesota BP (11) program, complicated vaginal deliveries are 
excluded. Although the payment model is limited to the hospital (i.e. one provider only), 
this model contains a financial incentive to perform fewer Caesarean sections. Therefore, 
one may conclude that the financial risk in this model is partially shifted from the payer 
to the care provider(s). That is why we decided to classify this model as an APM and 
included it in our overview.
One initiative (BirthBundle (12) implemented a retrospective model. The integrated fee 
that is charged for a maternity care episode is in fact a ‘virtual’ fee, which is reconciled at 
the end of the episode by totaling the FFS for all the services delivered. If the spending 
turned out lower or higher than the virtual fee, the difference is transferred to the 
accountable entity, which is the birth center (BirthBundle (12)).
Five initiatives (The Dutch BP (13), Maternity Pathway BP (14), Providence (15), GHS 
(16) and LMC (17)) implemented prospective bundled payment models. All the services 
specified in the entire maternity care program (or split up into three or four phases 
(prepartum, delivery and postpartum) (The Dutch BP (13), Maternity Pathway BP (14), 
LMC (17)) are contracted, delivered and claimed as a single product by the accountable 
nurse or midwife or obstetrician. These prospective bundled payment models replaced the 
existing FFS models. No reconciliations are performed as in the retrospective models.
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Risk mitigation
The pay-for-performance models (n=2) employ no risk mitigation strategies.
In the one-sided shared savings models (n=2), the Horizon program (3) includes both 
low- and high-risk pregnancies, but excludes several comorbidities in pregnancy such 
as HIV and cancer and neonatal care to set the benchmark. Baby+Company (4) only 
includes low-risk pregnancies. Other risk mitigation strategies were not found.
The two-sided shared savings models (n=3) (TennCare (5), Arkansas (6) and Ohio (7)) 
includes only low-risk pregnancies and excludes pregnancies ending in stillbirth. In 
addition, women with several comorbidities are excluded from the model, as is care for 
the newborn. These three initiatives (5, 6, 7) include a stop-loss provision for individual 
cases that exceeds more than three standard deviations above the risk-adjusted mean. 
CHC (8) and New York (9) includes also high-risk pregnancies in addition to newborn 
care, and applies an aggregate stop-loss provision.
For the retrospective bundled payment model (n=1), BirthBundle (12), we did not find 
any risk mitigation strategies.
The prospective bundled payment models (n=5) (The Dutch BP (13), Maternity Pathway 
BP (14) and LMC (17)) includes low- and high-risk pregnancies. Providence (15) and 
GHS (16) only includes low-risk pregnancies. GHS (16) excludes late referrals or 
members not enrolled at least 12 continuous weeks of the prenatal phase. The Maternity 
Pathway BP (14) and the Providence (15) initiative also include care for the newborn, 
although health problems in the newborns are excluded in the Maternity Pathway BP 
(14). In the other initiatives (16, 17), care for the newborn is excluded. In the Netherlands 
(13), in most regions, stop-loss provisions are applied to which new negotiations would 
start to decide what to do with the gains or losses. Other risk mitigation strategies were 
not found. As a quality assurance measure with respect to the care delivered, payers 
generally required providers to file yearly reports on quality indicators (accountability 
data).
Table 3 provides a schematic overview of the various payment models, showing the level 
of integration and the level of financial accountability. APMs that employ the highest 
level of integration and highest level of financial accountability are Maternity Pathway 
Bundled Payment, GHS and LMC.
5
541371-L-bw-deVries
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Processed on: 24-2-2020 PDF page: 219
219
Alternative payment models in maternity care
Effects of the APMs on maternal and neonatal health outcomes and health 
spending
Table 4 shows results of the available evaluations from four of the 17 initiatives that 
implemented an APM in maternity care (Texas, Arkansas, CHC and GHS). In two 
studies, a beneficial effect of the APM on the health outcomes was observed [25, 52]. 
The other two studies that did evaluate the effects of the APM [32, 45] did not show 
improvement on health outcomes. To studies [32, 45] gauged the effects of the scheme 
on health care expenditures, reporting positive effects.
Three out of four studies reporting evaluations were assigned moderate rating for the 
quality of the evidence. No studies evaluating APM in maternity care received a strong 
rating. Appendix D summarizes the details of quality of the evidence assessments that 
we conducted.
DISCUSSION
As APMs are increasingly implemented in maternity care, more insight in APMs 
and empirical evidence about the effects of APMs on maternal and infant health 
outcomes and spending is needed. We identified 17 initiatives implementing APMs 
in maternity care: pay-for-performance models (n=2), shared savings models (n=7) 
and bundled payment models (n=8). APMs that shifted more financial accountability 
towards providers seemed to include more strategies that mitigated those risks. Risk 
mitigation strategies included population and care exclusions, stop loss provision and 
risk adjustment. Of the seventeen initiatives, we found four empirical effect studies 
evaluating the APMs on health outcomes and health spending. Two studies found 
an association of the APM with an improvement in health outcomes and two studies 
described an association with a reduction in health spending.
Although the first studies examining the effects of APMs on health outcomes and health 
spending in maternity care seem tentatively positive, extensive conclusions on the effects 
of the APMs cannot be drawn; we did not find a ‘one size fits all’. That is because it 
may take considerable time for the impact of an APM to be fully observable. As these 
studies captured early results, it is unclear what effects are in the longer run. Moreover, 
multiple types of APM with multiple key elements were implemented of which four 
were evaluated using varying indicators. Consequently, which element of which APM 
has which effects in which type of health system is therefore unknown. Further research 
should address these matters, but results cannot be expected in short term.
5
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Yet, to deal with the current demand for payment reform [14], we identified two issues 
that should be addressed in order to design an APM that fits the health care setting at 
hand and works towards the desired goals.
First, a detailed understanding of the specific elements of the APMs is required with 
providers and payers that work to implement APMs. In this review, we found that 
currently there is a multiplicity of complex terminology and ambiguous definitions that 
confuses the understanding of APMs. For example, we found that descriptions of APMs 
often used the terms ‘shared savings’ and ‘bundled payments’ rather interchangeably. 
That was notably the case in initiatives that employed a two-sided shared-savings model 
or a retrospective bundled payment model. Presumably, the conflation of the two notions 
arises from the conceptual similarities between the two payment models. For example, 
the proportion of risk borne by the care providers working under the model is 100% in 
bundled payment contracts, and it is smaller (perhaps 50% or 70%) in shared-savings 
contracts. Such a distinction was not clearly made in several of the descriptions, and 
as such confusing the two terms. A clear definition of terminology will contribute to a 
better understanding of the key elements of the APMs.
Second, key elements of the APM including risk mitigation strategies may be best 
designed from the providers’ perspective. For example, feasibility considerations may 
play an important role in designing the APM. We found, for example, that in some 
initiatives had been superimposed onto the existing FFS model for the single reason that 
retrospective reconciliation is easier to administer within the current FFS environment 
(also see [56]). This aligns with the theoretical notion that the ‘best’ APM shifts only 
that part of the accountability towards the provider that actually can be influenced by 
the provider. Careful deliberation that is based on the level of accountability the provider 
is willing and able to bear, should lead to which type of APM is the most optimal one 
to apply in order to deliver optimal care for the best attainable health for mothers and 
children.
Limitations of this study include that we might have missed relevant initiatives 
implementing APMs in maternity care by, for example, the use of different terminology. 
Nevertheless, as the aim was to provide an exhaustive list of these initiatives, we 
deliberately chose to use other sources than peer-reviewed journals, such as government 
documents and white papers. Therefore, we are confident that we captured the majority of 
the initiatives implementing APMs in maternity care in high-income countries. Another 
limitation is that we did not include grey literature in the search for the evaluations on 
the effects of APMs in maternity care. Although we may have missed relevant insights 
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in the effects of APMs on health outcomes and spending, we are convinced that we were 
able to assess the quality of the included studies by using the Effective Public Health 
Practice Project Quality Assessment Tool for Quantitative Studies (on peer-reviewed 
evaluation studies only).
Conclusions and implications
In our review, we identified maternity care APMs in the United States, New Zealand, 
United Kingdom and the Netherlands. All such APMs intended to improve health 
outcomes and reduce the spending level of maternity care by shifting financial 
accountability from payers to providers. We found that key terms describing the models, 
for example ‘shared savings’ and ‘bundled payments’, were used interchangeably and 
key design elements of the models varied highly. Although first evaluations of APMs 
in maternity seem tentatively positive, due to a variety of model elements and health 
system characteristics they operate into, extensive conclusions could not be drawn. 
Further research, clearly defining the key elements and an in-depth understanding of 
key elements and their effects under the influence of unique characteristics of health 
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ADDITIONAL FILES
A1. Search strategy









#13 NOT (‘asia’/exp OR ‘africa’/exp OR ‘south and central america’/exp)
937
#13






letter:it OR note:it OR erratum:it OR news:it OR ‘conference abstract’:it OR 
‘conference paper’:it OR ‘conference review’:it
1,326
#10
#3 AND (#4 OR #5 OR #6 OR #7 OR #8 OR #9)
29,268
#9
‘new zealand’/mj OR ‘new zealand’:ti
64,271
#8
‘prospective payment’/mj OR ‘bundled payment’/mj OR ‘reimbursement’/mj OR 
‘healthcare financing’/mj OR ‘financing, organized’/mj OR ‘financing, government’/
mj OR (‘integrated health care system’/de AND pay*:ti,ab)
156
#7









‘value based reimbursement’:ti,ab OR ‘funding model’:ti,ab OR ‘integrated funding 
model*’:ti,ab OR ‘case rate payment*’:ti,ab OR ‘individualised funding’:ti,ab OR 
‘individualized funding’:ti,ab OR ‘personalised funding’:ti,ab OR ‘personalized 
funding’:ti,ab OR ‘individualised budget*’:ti,ab OR ‘individualized budget*’:ti,ab 
OR ‘personalised budget*’:ti,ab OR ‘personalized budget*’:ti,ab
673
#5
((bundle* NEAR/5 pay*):ti) OR ((episode* NEAR/5 pay*):ti,ab)
45,105
#4
((payment* NEAR/3 model*):ti,ab) OR ((alternative NEAR/3 payment*):ti,ab) OR 
‘funding source*’:ti,ab OR ‘funding strateg*’:ti,ab OR ‘funding system*’:ti,ab OR 
‘service funding’:ti,ab OR ‘financing source*’:ti,ab OR ‘financing strateg*’:ti,ab OR 
‘financing system’:ti,ab OR ((pay NEAR/3 expenses):ti,ab) OR ‘bear cost*’:ti,ab OR 
‘payment system*’:ti,ab OR reimbursement:ti,ab OR ‘payment reform*’:ti,ab OR 






‘maternity ward’/de OR ‘obstetric delivery’/de OR ‘home delivery’/de OR ‘obstetrics’/
de OR ‘obstetrical nursing’/de OR ‘nurse midwifery’/de OR ‘midwife’/de OR ‘newborn 
nursing’/de OR ‘neonatal nurse practitioner’/de OR ‘perinatal care’/de OR ‘perinatal 
nursing’/de OR ‘perinatal mortality’/de OR ‘perinatal outcome’/de OR ‘postnatal 
care’/de OR ‘newborn care’/de OR ‘newborn assessment’/de OR ‘newborn death’/
de OR ‘newborn intensive care’/de OR ‘newborn intensive care nursing’/de OR 
‘newborn intensive care unit’/de OR ‘newborn monitoring’/de OR ‘maternal care’/
de OR ‘maternal health service’/de OR ‘prenatal care’/de OR ‘prenatal diagnosis’/de 
OR ‘prepregnancy care’/de OR ‘pregnancy outcome’/de
25,175
#1
‘birthing centers’:ti OR ‘birthing centres’:ti OR ‘obstetric care’:ti OR ‘obstetric 
services’:ti OR ‘obstetric health services’:ti OR midwifery:ti OR midwives:ti OR 
‘birth attendants’:ti OR deliveries:ti OR ‘prenatal care’:ti OR ‘antenatal care’:ti 
OR ‘natal care’:ti OR ‘birth care’:ti OR ‘neonatal care’:ti OR ‘perinatal care’:ti OR 
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‘perinatal health’:ti OR ‘perinatal services’:ti OR ‘perinatal population*’:ti OR 
‘perinatal outcome*’:ti OR ‘maternal care’:ti OR ‘maternal health services’:ti OR 
‘maternal services’:ti OR ‘maternity care’:ti OR ‘pregnancy care’:ti OR ‘pregnancy 
services’:ti OR ‘pre-pregnancy care’:ti OR ‘prepregnancy care’:ti OR ‘pregnancy 
related services’:ti OR homebirth*:ti
5
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Population health management (PHM) initiatives aim for better population health, 
quality of care and reduction of expenditure growth by integrating and optimizing 
services across domains. Theoretically, a precondition for PHM is to shift from 
traditional fee-for-service towards value-based payment models. We aimed to gain 
insight into payment reform in nine Dutch PHM sites. Specifically, we investigated 
1) the type of payment models implemented, and 2) the experienced barriers towards 
payment reform. Between October 2016 and February 2017, we conducted 36 (semi-)
structured interviews with program managers, hospitals, insurers and primary care 
representatives of the sites. We addressed the structure of payment models and barriers 
to payment reform in general. After three years of PHM, we found that four shared 
savings models for pharmaceutical care and five extensions of existing (bundled) payment 
models adding providers into the model were implemented. Interviewees stated that 
reluctance to shift financial accountability to providers was partly due to information 
asymmetry, a lack of trust and conflicting incentives between providers and insurers, 
but all the same to a lack of a sense of urgency. Small steps to payment reform have been 
taken in the Dutch PHM sites, which is in line with other international PHM initiatives. 
While acknowledging the autonomy of PHM sites, governmental stewardship (e.g. 
long-term vision, supporting knowledge development) can further stimulate value-based 
payment reforms.
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INTRODUCTION
Increasingly, population health management (PHM) initiatives are being implemented 
across Western countries [1] striving for better population health, better quality of care 
and a reduction of the cost growth (i.e. Triple Aim). The essence of PHM is to integrate 
and optimize services across prevention, care, cure and social care for a pre-specified 
population within the region [2]. In regional networks of healthcare providers, insurers, 
local governments (municipalities) and other health organizations, several interventions, 
such as setting up integrated elderly care, substituting low-complex medical activities 
to a primary care setting and others, for improved collaboration and coordination of 
services, are implemented in PHM.
Theoretically, a key precondition for successful PHM is to shift away from the traditional 
fee-for-service (FFS) payment models to more value-based payment models [3, 4]. 
FFS models are known to incentivize each provider to increase the amount of services 
produced (as long as price is above marginal cost). As FFS models are designed for 
acute care specifically, they do not automatically align with the Triple Aim [5]. Payment 
models such as bundled payments or global payments are more aligned with the Triple 
Aim. They increase financial accountability for (groups of) providers and, in that 
manner, incentivize better coordination of care and support the integration of services 
over domains within the bundle or budget. At the same time, they reduce incentives for 
overtreatment and low-value care [6].
Nevertheless, there is uncertainty regarding how to successfully develop and implement 
value-based payment reform. Currently, several PHM initiatives are experimenting 
with payment reform [7], yet studies on their impact are few. Well-known examples are 
Gesundes Kinzigtal in Germany [8] and the Alternative Quality Contract (AQC) in 
the U.S. [9]. Gesundes Kinzigtal implemented a long-term shared savings contract [8], 
while in the AQC providers are being paid a risk-adjusted global budget [10]. Also in the 
Netherlands, PHM initiatives have been initiated [11, 12], which currently explore more 
value-based payment schemes as part of their efforts in moving toward the Triple Aim 
[12]. Few empirical studies evaluating payment reform have been conducted, showing 
some promising effects. For example, two studies [8, 13] showed beneficial outcomes of 
Gesundes Kinzigtal; savings and a lower mortality rate compared to the control group. 
In addition, AQC enrollees had lower spending growth and generally greater quality 
improvements after four years, as compared with similar populations in other states [10]. 
The authors conclude that payment reform in AQC’s, i.e. global budget contracts with 
6
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quality incentives, contributed to these results, even though other factors also played 
a role [10].
Moreover, studies on the barriers and enablers to payment reform are scarce and are 
generally more theory-focused (e.g. [14, 15]). The few studies which have discussed 
experiences from the field highlighted that there is a need for a neutral convening 
party that maintains the commitment of providers and payers, a need of flexible, stable 
leadership, pressure from public and private payers, and an increased investment to 
support infrastructure, care management and human resources [16]. These findings were 
solely based on U.S. experiences. Since the organization of health systems differs, PHM 
initiatives in other countries may face different challenges. Therefore, it is important 
to broaden the scope of the literature including initiatives in other healthcare systems. 
The Netherlands has a system of regulated competition and includes mandatory health 
insurance and the expectation of competition between private insurers [17]. We aimed 
to gain insight into the process to payment reform in the Dutch PHM sites. More 
specifically, we aimed to 1) provide insight into the type of payment models that were 
introduced, and to 2) provide an overview of barriers during the implementation of 
payment reform based on the experiences of relevant stakeholders. This study is part of 
the National Monitor Pioneer sites (NMP) which monitors the progress of nine Dutch 
PHM sites from 2013 until 2018 [18].
MATERIALS AND METHODS
Study setting
Dutch PHM sites are regionally oriented network organizations varying in population 
size, participating organizations and interventions. Table 1 shows the general 
characteristics of the Dutch PHM sites. The population size ranged between 42,000 and 
646,200 residents. Participating organizations included insurers, primary care providers, 
hospitals, municipalities, citizen representative organizations and employers [19]. All 
networks aim to integrate and optimize services across domains by implementing 
two types of interventions. First, PHM sites implement interventions to improve 
the organization of care through e.g. better data infrastructure. Second, PHM sites 
implement interventions to improve the delivery of care through substitution and 
integration of care and better self-management. Examples are substituting brand with 
generic medication, substituting secondary care with primary care, improving existent 
chronic care bundles, integrating care for elderly and prevention activities [19].
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The PHM sites operate within the context of the Dutch health system where providers 
are predominantly being paid by FFS (for each visit or for each service) or diagnosis-
related group (DRG). GPs are being paid through capitation augmented with FFS per 
visit and/or service. Basic mental health care, physical therapy, postpartum care and 
home care is being paid for through FFS. Additionally, services such as lab-testing and 
medication are being paid for through FFS. Hospitals are being paid through a type 
of DRGs which are episode-based bundles defined by the combination of diagnosis 
and treatment. As from 2007, bundled payments for integrated chronic care (diabetes, 
chronic obstructive pulmonary disease (COPD) and cardiac vascular risk management 
(CVRM)) have been introduced in the primary care setting [20]. Bundled payments 
for birth care, including primary and secondary care organizations, were introduced as 
from January 2017. These bundled payments are not mandatory; providers and health 
insurers can still choose to use the traditional FFS model. The decision to implement 
these bundled payments is left to the PHM sites. Furthermore, within the Dutch system 
there is room to experiment temporarily with new, locally defined, payment models. 
Also, providers and health insurers in PHM sites can make contractual agreements on 
e.g. shared savings or pay-for-performance.
Definitions – payment reform
We defined payment reform as PHM interventions that 1) made changes to the type of 
payment (i.e. moving away from traditional FFS) and/or 2) made changes in the number 
of participating providers in existent payment models.
Combining elements of previous work of the Health Care Payment Learning Action 
Network [21], Stokes, Struckmann [22] and Struijs JN [23], we distinguished between 
several types of payment models and the level of integration of the payment model. We 
distinguished between three base payment models: FFS, bundled payments and global 
payments. Under FFS providers are paid a fee for each services delivered and therefore 
incentivizes increasing the volume of care [24]. On top of the FFS structure, pay-
for-performance, shared savings or retrospective bundles may be added to incorporate 
additional incentives. In pay-for-performance, on top of FFS, a bonus or a malus is 
paid for attaining some quality threshold. The additional payments can be employed for 
improving coordination, efficiency of care delivery or quality of care [25]. In a shared 
savings model, individual providers are each paid on a FFS bases and then there is 
reconciliation between the target episode price and the actual episode average price that 
is attributed to a provider (HCPLAN 2016), which is shared with the payer. Shared 
saving models that share in gains only are called one-sided. In two-sided models, also 
risks are shared. In our definition, shared savings models differ from bundled payments 
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as in bundled payments bonuses are not shared with the payer. In retrospective bundled 
payment, there is a virtual budget negotiated upfront, providers are being paid by FFS 
and retrospectively, the target prices is reconciled fully [23].
Prospective bundled payment is not based on the FFS base structure, as it pays a 
prospectively defined price that is paid as one payment with no reconciliation [21, 23].
In global payments, the entire population and the entire continuum of care is included. 
The accountable providers is paid a fixed fee per head of the population. Moving away 
from FFS (i.e. adding additional payment components (pay-for-performance or shared 
savings) or implementing another base payment structure (prospective bundled payment 
or global budget)) indicates increased financial provider risk.
The level of integration refers to the type and the scope of providers that are involved in 
the payment model. We distinguished between payments that are horizontally integrated 
(e.g. only covers providers within primary care) and payments that are vertically 
integrated (e.g. includes multiple types of providers – primary care and secondary care 
or over multiple domains, e.g. care and cure) in the payment model [22]. The latter refers 
to a higher level of integration.
Study design and sample
This qualitative study consisted of two parts. In the first part (October 2016), we 
conducted exploratory interviews with program managers (n=9) in order to identify 
and gain insight into the type of payment reforms within the PHM sites.
In the second part (November 2016 through February 2017), 27 relevant stakeholders 
concerning the identified payment reforms were interviewed to explore the experiences 
with payment reform in general (i.e. the interviews were not restricted to the payment 
reforms that we identified during the first part).
We used purposive sampling [26] in order to ensure that experiences of key stakeholders 
within the PHM regions were sufficiently reflected within the sample. Therefore, per 
site, we interviewed professionals who were involved in payment reform from varying 
sectors and organisations (program manager (8), health insurer representative (9) from 
six different insurer companies, care group or primary care organization representative 
(8), municipality civil servant (1) and hospital board member (1). The professionals were 
recruited through the network of the NMP. Whenever participants showed interest, 
they were emailed to schedule an appointment.
6
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In the first part, the interviews (by phone) were based on a topic list (see Appendix 
A) that included, among others, a description of the PHM interventions, funding 
and payment model. The answers were written down in a fixed format containing all 
interview topics. All program managers checked, adapted if needed and approved the 
content of the forms.
In the second part, participants were asked to sign a consent form. A semi-structured 
interview guide was used during the interviews (of +/- 1 hour) to identify different 
barriers to payment reform (see Appendix B). For the development of the guide, the 
authors build on issues raised in previous research (refs rapport). Interviews took place 
face-to-face (n=21) at the professionals work space or in a restaurant or by telephone 
(n=6).
Data analysis
In the first part, we selected payment reforms (see definition in conceptual framework) 
that had to be in effect before, or at the time of, the interviews. Following, we described 
the targeted condition, the participating providers and the type of payment model that 
was implemented. For definitions, see ‘conceptual framework’.
In the second part, the 27 interviews were audio recorded, transcribed verbatim and 
approved by the interviewee. The interviews were coded inductively using MAXqda 
software. Based on the first two interviews, EdV coded the interviews inductively per 
interview guide topic. Next, the coding scheme was discussed with HD and adapted 
to focus on themes that were brought up by the interviewees. Following, the remaining 
interviews were coded by EdV and the coding was checked by HD. Finally, drafts of 
the summary results were discussed with all authors and approved by all authors.
RESULTS
Type of payment reform
Table 2 describes the nine PHM payment reforms by their type of payment model, the 
aim of interventions, the targeted conditions, the level of integration (i.e. the included 
providers) and the payment flow. We identified FFS (n=3), prospective bundled payment 
(n=2) and one-sided shared saving models (n=4). Generally, the aim of the payment 
reforms was to substitute secondary with primary care or substitute brand with generic 
medication. Targeted patients were chronic conditions such as diabetes, CVRM or 
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mental health problems. One payment reform targeted musculoskeletal patients. The 
level of integration was mostly (n=8) vertical, as the payment reform general practitioners 
and medical specialists (n=4) and in four reforms also pharmacists were included. One 
reform was only horizontally integrated, it included mental health professionals, all in 
primary care.
Experienced barriers to payment reform
Table 3 presents a summary of the experiences of the participants (program managers, 
health insurer representatives, care group or primary care organization representatives, 
municipality civil servants and hospital board members) with the barriers to implement 
payment reform in general. Multiple barriers were mentioned per site and per participant. 
The following section discusses the experiences by theme.
Table 3: Experienced barriers to payment reform in nine Dutch PHM sites
Experienced barrier
1 Information asymmetry.
2 Worsening reputation of insurers.
3 Lack of trust as a result of failed reform attempts.
4 Misaligned incentives in the hospital setting.
5 Hesitation to accept financial accountability.
6 Lack of start-up funding.
7 Lack of leadership and intrinsic motivation.
Information asymmetry
Health insurer, program manager and primary care organization participants mentioned 
information asymmetry as barrier towards payment reform. Insurers and program 
managers indicated information asymmetry at the favor of providers. Accordingly, some 
insurers stated that they need the transparency to be improved in future negotiations, 
as they are of the opinion that the prices are too high. They indicated that shifting 
accountability to providers would increase the information asymmetry at the benefit 
of providers.
“We need to remove information asymmetries. And make agreements with each other. It is not 
going to work without proper agreements. Providers need to realize that; they have freedom 
to organize care between provider and patient. But that doesn’t mean that they don’t have to 
justify themselves. So, as you get more freedom to act, your accountability also increases. That 
is, exactly, well, that is exactly what it’s about in the pioneer site, in this contract. You get a 
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standard contract. And you are allowed to deviate, but then you have to accept that you increase 
your accountability. And that means that you need to provide data more often.” (program 
manager)
At the same time, participants from primary care organizations expressed the need to 
limit the information asymmetry at the favor of insurers. As such, a couple of physician 
provider organizations said to use their knowledge on the prices in the negotiations 
with insurers, trying to incorporate some playing room for overhead and efficiency 
improvements by revealing the true costs at a certain point in time.
All interviewees agree on that the lack of data infrastructure and privacy issues are 
important barriers to reduce the information asymmetry. In one pioneer site, the 
respondents state that they are experimenting with innovative data sharing mechanisms, 
to provide real time data to insurers and providers as part of the contract. According to a 
program manager from another site, another solution would be to create an independent 
party who collects and analyses patient data to get around privacy issues.
Worsening reputation of insurers
Insurer interviewees also described the worsening reputation of insurers as a barrier 
towards payment reform. Some insurers stated that payment reform would be perceived 
as a ‘cost cutting’ measure and therefore will worsen their reputation.
“Yes, absolutely. That is one of the issues. […] The reputation that we have, that is another 
issue. We say: “It is not up to us to perfom a certain surgery 90 times, as opposed to 80 times, 
thats the minimum. Who are we to say?” Well, then you can picture the headlines in the papers 
already.” (insurer)
Instead, insurers say they offer long-term contracts with the possibility to slowly decrease 
hospital production using a virtual budget, which aims to let professionals take the lead:
“It says, the medical personnel, well, most often it are doctors.. We have formulated it more 
broadly. Well, they actually initiate interventions. When we start them, they think it is not 
good.” (insurer)
Lack of trust as a result of failed reform attempts
Another theme was a lack of trust as a result of failed reform attempts, that was mentioned 
by participating insurers, primary care providers and hospitals after failed attempts to 
implement shared savings programs.
6
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“Because, at first, the idea was that the savings would go to the providers, as an individual 
bonus. That is something I was against, from the start. I always say, we are not going to refer 
patients over their heads. Or, realizing certain things, because it will come back at us, in 
such way, that we gain from it financially. So, we want to profit from it, but then to invest 
collectively in this new innovation […]. Well, the deep fear of insurers, they thought they couldn’t 
get it from the hospitals. So, that they have to pay us savings, because we showed that we had 
savings, but they, they would lose even more.” (physician organization)
Participating insurers, primary and secondary care providers disagreed on how to spend 
the potential savings, which negatively impacted levels of trust between stakeholders.
Misaligned incentives in the hospital setting
All interviewees mentioned misaligned incentives, especially in the hospital setting. 
These misaligned incentives were experienced between insurer and hospital boards and 
between hospital boards and medical specialists:
“[…] Payment systems need to be based on value, and not volume. […] But we have volume 
caps negotiated with the insurer. […] So it is vital for me to maximize revenues within the 
cap. […] The problem is that I have to work on World Peace, but I’m financed like I’m in truce. 
When I go out there, I know I’m in war with my specialists, because they will say: ‘You are not 
taking good care of me’.” (hospital board member)
All respondents stated that the volume-based payments do not stimulate to reduce 
production in hospitals in order to substitute care towards the primary care setting, 
as medical specialists and medical specialist parterships are incentivized by the FFS-
structure to provide more services. The respondents agreed that volume caps between 
insurer and hospital increases the interest of hospital board members to maximize 
production within the cap, because future caps are generally determined by historical 
production.
Additionally, an insurer stated that the FFS incentive at the level of the medical 
specialists and the parternships in the hospital is barely limited by the cap. Insurer 
respondents state that they try to create comfort for hospitals by slowly reducing 
production using long-term contracts with virtual budgets.
“And then you have to think about it in this way, that, well, that they at the moment their 
volume declines, they implement flanking policies. That means that, at least for the fixed costs, 
that they do not disappear in it one by one. Because, at the moment you do not see any patients 
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anymore, you cannot claim the tariffs, so there is less revenue. […] While the fixed costs do 
not decline. […] So, well. So we try to make arrangements in order to reduce it more slowly.” 
(insurer)
An insurer added that this is also influenced by the pressure of the cost growth reduction 
of the budgetary framework from the Dutch government that exerts similar incentives 
as the cap.
The combined threat of a reduction of the hospital budgets by the volume caps and the 
budgetary framework from the Dutch government hinders hospital boards to accept 
payment reform, as hospital boards employing medical specialist partnerships already 
experience difficulties to act on the volume caps in the current FFS structure.
Hesitation to accept greater financial accountability
Some providers stated to feel hesitant to accept greater financial accountability. Primary care 
representatives expressed worries that they are too small and have too little financial 
reserves to carry these risks. Additionally, a primary care representative worries that 
they are becoming accountable for outcomes they cannot control.
“[…] but, then you have to select those indicators of which you know you can influence as a 
provider, that is directly linked to the achievements providers can make, and then you could say, 
well, if you meet this and that threshold, you can get a bonus, this could work. The only thing 
is, that in these types of things, they say, we don’t have any influence on what patients do. So 
it’s very hard to select these things, I guess.” (primary care representative)
At the same time, primary care representatives stated that they fear that budget from 
secondary care will not follow the substitution of care sufficiently towards primary care; 
while they do feel that more time or budget is necessary for the additional tasks they 
perform. This was confirmed by an insurer who stated that he feels reluctant to promise 
structural additional revenues to primary care, as long as secondary care payments have 
not reduced.
Lack of start-up funding
Most respondents of provider representatives stated that insurers should invest more 
in payment reform, while bearing in mind that experimenting with payment reform 
requires risk capital. Some insurers stated that they are reluctant to invest in those 
programs, since the financial benefits are often generated after several years only.
6
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“[..] if they talk about shared savings, thats fine, but in 2017, we get 1/3 of it.. They make their 
business case that the benefits will flow to them first. But we say, you have to reimburse for the 
costs first! And when there are actually savings, ofcourse, we will share them. Otherwise we 
are waiting for 5, 6, 7 years on our money. So you see, to define what it is and understand each 
other’s point of views and under which conditions, it is quite new ground.” (insurer)
The same insurers said that if they would invest in payment reform, they would first want 
their investments back, before they pay out savings to the participants.
Lack of leadership and intrinsic motivation
In general, primary care representatives and some insurer representatives expect the 
government to stimulate payment reform and to provide with funding and knowledge 
to facilitate the reform. Conversely, (three) other insurer representatives and one primary 
care representative feel that risk appetite and providers’ intrinsic motivation need to be 
stimulated directly, by giving providers more freedom to reorganize care delivery. Other 
insurer representatives feel that the intrinsic motivation to reform should stem from 
higher levels of trust between stakeholders, leadership and through quick wins in (e.g.) 
pharmacy-related shared savings programs, which were implemented as a reaction to 
the failed shared savings programs:
“Even more, if you can show that you can do something and it results in a small fund.. I have 
seen what the project, how it got people enthusiastic. Anyway, in two sites, people worked 
together for the first time, because of that project!” (Insurer)
Shifting a part of the financial accountability to providers, by tying quality performances 
to bonuses, is not perceived as a solution by both insurers and providers. They fear that 
focusing on a defined set of quality indicators will destroy the intrinsic motivation of 
professionals to deliver high quality care, and that it may result in avoiding complex 
patients.
DISCUSSION
In this study, we aimed to provide insight into the process towards payment reform 
in nine Dutch PHM sites by investigating to what extent payment reforms were 
implemented and the experienced barriers to payment reform. This study showed that 
payment reforms currently include expanding the number of providers in existing fee-
for-service or bundled payment models and implementing pharmacy-related shared 
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savings programs in pharmaceutical care in the cure sector. Bundled payments or global 
payments including providers over the domains (cure, prevention or social care) have not 
(yet) been launched. The shared savings programs in pharmaceutical care mainly aimed 
to create trust to encourage motivation to reform. Previous shared savings attempts, 
that tried to include multiple providers, failed and negatively affected mutual trust. The 
interviews revealed reluctance to shift financial accountability to providers from both 
an insurer as well as a provider perspective. This was mainly due to a lack of trust and 
information asymmetry at the favour of providers. Furthermore, conflicting incentives 
at organization level and physician or specialist partnership level, a worsening reputation 
of insurers and a lack of funding and leadership hindered further reform. Above all, a 
lack of a sense of urgency hinders the payment reform in the Dutch PHM sites.
Small steps are taken in the progression towards payment reform in the Dutch 
PHM sites. This is in line with other PHM initiatives such as Accountable Health 
Communities in the U.S. [27] and the Vanguards in the UK, as they similarly focus on 
care redesign instead of payment reform. Examples of more disruptive payment reforms 
are few. The AQC in the U.S. and Gesundes Kinzigtal in Germany implemented global 
payments or shared saving programs including multiple providers, but those reforms 
are limited to the cure sector. Therefore, it seems in place to acknowledge that payment 
reform takes time, especially in PHM that aims to connect efforts over the domains 
of cure, care and prevention, as it is challenging to change within the complex and 
fragmented health system.
Although at the time of this study, the Dutch PHM sites were just three years in effect; 
it is interesting to explain the experienced barriers towards payment reform, because 
it helps to understand the problems PHM initiatives all over the world are currently 
facing. Our study corresponds with findings from earlier U.S. studies by showing that 
there is a need of stable leadership and increased funding to support infrastructure [16, 
28]. Our findings extend to the existing literature by showing that there is a vacuum 
where various stakeholders expect others to take action. Especially, insurers and large 
providers are being accused of a lack of a sense of urgency to pursue the reform. This 
is illustrated by insurers’ fear for an increased information asymmetry that will lead to 
an increased power imbalance between insurers and large provider organizations at the 
favour of providers (in accordance with Schut and Varkevisser [29]). The mechanisms 
at play are complicated and relate to factors such as leadership, alignment of goals and 
incentives, shared norms and values as well as the relations between the actors [30].
6
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This might – in part, be explained by differences in the US and Dutch health systems. 
In the US, the Affordable Care Act (ACA) explicitly dictated to establish the Medicare 
Shared Savings Program that encourages various regional stakeholders to form ACOs 
and several types of bundled payment models [31]. In that way, the US government 
exerts pressure to payment reform of the public health system, to start the care delivery 
reform specifically. In the Netherlands, the role of the government is less clear. And even 
though it is the responsibility of the Dutch government to regulate the preconditions 
within the system of regulated competition with private payers [32], it is the question 
to what extent the government should interfere to increase the sense of urgency to 
payment reform. Inherently, PHM initiatives require decentralization to a certain 
extent. Specifically in the Dutch context, payment reform is seen as a part of the move 
towards PHM, instead of being the start of the reform. Yet, our study showed that some 
interviewees expect the government to provide more guidance or assistance on payment 
reform by creating a platform for knowledge. This platform could provide a long-term 
vision with information on the implementation and potential impact of different types of 
payment reform. Such governmental stewardship might resolve a part of the hesitance in 
moving towards value-based payment models. An example where the Dutch government 
exerted more pressure is in bundled payments for birth care. Here, the Ministry of 
Health strongly recommended the (voluntary) uptake of bundled payments [33] and 
provided subsidies to develop knowledge and tools and made available specific payment 
(infra)structures. It seems to have created a sense of urgency for implementing payment 
reform. However, as PHM sites need autonomy to operate, finding the optimal balance 
between top-down efforts from the government and bottom-up efforts from providers, 
insurers and sites seems essential for successful PHM [34]. Therefore, strong leaders 
who are aware of the need for change, with experiences in the health care market and 
who are able to create a new impulse in the insurer-provider relationship are required 
to align goals and incentives.
Aligning incentives with the Triple Aim seems to require a shift towards more value-
based payment models. However, as internationally implemented payment reforms are 
scarce and do not (yet) stretch further than the cure sector, it is unknown how to align 
incentives for multi-stakeholder initiatives that services several patient groups over 
the domains of care. Payment models for chronic care demand other incentives than 
payment models for screening activities. Therefore, successful PHM probably requires 
a combination of value-based payment models adjusted to the complex and dynamic 
PHM setting.
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This study has several limitations. First, not all Dutch payment reforms were included 
as they were not part of the PHM pioneer sites. For instance, the previously mentioned 
bundled payments for birth care were not included. Second, as only one researcher 
coded the interviews, the results may have been influenced by the researchers’ subjective 
interpretation. To minimize the bias, another researcher checked the coding work and 
the summary results were discussed until consensus was reached with all authors. 
Third, as we inductively gathered experienced barriers, we might have missed insights 
from the PHM sites that were not monitored in this study, as for example the view of 
municipalities. Nevertheless, based on efforts to study other PHM initiatives [11] we are 
confident that we have shown a fair representation of the situation in Dutch PHM sites. 
We suggest future research to follow efforts to payment reform closely, to qualitatively 
investigate what works and what does not, to investigate potential solutions for barriers 
encountered and to quantitatively support those finding on the Triple Aim goals.
Conclusions
During the first three years of the Dutch PHM sites, payment reforms included paying 
for consultation of medical specialists in a primary care setting through traditional 
fee-for-service models, adding secondary care in existent bundled payment models for 
chronic care and shared savings programs in pharmaceutical care. Bundled payments or 
global budgets including providers over the domains (cure and prevention or social care) 
have not (yet) been launched as PHM intervention. PHM representatives stated that 
reluctance to shift financial accountability to providers was partly due to information 
asymmetry, a lack of trust between providers and insurers and conflicting incentives, 
but all the same to a lack of sense of urgency. Small steps to payment reform have been 
taken in the Dutch PHM sites, which is in line with other international PHM initiatives. 
While acknowledging the autonomy of PHM sites, governmental stewardship (i.e. long-
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A1. Interview topic list
1. Contract
a. Level of contract (at the PHM site level and insurer?)
b. Scope (financing sources (overhead and care related, included population)
c. Preconditions (monitoring or IT?)
d. Design of the model and incentives (tied to quality of care?)
e. Inclusion criteria patients
f. Duration














A2. Semi-structured topic list
- What is necessary for realizing the Triple Aim?
- What are your expectations regarding payment reform?
- What are your previous experiences with payment reform?
- What are your thoughts of payment reform in relation to:
   o  Market position
   o  Role of government
   o  Other stakeholders
   o  Competition
   o  Funding
   o  Structure of the PHM site
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Background and thesis aims
The increasingly pressured sustainability of health systems challenges Western countries 
to improve the value of their health systems. Value can be increased by improving 
population health, reducing spending levels or both. One of the main responses across 
countries is to improve health care delivery by integration of services across medical 
care, social care and public health within regions, which is called population health 
management (PHM). This thesis aimed to contribute to the existing literature on PHM 
by:
A. exploring how to measure the concept of value for monitoring and budget 
allocation decision making within and across PHM regions.
B. gaining insight into experiences with, and the types and effects of, alternative 
payment models (APM) in order to assess its possible role in PHM.
The remainder of this chapter presents the main findings of this thesis, reflects on the 
main findings and discusses implications and further steps.
Main findings
Part A: Measuring value in population health management
Part A explored how to measure the concept of value in a PHM setting; by reviewing 
the current state of low-value care indicators (chapter 2) and by exploring how to 
operationalize the concept of value within observational datasets (chapter 3 and chapter 
4).
Chapter 2 showed that the majority of low-value care indicators are in medical (primary 
or secondary) care (87 out of the 115 listed low-value care indicators). The remaining 
indicators were found in prevention (n=25) and in long-term care (n=3). No indicators 
were found in social care. Three indicators were assigned the highest level of evidence 
as they were underpinned by both guidelines and evidence from the literature. Other 
indicators were underpinned by clinical guidelines or Choosing Wisely recommendations 
[1]. Despite the fact that several indicators are used in provider-payer contracts, no 
information on the validity of the indicators was found in the literature.
Chapter 3 analyzed the drivers of regional variation in medical spending by looking 
at subgroups (i.e. individuals with diabetes and depression) in addition to the total 
population. Heterogeneity issues with regard to case-mix were aimed to overcome 
by using an extensive dataset (secondary health survey data linked with claims data, 
health care supply data and municipality registration data), in addition to the selection 
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of subgroups. The results showed that PHM regions with above (or below) average 
spending for the general population mostly showed above (or below) average spending 
for diabetes and depression as well. Yet, the drivers of the variation at the regional level 
varied between subgroups. Demand factors explained most variation across regions in 
medical spending for depression and explained 88% of the variation for diabetes. The 
variation left unexplained (12% for diabetes) indicates differences across regions due 
to inefficiencies. This suggests that the extent to which regional variation in medical 
spending can be considered as inefficiency may differ between regions and subgroups.
In chapter 4, we described the variation of six proposed value-indicators for maternity 
care across Dutch Maternity Care Networks (MCNs). Specifically, we used the 
association between low-value services utilization and maternal and neonatal health 
outcomes as measures of value across the MCNs. We found substantial variation across 
MCNs for the six value-indicators. The additional analyses suggested that the inputs (i.e. 
low-value care indicators) have captured a part of value. We could not rule out that these 
findings were due to differences in case-mix, despite the use of many case-mix variables.
Part B: gaining insight into alternative payment models
Part B gained insight into the current state of alternative payment models (APMs) 
using international literature (chapter 5) and experiences of PHM stakeholders in the 
Netherlands (chapter 6).
Chapter 5 reviewed what types of APMs have been implemented in maternity care 
in Western countries. Seventeen initiatives employed APMs in the United States 
(n=13), the United Kingdom (n=2), New Zealand (n=1) and in the Netherlands (n=1). 
Within these initiatives, pay-for-performance models (n=2), shared savings models 
(n=7) and bundled payment models (n=8) were found. Key design elements (such as 
eligible population, episode time span, care providers that participated in the model, 
care activities covered by the model, risk mitigation strategies) varied highly. Key terms 
describing the type of payment model (e.g. shared savings and bundled payments) were 
used interchangeably. APMs that shifted more financial accountability toward providers 
tended to include more strategies that mitigated financial risks. The first evaluations 
(n=4) on the effects of APMs are tentatively positive on different indicators of health 
and spending. Two studies found a positive association with health outcomes and two 
studies found a positive association with a reduction of medical spending.
Chapter 6 investigated what types of payment models were implemented in the Dutch 
PHM regions and what barriers were experienced towards payment reform. After three 
7
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years of PHM, shared savings models for pharmaceutical care (n=4) and extensions 
of existing (bundled) payment models adding providers into the model (n=5) were 
adopted. The experienced barriers included information asymmetry between providers 
and insurers, worsening reputation of insurers, lack of trust as a result of failed reform 
attempts, misaligned incentives in the hospital settings, hesitation to accept financial 
accountability and lack of start-up funding, leadership and intrinsic motivation to 
reform. According to the interviewees, these experienced barriers were partly due to a 
lack of a sense of urgency.
Reflections on the main findings
Part A: Measuring value in population health management
Although the concept of value originated in a disease-specific context, it gained 
popularity in integrated services settings, such as PHM. The concept of value, which is 
defined as health outcomes that matter to the patient relative to spending, is important 
in PHM as it is linked with the interdependent PHM goals (i.e. increasing population 
health outcomes and quality of care while slowing the cost growth). Following 
Struijs’ framework [2] (see Chapter 1, Figure 2) it is essential to continuously monitor 
progress on these goals in order to (re)allocate resources in such a way that the needs 
of the population are met. The following section discusses the several conceptual and 
methodological issues the we encountered in our exploration to measure value.
Gaps in availability of indicators of value and data across domains
This thesis has shown that there are currently gaps in the availability of indicators 
of value in two ways. First, low-value care indicators are currently found in medical 
care mainly, and domains such as prevention, long-term care and social care are 
underrepresented (chapter 2). This is not surprising, considering the origin of value 
and Value-Based Health Care (VBHC) initiatives that are particularly popular in, 
and designed for, medical care [3]. Yet, previous research [4-6] has indicated (e.g. 
through measuring practice variations) that low-value care is also present in other 
sectors along the care continuum. Second, within medical care, most health outcome 
indicators are observational outcomes (e.g. Apgar scores, admission rates, mortality), 
and currently information on the experiences of patients is lacking. Patient Reported 
Outcome Measures (PROMs) and Patient Reported Experience Measures (PREMs) are 
important for measuring value in PHM, because they reflect outcomes and experiences 
that matter to the patient. Therefore, such indicators comprise an essential part of the 
value concept [3]. The International Consortium of Health Outcome Measurement 
(ICHOM) continually works on developing PROMs and PREMs.
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The spending part of value is endogenous
Operationalizing the spending part of the value-equation can be problematic due to 
endogeneity. The problem is that spending encompasses both the treatment and the 
complications that may be caused by the treatment itself. Moreover, health care spending 
may reflect the health status of persons rather than the contribution of health services 
to health outcomes, even when adjusted for case-mix (chapter 4). Because we had access 
to an extensive set of case-mix variables from multiple data-sources, the question arises 
whether the presence of even more case-mix variables in the data would help to limit 
bias. Although this problem is acknowledged by multiple authors (e.g. [7, 8]), spending 
is still being used in studies regarding efficiency and value [8, 9]. Chapter 4 aimed to 
avoid endogeneity by replacing medical spending with low-value care indicators, but this 
strategy also has methodological and conceptual drawbacks. For instance, using a single 
low-value care indicator reduces the sensitivity of value dramatically, and therefore, is 
not suitable for assessing value across services or even across multiple domains (like 
in PHM). Another drawback is that, based on available data, it is sometimes hard 
to disentangle whether a service is of high-value or of low-value [10]. For example, a 
caesarean section is of high-value when fetal and/or maternal distress occurs. When 
there is no medical need, a caesarean section is of low-value. Instead, the caesarean 
section may even impose harms, because such invasive medical procedures are not 
risk free and may cause, for example, serious infections [11]. Furthermore, using solely 
low-value care indicators instead of spending implicitly filters out the contribution of 
high-value services, which is equally relevant in determining value [12]. For instance, 
effective identification of what type of care is necessary for whom and continuity of care 
professional are services of high-value in maternity care that should be acknowledged 
in the conceptualization of value.
Considering these issues, it is essential to align the operationalization of value to the 
research question and the level of measurement. As such, despite the endogeneity 
problems, it may be more feasible to use spending in the value-equation if the 
question is to monitor progress towards value over time in a country. In this example, 
the endogeneity problems may have less harmful consequences, than when value is 
measured across regions to determine the quality of care for consumer information 
or tying payment to. In addition, depending on whether the goal is to improve value 
by reducing spending (growth) and maintaining health outcomes or improve value 
by maintaining spending (growth) and improving health outcomes, it makes sense to 
include either low-value or high-value indicators.
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Can value be influenced at the regional level?
Conceptually, value can be captured at each decision-making level [13], which includes 
the system-level, regional level, provider organization level, and of course, the level of 
the communication between care provider and patient. This thesis implicitly assumed 
that regional level policies affect value by influencing provider behavior [14]. More 
specifically, the assumption was made that PHM may lead to improved value by 
increased collaboration and integration among providers. This assumption was based 
on examples from the literature where regional policies affected provider behavior, such 
as implementing APMs [15], making budget allocation decisions [16, 17], adopting 
integrated care delivery models [18], standardizing clinical practices by improving 
guideline adherence [19, 20], or adopting new practices as a consequence from contact 
with (new) colleagues [21]. This thesis showed (small) variation between subgroups 
within and across regions, that persisted after correction for case-mix. Therefore, we 
cannot rule out the possibility of differences at the regional (and subgroup) level due to 
inefficiencies [13, 22]. This is in line with our assumption and other studies showing 
small regional differences [13, 23, 24]. At the same time, we acknowledge that variation 
can occur at other levels, for example at the provider (organization) level (e.g. [25]) or at 
the system level (e.g. [23]), which are additionally important to study.
Part B: Gaining insight into alternative payment models
A frequently discussed theme in the quest of PHM initiatives to improve value is 
alternative payment models (APMs). Shifting away from the traditional FFS models 
to more value-based payment models is perceived by many to be a precondition for a 
successful implementation of PHM [26-28]. In practice, many PHM initiatives struggle 
on how to design and implement APMs, and there are doubts on whether APMs will 
turn out to be valuable. Below, we discuss some topics, which can be helpful in the 
discussion regarding to the role of APMs within PHM initiatives.
The complexity of alternative payment models
Although APMs generally search for the optimal allocation of risks between payer and 
provider [29], there is not a one size fits all. The optimal allocation of risks will differ, 
depending on the specific aims and settings of the APMs and care settings. Chapter 
5 reviewed the use of APMs in maternity care and found that currently multiple types 
of APMs (pay-for-performance, shared saving models, bundled payment models) are 
adopted in practice. Moreover, key elements, such as the included population, included 
care professionals, time span, and the link with quality of care and risk mitigation 
strategies varied widely across the initiatives. The high variety of APM elements may 
indicate that initiatives actively try to adjust the APM to the contextual factors of the 
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health system at hand, such as scale (i.e. small practice, practice groups, hospitals, etc.) 
[30] and the level of risk that providers are able and willing to bear. As such, when 
relatively more financial accountability is shifted, more risk mitigation strategies are 
applied (chapter 5). This indicates that there is a lack of trust, probably of providers, in 
techniques to allocate insurance risk only with the insurer, and provider risk only with the 
provider [31, 32] (for more information on insurer risk and provider risk, see Chapter 1). 
In turn, providers become reluctant to adopt (increased) financial accountability (chapter 
6) and have a desire for more comfortable adoption of APMs. Moreover, there is a 
variety of complex terms and ambiguous definitions that lead to key terms are being used 
interchangeably, and therefore, confuses understanding of stakeholders. For example, the 
finding that ‘shared savings’ and ‘bundled payments’ are used interchangeably (chapter 
5) indicate that there is no common language for the APM typology, which further 
complicates the discussions about the adoption of APMs in practice.
Will alternative payment models help to improve value?
There is much debate on what to expect from APMs. Therefore, this thesis aimed to 
contribute to the discussion by reviewing the literature about the effects of APMs in 
maternity care on the two pillars of value; spending and health outcomes. Chapter 5 
found that, for maternity care, only four evaluations in peer-reviewed journals were 
performed, which were tentatively positive. This is in accordance with literature 
evaluating the effects of APMs for other episodes of care, which results also seem 
tentative. Most studies find evidence for APMs to reduce spending [33, 34], but there are 
also studies suggesting that spending is being shifted outside the scope of the APM [35]. 
Commonly, studies do not find much evidence for APMs to improve health outcomes 
[33, 34]. The lack of conclusive evidence in the literature may be due to that it may take 
longer for initiatives to make changes visible. For example, Song et al. [36-38] showed 
increasing effects of their global payment model after 1, 4 and 8 years. Another reason for 
the lack of empirical evidence is the difficulty to isolate the impact of APMs from other 
(policy) changes at the same time, which is a common problem in the evaluation of policy 
changes. Moreover, it seems sensible to select indicators for an empirical evaluation 
based on what the APM is expected to contribute to what aspect in the health system. 
However, the complexity of the (terminology of the) APMs and the high variety of 
key elements complicates the selection of the indicators that measure the effect of the 
APM. Chapter 5 summarized evaluations of APMs in maternity care and found that 
evaluations used different indicators of health and spending. This underlines one of the 
main problems (which also concerns the above discussion in measuring the concept of value 
in a PHM context) as formulated by Glied [39]: we don’t really know what we mean by 
value, and therefore, we don’t really know how to pay for it [39] and how to measure it. 
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When value is measured differently across initiatives, it is not surprising that conflicting 
conclusions are drawn from different studies. This is problematic for both the evidence 
base of APMs, as the incentives that are intended to follow from the APMs.
Besides all that, it may be that initial expectations about the effects of APMs were too 
high or not correct. The articles that formulated that one of the solutions to keep health 
systems sustainable is the introduction of alternative payment models [40, 41] may have 
contributed to those expectations. In reality, the effects of APMs on value may be more 
nuanced. APMs can contribute to increased value by providing incentives to efficient, 
high-value care, which should be understood in the context of many other factors that 
play a role in the reform towards more integrated care [42], which could contribute to 
a better value health system.
Future research and policy implications
Aforementioned issues should be considered in order to operationalize value in a PHM 
context for monitoring and budget allocation purposes, and to design and adopt APMs 
that are aligned with the PHM goals. The following section discusses future research 
and policy implications.
Develop indicators of value along the care continuum at each relevant level
As the need to improve the sustainability of health systems in Western countries 
will continuously increase, the urge to measure the progression towards value will 
also increase. This thesis showed that there are currently gaps in the availability of 
indicators to address the full concept of value. At the same time, PHM initiatives such 
as the Accountable Health Communities (AHC) and the Dutch PHM regions develop 
interventions that include multiple domains along the care continuum. Therefore, it is 
important to further develop value-indicators, which are aligned with the goals and the 
activities of PHM initiatives. In the last couple of years, low-value care indicators gained 
increasing attention, but there should also be attention for the development of high-value 
indicators. Moreover, health indicators that reflect outcomes and experiences that matter 
should be developed in addition to the high- and low-value indicators. Future research 
should focus on the development of a valid set of value-indicators that reflect value 
along the entire care continuum according to the population, and for use at the point of 
care, for each individual specifically. Comprehensive sets of value-indicators should be 
developed that can be used for monitoring purposes, budget allocation decisions or direct 
provider feedback. The sets of value-indicators should not be too narrow and should not 
be too wide. Too narrow sets of indicators may lead to, for example in provider-payment 
contracts, in a simple cost-containment strategy or even adverse health effects. Too broad 
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or too complex sets of indicators may lead to complex interpretation of the ‘scores’ for 
the user [43]. Instead, a comprehensive small number of meaningful indicators with a 
solid evidence base and validity could incentivize value better [43]. Hereby, transparency 
is essential, as using indicators of low quality might lead to (depending on the goal) 
negative consequences, such as underuse of indicated services, patient- and provider 
dissatisfaction, adverse health outcomes or patient selection [10].
Carefully design alternative payment models to each specific situation
For APMs to be valuable, it is important to carefully design APMs based on the specific 
care setting at hand [30]. As such, APMs should be designed depending multiple factors, 
such as the scope and the type of population, the level of standardization of care, the type 
of providers and the level of risk providers are able and willing to bear. At first sight, and 
apart from discussions on terminology of the models, the type of APM should vary with 
the level of risk the payment model imposes on (groups of) providers (also see Figure 2 
[29]). The exact amount of risk that is imposed on (groups of) providers can be finetuned 
by using risk mitigation strategies. Conceptually, this creates a distinction between 
provider risk and provider accountability. That is, because risk mitigation strategies limit 
the financial risk that providers bear for while holding providers still accountable. The 
actual level of risk should be adjusted to what providers are able and willing to bear, 
while the accountability of providers may be larger. Key elements of APMs and risk 
mitigation strategies within the APM must be designed in such a way that it supports 
the intrinsic motivation of providers to deliver high value care [44]. That means that the 
model should, among others, not lead to excessive administrative burdens.
In the search to discover what works in which situation, it is important that space is 
being created to learn from best practices and also to learn from mistakes. Transparency 
about the aspects of APMs that need further development is required to prevent that 
unwanted incentives result from the APMs. Best practices, learning points, and also 
theoretical knowledge could be shared by using platforms. One aspect that deserves more 
attention is the notion that measurement of value is critical in designing APMs [30] 
and that, currently, we don’t know how to measure value fully. This implies that tying 
payments to value-indicators makes more sense when value-indicators are considered 
to be valid. Another related aspect is that risk mitigations strategies, and in particular 
risk-adjustment, needs further refinement to properly separate out insurance risk and 
provider risk. Research on how to deal with population heterogeneity may also inform 
these issues. This is important to protect providers from incurring too much risk, and 
also to lower barriers for providers to participate in APMs. But most importantly, the 
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adoption of APMs should be approached as a part of a broad transformation including 
many factors that together may lead to a more valuable health system.
Conclusions
This thesis aimed to grasp the concept of value in a population health management 
context. By exploring how to measure value, this thesis showed that there is a need to 
develop comprehensive sets of value-indicators capturing the full continuum of care and 
outcomes that matter to the population. By gaining insight into what types of APMs 
are currently implemented and what experiences are, this thesis showed that progress to 
validly measure value is essential for the design and adoption of APMs. In the meantime, 
APMs should be carefully designed to care context at hand, while being transparent 
about their stage of development, available evidence and realistic expectations.
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Dan wil ik graag mijn (co)promotoren bedanken. Caroline, bedankt voor de vrijheid die 
je me hebt gegeven om mijn weg te vinden als onderzoeker, maar ook als vrouw binnen 
een organisatie. Ik ben dankbaar voor je scherpe vragen en bewonder je heldere denken. 
Je hebt mij geleerd hoe je nuance kunt aanbrengen in het werk, en vooral hoe belangrijk 
de nuances zijn. Richard, jou wil ik graag bedanken voor je scherpte in je commentaar. 
Sinds je start bij de NZa was je wat meer op afstand, maar ondanks dat heb je je altijd 
goed kunnen inlezen en had je goede adviezen. Daarnaast was je door je kalmte een 
baken van rust, wat op sommige momenten erg fijn was. Jeroen, ik heb genoten van 
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en geboorte te ontwikkelen. Ik ben blij dat we ook in de toekomst zullen blijven 
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Een aanzienlijk deel van dit proefschrift is tot stand gekomen dankzij de beschikbaarheid 
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en Vektis, te bedanken voor het beschikbaar stellen van data. Daarnaast wil ik graag 
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verantwoorde wijze de veelheid aan data te kunnen koppelen en analyseren van wezenlijk 
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de frustraties die komen kijken bij het schrijven van een proefschrift. Daarnaast wil 
ik Albert, Eelco, Hanneke, Mieneke en Roy bedanken voor jullie adviezen en het 
meeschrijven aan mijn artikelen. Joyce en Zoë, ik ben blij dat jullie er zijn. Samen 
met Jeroen vormen we een echt team, en ik heb veel zin om samen met jullie verder de 
mogelijkheden van DIAPER te verkennen! Josefien, bedankt voor het aller gezelligste 
congres ooit; San Sebastian zal ik nooit vergeten. Super leuk dat je vanaf januari 2020 
nu ook officieel mijn collega bent.
Lieve vrienden, ik wil jullie allemaal bedanken voor de gezelligheid, borrels en 
vriendschap. In het bijzonder wil ik MASSEL, Maaike, Astrid, Sabine (Zeebaain), 
Suzanne en Laura, bedanken. Dankzij jullie ben ik het gaan waarderen om onderdeel te 
zijn van een groep vrouwen. We hebben samen veel meegemaakt in de afgelopen jaren. 
Lol, feest en stapels nieuwe kinderen, maar ook verdriet en verlies. We zijn allemaal 
compleet anders, maar stuk voor stuk zijn jullie fantastisch. Door onze drukke levens 
lukt het vaak niet meer om elkaar wekelijks te zien, maar daar wordt de vriendschap 
niet minder door. Ik ben dankbaar dat jullie er voor me zijn. Joanne, jij bent mijn oudste 
vriendin. Ik kijk met veel plezier terug aan de te gekke momenten die we als pubers 
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hoor. Ook wil ik graag mijn paardenvriendinnen, Anja, Christy, Myrthe, Stephanie en 
Yvette, bedanken. Voor het delen van onze hobby, de gezellige lessen en de hilarische 
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gesprekken en steun.
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hebben samen veel meegemaakt, je hebt mij op m’n best gezien en op m’n slechtst. 
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te weken rond lunchtijd. Bedankt voor de komische intermezzo’s, IT Crowd en de goede 
gesprekken. Sorry Ben en Gerben, volgende keer mogen jullie mijn paranimfo’s zijn.
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levenslessen en alles wat jullie mij hebben gegeven om te worden wie ik nu ben. Ik wens 
jullie alle goeds en vele gezonde en gelukkige jaren toe. Ik ben wel enorm opgelucht 
dat jullie me nu niet meer gaan vragen of ik al ‘afgestudeerd’ ben. Lieve zus, jou kan ik 
natuurlijk niet weglaten in dit rijtje. Hoe is alle zorg die jij hebt ontvangen voor jou van 
waarde geweest? Voor veel ben ik dankbaar, maar in het kader van dit proefschrift wil 
ik je bedanken voor het inzicht dat een op zichzelf staande handeling in de zorg weinig 
kan betekenen. De zorg levert alleen echt iets op als alle zorg, op alle mogelijke gebieden 
rond het leven van een persoon, in samenhang georganiseerd wordt. Allerliefste oma, 
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voor mij geweest en met jouw 91 jaar ben je nog steeds van alles perfect op de hoogte. 
Ik vind het prachtig hoe je met Floris bent. Dank je wel voor alles.
Lieve Ard en Floris, ik bof maar met jullie. Jullie zijn mijn veilige thuis. Ard, ik ben 
onder de indruk van jouw discipline, rechtvaardigheidsgevoel en geduld. Ik hoop dat ik 
in de jaren samen wat van jou heb geleerd op die vlakken. Je geeft mij alle ruimte om mij 
te ontwikkelen en dat heeft mij enorm geholpen bij het afronden van dit proefschrift in 
combi met onze kleine boef. Bedankt dat je er bent en dat je zoveel geduld hebt met mij. 
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Lieve Floris, ik geniet elke dag van jouw aanwezigheid. Ik kijk uit naar onze toekomst, 
zonder al die extra proefschriftuurtjes!
Poging mislukt, het is een aardig zoetsappig dankwoord geworden..
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